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Arsenicals were therapeutic mainstays for various diseases in the 18th, 19th and 
early 20th centuries. Fowler’s solution (1% potassium arsenite) was a famous example, 
which was a key medicine for treatment of chronic myeloid leukemia (CML) until the 
1930s, thereafter it was gradually replaced by radiotherapy and other cytotoxic 
chemotherapeutic agents. Decline in the medicinal use of arsenicals in the mid-20th 
century can be traced to the concerns about their toxicity and carcinogenicity. Arsenic 
trioxide (As2O3) was reintroduced as an anticancer agent after reports emerged from 
China of the success of an arsenic trioxide-contained herbal medicine for treatment of 
patients with acute promyelocytic leukemia (APL) in 1970s. Commercial available 
arsenic trioxide product, TrisenoxTM, was approved by the American Food and Drug 
Administration (FDA) in 2000 for treatment of patients with APL, who have not 
responded to or have relapsed following the use of all trans-retinoic acid (ATRA) and 
anthracycline-based chemotherapies.  
Since arsenic trioxide can cause serious liver damage if given orally, it must 
be administered intravenously daily as an infusion over 1 to 4 hours, which makes 
consolidation and maintenance therapies difficult. Therefore, an alternative oral agent 
with similar therapeutic effects and fewer side effects would provide not only cost and 
quality-of-life benefits but also easy access to the consolidation and maintenance 
therapies. Moreover, such oral agent would give opportunity for further combination 
with other agents of interest. Realgar (As2S2) and orpiment (As2S3) could be such 
candidates. Both realgar and orpiment are reportedly the oldest drugs. The first 
mention of arsenicals was made by Hippocrates (460-370 BC), who used realgar and 
orpiment pastes to treat ulcers. Realgar and orpiment are defined as mild-toxic 
compounds. Recent years, mainly in China, realgar and orpiment became research 
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focus for their promising anticancer effects.  
 Although some clinical trials conducted in China reported that both realgar 
and orpiment achieved promising outcomes in treatment of patients with APL at 
different disease stages, there is extremely limited information of these arsenicals in 
terms of the mechanisms of action, toxicity, as well as pharmacokinetic and 
pharmacodynamic profiles. The lack of information could be caused by the water-
insolubility of realgar and orpiment. Both realgar and orpiment are crystal with high 
native lattice energy, which results in the difficulty of breaking apart the respective 
molecules into surrounding media including aqueous and most organic solvents.  
The water-insolubility of realgar and orpiment is a key obstacle for their 
investigation, development and final commercialization. In order to improve the poor 
water-solubility of realgar and orpiment, alkalization approach by directly dissolving 
both compounds into alkali solutions was usually applied. We established capillary 
zone electrophoresis (CZE) method to identify the exact composition of realgar and 
orpiment in sodium hydroxide solution. Our findings showed that realgar and 
orpiment would be converted to arsenite and arsenate with different proportions 
instead of intact molecules, suggesting that the conventional alkalization approach is 
not appropriate for enhancement of the water-solubility of realgar and orpiment.  
Nanosized realgar and orpiment particles were prepared by cryo-grinding 
technique with the assistance of biocompatible water-soluble polymer 
polyvinylpyrrolidone (PVP) and surfactant sodium dodecyl sulphate (SDS). Improved 
water-solubility of nanosized reaglar and orpiment particles were achieved as 
indicated by the increased soluble arsenic contents, i.e. 134.20 ± 4.30 ppm and 152.80 
± 5.54 ppm, respectively, of R/PVP/SDS and O/PVP/SDS nanosuspensions compared 
with those, i.e. 0.52 ± 0.03 ppm and 0.51 ± 0.03 ppm, respectively, of original realgar 
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and orpiment filtrates. The effects of PVP and SDS not only increase the grinding 
efficiency but also effectively stabilize the realgar and orpiment suspensions through 
the formation of steric and ionic barriers on the surfaces of drugs particles.  
Bioavailability of orally administered drugs with poorly water-soluble is 
usually poor and highly variable. In the in vivo study, bioavailability expressed by 
urinary arsenic recovery of orally administered reduced sized realgar and orpiment 
particles to rats were obviously improved when compared with the original coarse 
realgar and orpiment powders. For example, within 96h, up to 85.4 ± 24.4% of dose 
was recovered in urine after oral administration of R/PVP/SDS suspension, whereas 
original realgar course powders gave a urinary recovery of 31.9 ± 13.6%. In the case 
of orpiment administration, 75.8% ± 27.2% and 33.2% ± 14.2% were the respective 
recovery of orally administrations of O/PVP/SDS suspension and original orpiment 
course powders. 
In the in vitro cytotoxicity study, nanosized realgar and orpiment particles 
inhibited proliferation of the selected gynecological cancer cell lines including the 
ovarian cancer cell lines of CI80-13S, OVCAR, OVCAR-3, and a cervical cancer cell 
line of HeLa, whilst leaving the chosen control cell lines of normal human lung 
fibroblast cell line of MRC-5 and normal human dermal fibroblast cell line of HF 
unaffected. IC50 values were estimated. Comparison analysis of IC50 values of realgar 
(4.06 ± 0.45 on OVCAR-3 cells; 3.51 ± 0.48 on HeLa cells), orpiment (3.11 ± 0.44 on 
OVCAR-3 cells; 3.21 ± 0.46 on HeLa cells), and arsenic trioxide (2.37 ± 0.33 on 
OVCAR-3 cells; 1.85 ± 0.54 on HeLa cells) on the representative OVCAR-3 and 
HeLa cell lines demonstrated that there were no significant differences among realgar 
and orpiment and arsenic trioxide in terms of anti-proliferation effect on OVCAR-3 
cells (p > 0.05, arsenic trioxide vs realgar; p > 0.05, arsenic trioxide vs orpiment; p > 
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0.05, realgar vs orpiment); on HeLa cells, arsenic trioxide seemingly was more 
cytotoxic than both realgar (p < 0.05) and orpiment (p < 0.05) which had similar 
effect (p > 0.05). Apoptosis induced by the nanosized realgar and orpiment particles 
on both OVCAR-3 and HeLa certain cancer cell lines was observed and confirmed by 
cell morphology, flow cytometry and DNA fragmentation assay, which partially 
contributes to the anti-cancer activity of realgar and orpiment.  
In order to discern the possible underlying mechanisms of action of realgar, 
orpiment, and arsenic trioxide, preliminary screening for the effects of the target 
arsenicals on Hela cells was conducted by use of microarray technology. Alterations 
of some cancer-related genes, including BHLHB2, CAP1, CDC25A, CKMT1B, 
CLK2, CTPS, DCN, CTSC, DHCR7, E2F1, ETV3, FOSL1, IGFBP3, LAMB1, MYC, 
NME3, NR2F1, PCNA, PCTK3, RAP1A, RBBP4, TFDP1, TNFRSF1B, and TP53, 
obviously regulated by the target arsenicals were observed, however, further 
confirmation works should be done before drawing a final conclusion. Microarray 
study also showed that the effects of the arsenicals are species-dependent and dose-
dependent.  
Arsenic is well defined human carcinogen, although the mechanisms of 
carcinogenicity are not fully elucidated yet. The in vivo toxicity of realgar and 
orpiment and arsenic trioxide were assessed by measuring 8-hydroxy-2’-
deoxyguanosine (8-OH-dGuo) in urine, a biomarker of oxidative DNA damage, by 
means of isotope dilution high performance liquid chromatography coupled with 
tandem mass spectrometry (LC/MS/MS) after oral administrations of the test arsenic 
compounds to rats. The elevated formation of urinary 8-OH-dGuo in the rats was 
found after the arsenic compounds administrations compared with control rats (p < 
0.01, arsenic trioxide vs control; p < 0.01, realgar vs control; p < 0.01, orpiment vs 
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control). The in vivo toxicity studies showed that realgar and orpiment might be less 
genotoxic than arsenic trioxide (p < 0.001, arsenic trioxide vs realgar; p < 0.001, 
arsenic trioxide vs orpiment). Although our study showed that realgar and orpiment 
are somewhat genotoxic in terms of induction of 8-OH-dGuo, which indeed rings a 
warning bell for future medicinal application, it is still too early to tell whether realgar 
and orpiment are carcinogens before further evidences could prove it.  
In general, realgar and orpiment could be formulated as nanosized 
particles/nanosuspensions. Such formulations would contribute to improvement of 
bioavailability of orally administered drugs, and give opportunity for parenteral use as 
well. Nanosized realgar and orpiment effectively inhibited proliferation of some 
gynecologic cancer cell lines partially through induction of apoptosis, similar to 
arsenic trioxide. Multiple mechanisms are involved in the anticancer effects of realgar 
and orpiment as shown by the preliminary microarray study, which provides 
possibility for the combination therapy of realgar/orpiment with other therapies. 
Realgar and orpiment although are usually classified as mild-toxic compounds, both 
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1.1 Historical medicinal use of arsenical: One of the oldest drug in the world 
Arsenic is the 20th most abundant element in the earth’s crust with a natural 
abundance of 1.8 mg/kg [Frankenberger WT Jr, 2002a]. It has been estimated that 
more than 99% of total arsenic contained in the environment (such as oceans, soils, 
rocks, biota, and atmosphere) is associated with rocks and soils [Frankenberger WT Jr, 
2002b]. Arsenic-contained soils, sediments, and sludge are the major sources of 
arsenic contamination in food chain, surface water, ground water, and drinking water. 
Exposure to arsenical (arsenic-contained compound) by the general population occurs 
mainly through ingestion of arsenical existing in food and drinking water.  
The effect of arsenical on human health is an issue of global concern. The U.S. 
Environmental Protection Agency (EPA) has proposed a revision of the maximum 
contaminant level for arsenic in drinking water from 50 μg/L down to 10 μg/L 
[United States Environmental Protection Agency, 2001]. Total compliance costs for 
the regulation of 10 μg/L in USA have been estimated at $1.47 billion a year. 
However, it should be known that assessment of human health effects strictly based 
on total arsenic concentration intake is not reliable. Identification and quantification 
of individual chemical species of the element are required, because the environmental 
fate and behavior, absorption and bioavailability, toxicity and potential benefits to 
health vary dramatically with the chemical species in which arsenic exists. The 
importance of arsenic speciation will be discussed in detail in Chapter 2. The most 
often encountered arsenic forms are trivalent (3+) and pentavalent (5+) inorganic 
arsenic, and methylated organic arsenic compounds [Francesconi KA and Kuehnelt D, 
2004]. Three main inorganic arsenic forms, i.e. white arsenic (arsenic trioxide, As2O3), 
red arsenic (realgar, α-As4S4, often written as As2S2), and yellow arsenic (orpiment, 




Arsenical is viewed paradoxically as both a poison and a therapeutic agent. 
Arsenic is considered as a toxic and life-threatening element. Indeed, some arsenicals 
are well-documented carcinogens and human exposure is associated with an increased 
risk of developing tumors of the skin [Argos M et al., 2006; Rossman TG et al., 2004], 
bladder [Patton SE et al., 2002; Sternmaus C et al., 2000], liver [Chen CJ et al., 1992; 
Dopp E et al., 2005], kidney [Kurttio P et al., 1999; Hopenhayn-Rich C et al., 1998], 
or lung [Lundstrom NG et al., 2006; Boffetta P, 2006], even though the precise 
mechanisms of arsenic’s cancer-causing effects are not clearly elucidated. In 1979, 
the International Agency for Research on Cancer (IARC) introduced an overall 
classification system for carcinogens and placed arsenic and certain arsenicals in 
group 1, which is defined as agents that are carcinogenic to humans. Paradoxically, 
arsenic has never been shown to be carcinogenic in animal models [Goering PL et al., 
1999; Basu A et al., 2001]. In other words, although significant effort has been made 
in recent decades in an attempt to understand arsenic carcinogenesis using animal 
models, including rodents and larger mammals and even transgenic animals, all 
models have failed to elucidate satisfactorily the actual mechanisms of arsenic 
carcinogenicity. Despite the hazards, the potential for adverse effects should not deter 
physicians, especially clinical oncologists, from using arsenicals to treat patients with 
life-threatening diseases.  
Medicinal use of arsenicals dates back more than 2400 years to ancient Greece 
and China independently. The major historical medicinal use of arsenicals is 
described as follows. Hippocrates (460-370 BC) and Galen (130-200 AD) popularized 
arsenicals used as healing agents [Jolliffe DM, 1993]. In central and southern Asia, 
arsenic was already an ingredient of many folk remedies. Sun Simao (孙思邈, 581-




trioxide (砒霜) to treat malaria. Li Shizhen (李时珍, 1518-1593 AD) recorded the use 
of arsenic trioxide to treat a variety of diseases [Li SZ, 1593]. In Persian textbooks, 
Avicennes (980-1037 AD) wrote down the use of white arsenic to treat fevers. These 
texts, along with the writings by Paracelsus (1493-1541 AD) introduced arsenicals to 
Europe. William Withering (1741-1799), British physician, botanist and mineralogist 
who discovered digitalis, was a strong proponent of arsenic-based therapies. He 
argued, “Poisons in small doses are the best medicines; and the best medicines in too 
large doses are poisonous.” In 1786, Fowler of Stafford (1777-1843), a physician in 
England, recommended use of potassium arsenite, called Fowler’s solution, internally 
for the treatment of intermittent fever initially. Fowler’s solution gained great renown 
and was used to treat many ailments, including paralytic afflictions, rheumatism, 
hypochondriasis, epilepsy, syphilis, ulcers, cancer, and dyspepsia [Waxman S and 
Anderson KC, 2001]. In 1911, Fowler’s solution was utilized as a drug for pernicious 
anemia, asthma, psoriasis, pemphigus, and eczema. As indicated in the British 
Pharmaceutical and Therapeutic Products Handbook edited by Martindale in 1958, 
Fowler’s Solution was used in the treatment of leukemia, skin conditions (psoriasis, 
dermatitis herpetiformism and eczema), stomatitis and gingivitis in infants, and 
Vincent’s angina. It was also prescribed as a healthy tonic. Since the 18th century, 
arsenic-derived preparations began to flourish. Physicians prescribed arsenicals for 
both external and internal use throughout the 18th century worldwide. Arsenicals were 
key ingredients in antiseptics, antispasmodics, antiperiodics, caustics, cholagogues, 
hematinics, sedatives, and tonics [Waxman S and Anderson KC, 2001]. 
Approximately 60 different arsenic-contained preparations have been developed and 
distributed during the lengthy history of this agent. More than 20 of these preparations 




Andrew’s Tonic. Arsenic’s popularity peaked in 1910 when Paul Ehrlich (1854-1915), 
a German physician and founder of chemotherapy, developed an organic arsenical, 
Salvarsan (Arsphenamine), which was effective in treating tuberculosis and syphilis. 
Arsphenamine was the standard therapy for syphilis for nearly 40 years before it was 
replaced by penicillin [Kasten FH, 1996]. In fact, until the introduction and use of 
modern chemotherapy and radiation therapy in the mid 1900’s, arsenic was used as 
one of the standard remedies for chronic myeloid leukemia (CML) and other leukemia. 
As medicinal chemistry evolved, enthusiasm for arsenical waned.  
 
1.2 Arsenic trioxide (ATO): An anticancer drug  
Arsenic trioxide was revived as an anticancer agent after reports emerged from 
China of the success of an ATO-contained herbal medicine in the treatment of acute 
promyelocytic leukemia (APL). In 1971, a group from Harbin Medical University in 
China developed Ailing-1 (癌灵-1) which contained 1% ATO [Niu C et al., 1999; Zhu 
XH et al., 1999]. After studying the effects of Ailing-1 in more than 1000 patients, 
researchers found that Ailing-1 has achieved notable success in the treatment of APL 
in the clinical setting. Ailing-1 alone and in combination with other chemotherapies 
were able to induce high complete remission (CR) rates. Since 1994, clinical trials 
with pure As2O3 were performed in Shanghai Second Medical University in China 
[Shen ZX et al., 1997]. The efficacy of pure As2O3 in patients with APL who had 
undergone relapse after retinoic acid (RA) plus chemotherapy was confirmed. In 
addition, the absence of myelosuppression with ATO offers an advantage over 
conventional cytotoxic chemotherapeutic agents. Thereafter, similar outcomes were 
further achieved in clinical trials done in Japan, Europe, and the United States 




 Development of TrisenoxTM was rapid. In 2000, the U.S. Food and Drug 
Administration (FDA) approved arsenic trioxide injection (TrisenoxTM) for the 
treatment of patients with APL who have not responded to, or have relapsed following 
the use of the all trans-retinoic acid (ATRA) and anthracycline-based chemotherapies, 
which is considered first line therapy. The drug was approved for marketing only 3 
years after the study was first started in the US. TrisenoxTM was approved as an 
orphan drug, a drug intended for the treatment of rare diseases or conditions. The drug 
is now globally used to treat patients with APL who have suffered relapse from their 
primary therapy.  
 
1.2.1 Treatment of acute promyelocytic leukemia (APL) 
APL is a cancer of the blood and bone marrow, and is first recognized as a 
distinctive clinical entity in the 1950s. It is classified as a subtype of acute myeloid 
leukemia (AML), accounting for approximately 10% of AML. It was formerly 
associated with a high risk of early mortality before treatment or in the early treatment 
phase. Mean age at diagnosis is about 40 years. The male to female ratio is balanced 
[Groopman J and Ellman L, 1979].  
 APL is characterized by rapid accumulation of immature granulocytes called 
promyelocytes resulting in anemia, susceptibility to infection, bleeding, and 
hemorrhage. There are two morphological types of APL: the hypergranular form 
(AML FAB M3) and the microgranular variant (AML FAB M3v). The morphological 
diagnosis is confirmed by the APL specific translocation t(15;17). This translocation 
generates a fusion between the PML gene and the RARα gene, which encodes a 
transcription factor. The resulting PML/RARα fusion protein blocks the expression of 




involved in complex functions including growth arrest and apoptosis induction. 
Normally PML is located in the nucleus on a specific subdomain named PML nuclear 
body (NB). Expression of the PML/RARα fusion protein in leukemic cells disrupts 
the nuclear bodies, and the PML protein is dispersed into smaller fragments with loss 
of PML functions. 
 With initial therapeutic strategies which include induction with ATRA 
combined with anthracycline-based chemotherapy, followed by anthracycline-based 
consolidation and maintenance therapy, 70-80% of APL patients are alive and 
disease-free beyond 4 years [Degos L and Wang ZY, 2001]. Although the CR rate 
obtained is high, the toxicity of this approach is also high. Re-induction with ATRA 
in patients in first relapse after ATRA treatment leads to inconsistent results [Huang 
ME, 1988]. Furthermore, resistance to re-induction with ATRA is high, even in 
patients who have been off ATRA for more than one year. In addition, a deficiency of 
ATRA as a single agent is its inability to induce molecular remission in most patients, 
even in those patients with newly diagnosed disease and those who are ATRA naive. 
 More than 400 APL patients worldwide have received ATO treatment. The 
CR rates for newly diagnosed patients are 72-85% and 85-93% for relapsed APL 
patients [Zhang TD et al., 2001; Chen Z at al., 2001]. ATO is administered in the 
form of 1% solution at a dose of 0.16 mg/kg daily diluted with 5% glucose in normal 
saline given by intravenous injection over 1-4 h. Patients receiving treatment for 28-
44 days (rarely 60 days) achieve CR. Advantages of single-agent ATO are the 
consistently high CR rates in many studies and low resistance to the drug. More 
importantly, because ATO as a single agent induces molecular remission in almost all 
patients in relapse, other chemotherapy is not required, making this a less toxic 




ATO offers advantages over ATRA with anthracycline-based chemotherapy in the 
treatment of relapsed or refractory APL, and becomes a standard induction treatment 
in patients with relapsed or refractory APL [Douer D, 2006].  
The precise mechanisms of ATO action in APL are not completely elucidated 
yet. In general, a variety of in vitro studies suggest that several mechanisms may 
contribute to its effectiveness in vivo, mainly including induction of apoptosis, 
stimulation of differentiation, degradation of the specific PML/RARα fusion protein, 
and inhibition of angiogenesis [Zhu J et al., 2001; Miller WH Jr, 2002]. Numerous 
intracellular signal transduction pathways are involved.  
Furthermore, in vitro, ATO exhibits dose-dependent effects on APL cells 
[Zhang TD et al., 2001]. For example, at the higher concentrations (1.0-2.0 μM) 
apoptosis is preferentially triggered; at the lower concentrations (0.1-0.5 μM) partial 
differentiation of APL cells is induced. At both high- and low-doses, ATO promotes 
the degradation of PML/RARα fusion protein. 
It should be noted that because of its toxicity, As2O3 must be given at low 
concentrations, i.e. physiologically acceptable concentration < 5 μM; therapeutic 
index is therefore a key issue.  
ATO impacts on many cellular and physiological pathways, a wide variety of 
malignancies may be susceptible to therapy with ATO. As well, the multiple actions 
of ATO give the potential for synergy between ATO and other chemotherapeutic 
agents, thus providing enhanced benefits in cancer therapy. 
 
1.2.2 Treatment of other cancers 
 Inspired by the clinical success of ATO in APL, subsequently, intensive 




generalized response by different types of neoplastic cells would occur. Findings 
indicate that ATO is indeed active against many other cancer cells. Numerous studies 
highlight the potent cytotoxicity of ATO against a variety of hematologic 
malignancies such as chronic myelogenous leukemia (CML) [Jing HM et al., 2002], 
promonocytic leukemia [Park JW et al., 2001], T-cell leukemia [Mahieux R et al., 
2001] and multiple myeloma [Rousselot P et al., 2004]. ATO also exerts potent 
cytotoxic activity against a large variety of cancer cells of solid tumor origin such as 
neuroblastoma [Cheung WM et al., 2006], esophageal carcinoma [Shen ZY et al., 
2000], gastric cancer [Zhang TC et al., 1999], hepatocellular carcinoma [Chan JY et 
al., 2006], head and neck cancer [Huilgol NG, 2006], cervical cancer [Chun YJ et al., 
2002], prostate [Lu M et al., 2004], transitional cell cancer [Pu YS et al., 2002], 
glioblastoma [Haga N et al., 2005], renal cell carcinoma [Vuky J et al., 2002], and 
breast cancer [Chow SK et al., 2004]. For example, in a phase II trial in hormone-
refractory prostate cancer, treatment with ATO (0.2 mg/kg/d for two contiguous 5-day 
periods on a 28-day cycle or one cycle followed by twice a week thereafter) resulted 
in marked decreases in prostate-specific antigen levels in two of 15 assessable patients, 
and slowed the increase in prostate-specific antigen levels in another 12 patients [Lu 
M et al., 2004].  
 Mechanisms of action of ATO in cells without the PML/RARα fusion protein 
are summarized as below: 
 Inhibition of signal transduction and angiogenesis [Anderson KC et al., 2002] 
 Induction of oxidative stress, hydrogen peroxide, reactive oxygen species 
(ROS) and depletion of glutathione [Park MJ et al., 2005] 
 Induction of apoptosis through depolarization of mitochondrial membrane, 




 Engaging in the extrinsic pathway by up-regulation of surface expression of 
TRAIL and TRAIL receptors and activation of BID in cells expressing mutant 
p53 [Akay C et al., 2004]  
 Induction of the release of mitochondrial AIF to the cytosol, translocation of 




 The low therapeutic dose of ATO (about 0.15 mg/kg/d) used to treat APL is 
associated with a tolerable toxicity level without bone marrow hypoplasia or drug-
induced alopecia [Wang ZY, 2001]. The common non-life-threatening adverse events 
reported include nausea, rash, fatigue, neuropathy, fever, headache, vomiting, diarrhea, 
tachycardia, and hypokalemia [Zhang P, 1999]. The most prominent adverse events 
are weight gain and fluid retention, leukocytosis, APL differentiation syndrome, and 
prolongation of QT interval on the electrocardiogram [Wang ZY, 2001]. Sudden 
death has also been reported. Overall, ATO is quite well tolerated, and toxicities are 
manageable and reversible. In the treatment of APL, adverse events are less common 
during consolidation and maintenance cycles. Generally, most adverse events do not 
require discontinuation of treatment. 
 A drawback of ATO treatment is that it must be administered intravenously 
daily as an infusion over 1 to 4 hours since it causes severe liver damage if given 
orally, which makes the consolidation and maintenance therapy difficult [Lu DP et al., 
2002]. Thus, an oral agent with similar therapeutic effects and fewer side effects 
would provide not only cost and quality-of-life benefits but also easy access to 




opportunity for further combination with other agents of interest. Realgar and 
orpiment could be such candidates. Both realgar and orpiment are considered as non- 
or less-toxic compounds [Lu DP et al., 2002]. 
 
1.3 Realgar 
 The first mention of arsenicals was made by Hippocrates, who used realgar 
and orpiment pastes to treat ulcers. Realgar is commonly used in traditional Chinese 
medicine (TCM) and available as pills, tablets, and other preparations. According to 
Chinese Pharmacopoeia (2000 edition), realgar-contained formulations (23) account 
for 5.67% of total TCM formulations. They are used for psoriasis, syphilis, asthma, 
rheumatism, haemorrhoids, cough, and pruritus, and are also prescribed as a health 
tonic, analgesic, anti-inflammatory agent, and as a treatment for some malignant 
tumors [Pan B et al., 2004].  
Prompted by the success of ATO in the treatment of leukemia, along with 
medicinal application background of realgar, researchers turn their attentions to 
realgar. Huang SL et al first developed Chinese medicine Composite Indigo Naturalis 
tablets ( 复 方 青 黛 片 ) containing realgar, baphicanthus cusia, radix salviae 
mithiorrhyzae, radix pseudosatellariae, and pulverata levis to treat APL, achieving 
high CR rates [Huang SL et al., 1995]. Composite Indigo Naturalis is given orally at a 
dose of five tablets (0.25 g/tablet), three times daily. After one week, the daily dose is 
increased to 30 tablets. CR is achieved within 30-60 days in 60 APL patients enrolled 
including 43 newly diagnosed and 17 relapsed patients. Clinical trials of pure As2S2 
alone in the treatment of APL patients have been conducted in China since 1990s. Lu 
DP et al have published the outcomes of realgar in the treatment of APL [Lu DP et al., 




with APL were enrolled between December 1994 and December 2000. 19 of the 
patients had newly diagnosed APL, 7 had first relapse, and 103 had hematologic 
complete remission (HCR). HCR was achieved in all patients with newly diagnosed 
APL and in all those with hematologic relapse. In that study, chemically pure realgar 
(As2S2) was used together with an equal amount of ground Seman Platycladi as an 
excipient to make capsule containing 250 mg realgar. Realgar was orally administered 
at a dosage of 50 mg/kg of body weight per day, divided into 4 doses until HCR was 
achieved. For patients with HCR, the same daily dose was given on a treatment 
schedule of 2 weeks on and 2 weeks off in the first year. Thereafter, the treatment 
break was increased to one month within 4 years. Therapy was discontinued in the 
fifth year. Highly effective and safe for both remission induction and maintenance in 
all stages of APL have been observed. Table 1 and Table 2 outline the major results in 
newly diagnosed and relapsed APL patients after treatment with realgar, respectively.  
 
Table 1. Results in patients with newly diagnosed APL after treating with As2S2. 
Patient no./age 
(year)/gender Days to HCR 
Total As2S2 dose (g) till 
HCR 
Case 1/32/M 38 37.50 
Case 2/34/F 40 37.75 
Case 3/48/M 90 145.75 
Case 4/21/F 35 60.50 
Case 5/29/F 51 98.00 
Case 6/16/M 46 105.75 
Case 7/29/F 38 110.25 
Case 8/37/M 69 89.75 
Case 9/41/M 53 141.75 
Case 10/20/F 50 94.50 
Case 11/35/M 55 135.00 
Case 12/43/F 50 150.00 
Case 13/22/M 75 97.50 




Case 15/42/M 101 312.50 
Case 16/29/F 76 221.25 
Case 17/32/M 57 193.50 
Case 18/26/M 28 105.00 
Case 19/41/M 33 138.75 




In the newly diagnosed patient group, the estimated leukemia-free survival 
(LFS) for 1 and 3 years were 86.1% and 76.6%, respectively, with a median follow-up 
time of 13.5 months. . 
 
Table 2. Results in patients with relapsed APL after treatment of As2S2. 
Patient no./age 
(year)/gender Days to HCR 
Total As2S2 dose (g) till 
HCR 
Case 1/38/F 42 15.7 
Case 2/58/F 80 26.2 
Case 3/43/M 32 15.7 
Case 4/54/F 42 50.5 
Case 5/36/F 55 277.0 
Case 6/30/F 34 226.0 
Case 7/48/F 71 418.7 
Modified from Lu DP et al., 2002. 
 
 Cytogenetic and molecular CRs were achieved in five of the 7 relapsed 
patients. 
In addition, in the HCR group, thirty five out of 44 patients with PML/RARα 
positive were rendered to negative. The calculated LFS for 1 and 3 years was 96.7% 
and 87.4%, respectively, with a median follow-up time of 23 months. 
 Even though the promising clinical efficacy of realgar in the treatment of APL 




stage. In this introduction, major representative studies related to realgar are 
summarized in Table 3, which are retrieved from the search engine PubMed.    
 
Table 3. Results of in vitro and/or in vivo studies related to realgar. 
Research group Cell type Findings 
Chen SY et al., Center of 























Deng Y et al., Department of 
Chemistry, Huazhong 





Ye HQ et al., College of Life 
Science and Technology, 
Huazhong University of 





Li JE et al., Shanghai 
Institute of Hematology, 
Rujin Hospital, Shanghai 
Second Medical University, 
PRC 
 
ATRA resistant APL cell 
line: MR2 [Chen SY et al., 
2002] 
 
Myeloid leukemia cell line: 




Myeloid leukemia cell line: 







NB4 and MR2 [Zhao XA and 






Human umbilical vein 
endothelial cell line: ECV-





Myeloid leukemia cell line: 







Myeloid leukemia cell line: 
K562 
Fresh CML nomonuclear 
cells derived from CML 
patients [Li JE et al., 2002] 
 
Inhibition of growth and 
induction of apoptosis. 
 
 
Gene expression profile 
changed by realgar treatment: 
9 up-regulated and 37 down-
regulated. 
 
Gene expression changed 
after realgar treatment 
including 17 up-regulated 
(such as CCL2, CCL3, 
BTG1, TNFAIP3, TNFAIP8, 
SLC38A2, IGFBP4) and 3 
down-regulated genes.  
 
Realgar could down regulate 
the membrane PCA, TF 
antigen and TF mRNA 
transcription of both cell 
lines in a time-dependent 
manner. 
 
Reduction of cell viability in 
response to treatment with 
realgar suspension with 
particle size of 100 and 150 
nm and induction of 
apoptosis. 
 
Inhibition of cell growth and 
induction of apoptosis. 
Realgar treatment especially 
with nanosize grade 
accelerated membrane lipid 
peroxidation and LDH 
leakage. 
 
Inhibition of proliferation 
and induction of apoptosis in 
both cell lines. The decline of 
the Bcr-Abl protein and its 
PTK activity may contribute 
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Xiao YF et al., Department 
of Pediatrics, The Second 




Zhang C et al., TCM 
Hematology Institute of 
People’s Liberation Army, 
PRC 
 
Zhang J et al., Department of 
Biochemistry and Molecular 
Biology, Fourth Military 




Wu JZ et al., Department of 
Pharmacy, National 
University of Singapore, 
Singapore 
 






HL-60 and lymphocytic cell 





T lymphocytic leukemia cell 











Human ovarian cell line: 
CI80-13S, OVCAR, 
OVCAR-3; Human cervical 
cell line: HeLa [Wu JZ and 
Ho PC, 2006] 
 
Inhibition of viability and 
induction of monocytic 
differentiation involving 
some serine/threonine protein 
phosphatases.  
 
Survivin expression level 
decreased in both cell line 
during apoptosis induced by 
realgar probably through 
mitochondrial pathway. 
 
Inhibition of cell viability 




K562 cells were much less 
sensitive than NB4 cells to 
apoptosis induced by realgar, 
which probably due to high 
expression of bcl-x(L) in 
K562 cells. 
 
Inhibition of growth and 




Observations of the clinical utility of realgar in the treatment of APL have 
triggered investigations into the mechanisms of action by which realgar produces 
clinical benefits. Considerable preclinical evidences support the potential effects of 
realgar against a number of different malignancies. Studies in cultured cells showed 
that realgar inhibits growth and promotes apoptosis in myeloid leukemia, multiple 
myeloma, lymphocytic leukemia, and certain solid tumor cells, as shown in Table 3. 
 
1.4 Orpiment 
 Nowadays, medicinal use of orpiment still mainly stays as folk remedy in 




the promising outcomes of ATO and realgar in the treatment of leukemia and low 
toxicity of orpiment compared to ATO, and turned to orpiment, exploring its potential 
therapeutic effects for the treatment of cancer. Lu DP et al treated a single patient with 
newly diagnosed APL with pure orpiment (As2S3), and found that this patient entered 
HCR in 38 days and molecular CR in 128 days [Lu DP and Wang Q, 2002]. Table 4 
summarizes the main investigational results related to orpiment obtained so far, which 
are retrieved from the PubMed. Similar to realgar, orpiment was also found to have 
anti-leukemic effect.  
 
Table 4. Results of in vitro studies related to orpiment. 
Research group Cell type Findings 
Zhong L et al., Department 
of Leukemia Research, 
Shanghai Institute of 






Hao HY et al., Institute of 
Hematology, People’s 
Hospital, Peking University, 
PRC 
NB4 and HL-60 [Zhong L et 








NB4 [Hao HY et al., 2002] 
Inhibition of proliferation 
and induction of apoptosis. In 
detail, the fusion protein was 
no longer observed in NB4 
cells, PML protein was 
degraded. In HL-60 cells, 
PML protein underwent a 
similar progress. 
 
Induction of apoptosis 
through degradation of PRM-




1.5 Formulations to overcome absorption and bioavailability problems due to 
poor water-solubility  
Both realgar and orpiment are crystals with high native lattice energy, which 
reduces the tendency of the crystals to dissolve in most surrounding aqueous or 
organic media. Water-insolubility of realgar and orpiment is a crucial obstacle for 
their investigation, development, and final commercialization.  




Thus, they are frequently abandoned in the early drug development stage [Prentis RA 
et al., 1998]. When these compounds are formulated using conventional approaches, 
their performance in preclinical screens is often erratic and highly variable. In clinics, 
the conventional formulations of poorly water-soluble drugs are frequently plagued 
with problems such as poor and weird absorption and bioavailability. In addition, the 
conventional approach is to achieve the solution state of drugs, which is especially 
difficult to attain for realgar and orpiment which are insoluble in both water and oils. 
In the last few years, a novel drug delivery approach for poorly water-soluble 
compounds has come to light. In this approach, poorly water-soluble compounds are 
formulated as nanometer-sized drug particles.  
 
1.5.1 Nanonisation 
Nanotechnology has a long history. The development of a wide spectrum of 
nanoscale technologies is beginning to change the foundations of disease diagnosis, 
treatment, and prevention. In the pharmaceutical field, the term “nanoparticle” has 
been rather loosely applied to structures less than 1 μm in diameter [Kipp JP, 2004]. 
They can be produced by either chemical or mechanical means, and characterized by 
conventional analytical methods such as microscopy or light scattering. 
In pharmacology, bioavailability is one of the principal pharmacokinetic (PK) 
properties of drug. It is defined as the extent of a therapeutically active drug that 
reaches the systemic circulation and is available at the site of action. Drugs are 
commonly administered orally or parenterally by injection. Bioavailability of most 
orally administered drugs is less than 100%. For orally administered drugs, there are 
three major factors that could limit their bioavailability: (1) poor absorption from the 




hepatic first pass effect. In terms of oral absorption from the GI tract, the rate of 
dissolution is a crucial consideration. The theoretical basis of the dissolution velocity 
was established by Arthur Amos Noyes and Willis Rodney Whitney in 1897, as 
described by the Noyes-Whitney equation below: 
dc/dt = DA(cs-ct)/h 
where: dc/dt is the dissolution velocity (rate of dissolution) 
D is the diffusion coefficient 
A is the surface area of the drug 
cs is the saturation solubility 
ct is the bulk concentration of the drug in the surrounding liquid 
h is the diffusion distance above the drug particle surface 
In general, drugs possessing poor solubility (cs) exhibit a very low dissolution 
velocity. The dissolution velocity dc/dt is also a function of the surface area. 
According to this equation, there are two basic approaches to improve oral drug 
absorption: 
1. Increasing dc/dt by enlarging the drug particle surface;  
2. Increasing the saturation solubility, cs, of the drug 
This is a very simple traditional approach to increase the dissolution velocity 
by enlarging the surface, i.e. micronisation. The particle size of normally sized drug 
powders (approximately in the range of 20-100 μm) could be reduced to a size in a 
range of approximately 1-10 μm. However, many agents exhibit such a low solubility 
that the increase in surface area micronisation is not enough to achieve a sufficiently 
high dissolution velocity leading to therapeutic blood levels. Therefore, the next 
consequent step was taken, going from micronisation to nanonisation. Drug 




yield a mean diameter somewhere between 200 and 400 nm. Nanonisation has an 
additional effect compared to micronisation, it increases not only the surface area, but 
also simultaneously increases the saturation solubility cs. The solubility of normally 
sized powder is a compound specific constant, depending only on the temperature and 
the solvent. This changes when the particle size goes below a size of approximately 1 
μm. The dissolution pressure increases due to the strong curvature of the particles 
resulting in an increase in cs, based on the theoretical background provided by the 
Ostwald-Freundlich equation [Mosharraf MN, 1995] and the Kelvin equation 
[Simonelli AP et al., 1970]. According to Noyes-Whitney equation, this leads to a 
further increase in dc/dt in addition to the gain by an increased surface area. Therefore, 
nanosizing drug particles is a smart way to improve drug dissolution and 
bioavailability based on a universal principle that can be applied to any drug. The 
increase in the saturation solubility leads to the formation of a supersaturated solution 
compared to the solubility of normally sized powders.  
Enhancement of oral bioavailability by using drug nanoparticles has been 
reported, e.g., the gonadotropin inhibitor danazol administered as commercial 
dispersion (microsuspension) had a relative bioavailability of 5.1%, whilst as a 
nanosuspension had an increased bioavailability to 82.3% [Liversidge GG and Cundy 
KC, 1995]. 
Besides oral administration, drug nanoparticles can also be injected 
intravenously as an aqueous dispersion. Dispersion of nanoparticles generally consists 
of water, drug, and stabilizer. In the absence of an appropriate stabilizer, the high 
surface energy of nanometer-sized particles would tend to agglomerate and/or 
aggregate. To be effective, the stabilizer must be capable of wetting the surface of the 




of stabilizer are important to promote the particle size reduction process and generate 
physically stable formulations. Acceptable stabilizers for intravenous (i.v.) injection 
mainly include lecithin, Tween 80, Poloxamer 188, sodium glycocholate and low 
molecular weight polyvinylpyrrolidone (PVP) [Muller RH and Keck CM, 2004]. 
Stabilization of these formulations is often achieved using a combination of a non-
ionic plus ionic stabilizer. Theoretically, using the nanoparticle technology, any drug 
can be made 100% bioavailability.   
Furthermore, it has been reported that, in vivo, nanoparticles are surprisingly 
well tolerated [de Garavilla L et al., 1996].  
 
1.5.2 Methods for preparing solid drug nanoparticles 
Complete solubilization of a drug with very low intrinsic solubility may be 
very difficult or untenable. Very low water-solubility affects the quantities of 
cosolvents or surfactants necessary for complete dissolution; the ability to form 
inclusion complexes with cyclodextrins is also limited for those compounds having 
very low intrinsic solubility; very low drug water-solubility also hamper preparation 
of an emulsion. Currently, there are a limited number of formulation approaches 
available for compounds which are poorly water-soluble. The most direct approach 
for enhancing solubility is to generate a salt. If, however, the compound is non-
ionizable, solubility could be achieved by micronisation/nanonisation. Two 
commonly used preparation methods are described as follows: 
 Precipitation 
Precipitation has been applied for many years in the preparation of small 
particles, and within the last decade in the preparation of submicron particles for drug 




the drug is first dissolved in a solvent, and this solution is mixed with a miscible 
antisolvent. Simple precipitation methods, however, have numerous drawbacks. It is 
very difficult to control nucleation and crystal growth to obtain a narrow size 
distribution. Often a metastable solid, usually amorphous, is formed which is 
converted to more stable crystalline forms. Once nucleation occurs, crystal growth is 
spontaneous and difficult to control. Furthermore, non-aqueous solvents utilized in the 
precipitation process must be reduced to toxicologically acceptable levels in the end 
product.  
 Homogenization 
A simple process of particle diminution by high-pressure homogenization was 
developed at the beginning of 1990s [Keck CM and Muller RH, 2006; Krause KP and 
Muller RH, 2001]. When a suspension is homogenized, fluid shear, particle collision 
and cavitation are critical high-energy parameters. Microfluidization and piston-gap 
homogenization have been applied with success. In some cases, micronisation of the 
raw material was required before homogenization in order to obtain the desired final 
particle sizes. Jet milling or ball milling has been used for that purpose. In the liquid 
state, the dispersions are very stable, especially if the solubility of the drug is less than 
1 mg/ml. Dispersions of nanoparticles can be post-processed as a dry powder for solid 
dosage development or lyophilized for injectable products. These dried powders are 
designed to re-disperse into nanometer-sized particles when placed in water or an 
alternate water-based environment.  
 
1.6 Toxicity: Carcinogenicity 
 Chronic arsenic poisoning has been found in patients treated for long period 




cancer therapy is prolonged, therefore, special concerns should be paid about the 
arsenical-induced toxicity. Arsenic is a well-established human carcinogen based on 
epidemiological studies [Boffetta P, 2004], though the mechanisms of carcinogenicity 
remain unclear. The lack of suitable animal models as well as poor understanding of 
its carcinogenic/genotoxic mechanisms hampers accurate risk assessment of the 
health effects of arsenic. 
Several lines of evidence with cultured cells and experimental animals have 
indicated that arsenicals are capable of generating reactive oxygen species (ROS), 
especially superoxide and hydrogen peroxide, resulting in oxidative stress [Shi H et 
al., 2004; Harris GK and Shi X, 2003]. However, the underlying mechanisms for ROS 
regulation have not yet been fully identified. Recently, it has been proposed that 
arsenic may induce the formation of ROS through: (1) the ubiquinone site of the 
respiratory chain [Corsini E et al., 1999], (2) a decrease in cellular mitochondrial 
membrane potential [Woo SH et al., 2002], (3) alteration of glutathione (GSH) 
concentration [Dai J et al., 1999], (4) activation of NADH oxidase [Lynn S et al., 
2000], and (5) the oxidation of arsenite to arsenate [Del Razo LM et al., 2001]. 
Arsenic-induced ROS has been demonstrated to cause DNA damage [Dong JT and 
Luo XM, 1993], lipid peroxidation [Lin TH et al., 1995], and protein modification 
[Dong JT and Luo XM, 1993], as well as alteration of antioxidant defenses [Lee TC 
and Ho IC, 1995].  
 However, it is not reported so far whether arsenic trioxide, realgar and 
orpiment could cause oxidative stress. Thus it is worth to investigate possible 
carcinogenicity of these compounds to provide valuable references to the field of 





1.6.1 ROS and oxidative stress 
ROS is a collective term often used by biologists for the intermediates formed 
during oxidative metabolism, including both oxygen radicals and non-radical reactive 
derivatives. Mitochondria (oxidative phosphorylation), leukocytes (oxidative burst), 
peroxisomes (degradation of fatty acids), and cytochrome P450 system (mixed 
function oxidation system) can all release ROS [Wu LL et al., 2004]. ROS includes 
superoxide [O2·-], hydroxyl [OH·], peroxyl [RO2·], alkoxyl [RO·]), and certain other 
nonradicals that are either potential oxidizing agents and/or are easily converted into 
radicals, such as hypochlorous acid (HOCl), ozone (O3), peroxynitrite (ONOO-), 
singlet oxygen (¹O2), and hydrogen peroxide (H2O2) [Wiseman H et al., 1995]. 
Reactive nitrogen species (RNS) is a term becoming popular and encompasses 
nitrogen dioxide radical (NO2·), peroxynitrite, nitrous acid (HNO2), and related 
species [Wiseman H et al., 1995]. 
Cells can normally adapt to low physiological concentration of ROS/RNS with 
an elaborate antioxidant defense system consisting of enzymes such as catalase, 
superoxide dismutase, glutathione peroxidase, and numerous non-enzymatic 
antioxidants including vitamins A, E and C, glutathione, ubiquinone, and flavonoids 
[Urso ML and Clarkson PM, 2003]. In other words, under normal physiological 
conditions, there is a balance maintained between endogenous oxidants and 
antioxidants. When an imbalance occurs, created by the excessive generation of 
oxidants or a decrease of antioxidants, the abnormal oxidant system then enters what 
is called oxidative stress. In the presence of oxidative stress, ROS/RNS generated in 
vivo can cause oxidative damage to lipids, proteins and nucleic acids [Lunec J et al., 
1994]. Oxidative stress has been linked to neurological disorders, atherosclerosis, 





1.6.2 Oxidative DNA damage and repair products of 8-hydroxy-2’-
deoxyguanosine and 8-hydroxy-2’-deoxyadenosine 
DNA is probably the most biologically significant target of oxidative attack, 
and it is widely thought that continuous oxidative damage of DNA is a significant 
contributor to the age-related development of some cancers, such as those of the colon, 
breast, rectum, and prostate [Cooke MS et al., 2003]. Damage to DNA by reactive 
oxygen, chlorine, and nitrogen species generates a multiplicity of different base 
oxidation and other base modification products, which are repaired by a complex 
system of enzymes. It should also be noted that DNA oxidative damage can also 
occur from exogenous ROS, such as cigarette smoking, UV radiation, and ionizing 
radiation.  
Guanine and guanosine most readily undergo oxidation for possessing the 
lowest oxidation potential of the four purine nucleobases and nucleosides [Kasai H, 
1997]. The presence of the modified nucleobase, 8-hydroxyguanine (8-OH-Gua), and 
nucleoside 8-OH-dGuo during DNA replication can cause G:C-T:A transversion 
mutations [Cheng KC et al., 1992]. Therefore, oxidative lesions not repaired before 
replication can become mutagenic.  
Direct measurement of reactive species and free radicals is impractical 
because they are short-lived, due to their highly reactive nature. Thus, biomarkers 
have been used to reflect the degree of oxidative damage. Various markers of 
oxidative damage have been identified. In the past, the most popular markers were 
designed for lipid peroxidation, such as malondialdehye (MDA), oxidized low-density 
lipoprotein (LDL), MDA-modified LDL, auto-antibodies against oxidized LDL and 




detection of a new carbonyl group, dityrosine and oxidized histidine has been 
measured to indicate protein oxidation [Wu LL et al., 2004]. 
Markers for DNA oxidation were few. The repair product, such as 8-hydroxy-
2’-deoxyguanosine (8-OH-dGuo), is poor substrate for the enzymes involved in 
nucleotide synthesis, fairly water-soluble, and generally excreted into the urine 
without further metabolism [Cooke MS et al., 2003]. Indeed, animal experiments have 
shown that injected 8-OH-dGuo is readily excreted unchanged into the urine, whereas 
8-OH-dGuo in the diet or oxidation of dGuo during excretion does not contribute.  
Consequently, the oxidized nucleoside, urinary 8-OH-dGuo, is the most often studied 
biomarker of oxidative DNA damage. The formation of 8-OH-dGuo was first reported 
in 1984 by Kasai and Nishimura [Kasai H and Nishimura S, 1984]. Detection of DNA 
oxidative adducts represents the dynamic equilibrium between DNA damage and their 
repair and also may provide an opportunity to evaluate the carcinogenesis potential. 
Therefore analysis of 8-OH-dGuo as a repair product in urine reflects the amount of 
total body oxidative DNA damage. Figure 1 summarizes the pathway of commonly 
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Figure 1. Pathway of commonly measured biomarkers of oxidative stress. 
 
 
When deoxy-adenosine was oxidized by Fenton-type reagents, 8-hydroxy-
deoxyadenosine (8-OH-dAdo) was detected as the major product [Jaruga P et al., 
2001]. The yield of 8-OH-dAdo was comparable to that of 8-OH-dGuo. The presence 
of 8-OH-dAdo in vivo can cause GC-AT transition mutations are expected to occur in 
mammalian cells [Jaruga P et al., 2001].  
 
1.7 Hypotheses and objectives of the thesis 
In order to comprehend the activity and toxicity of arsenic, it is essential to 
understand its chemistry. Arsenic (atomic number 33, atomic weight 75) is a 
transitional element or metalloid under the nitrogen group in the Periodic Table. It can 
exist in four different valency states, including elemental (zero oxidation), divalent 
(AsII), trivalent (AsIII), and pentavalent (AsV). Arsenic forms alloys with metals and 




Trivalent arsenics are more toxic than the pentavalent ones [Duker AA et al., 2005]. 
The activity and toxicity of an arsenical could also vary with the physical state of the 
compound, and the rate of absorption and elimination. Therefore, we hypothesize that 
the differences among arsenic trioxide and realgar and orpiment in the activity and the 
mechanisms of action and basis of toxicity could be due to the difference in the 
valency states of these compounds. The difference in the rate of absorption of arsenic 
trioxide, realgar and orpiment could lead to different metabolism profiles that would 
have profound impact on the toxicity.  
For this study, we focus on four objectives: 
1. To confirm conversion of arsenic sulfides to trivalent and pentavalent arsenic 
compounds through alkalinization, a usual step employed to solubilize arsenic 
trioxide. 
2. To develop arsenic sulfides nanoparticles (based on the finding from Step 1) 
for the subsequent biopharmaceutical studies. 
3.  To compare the mechanisms of action of arsenic trioxide, realgar and orpiment 
based on the preliminary microarray study. 
4. To establish a reliable high performance liquid chromatography coupled with 
tandem mass spectrometry (LC/MS/MS) method for detection of an oxidative 
DNA damage biomarker induced by the respective arsenic compounds and to 
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2.1.1 Importance of arsenic speciation 
Arsenic compounds are ubiquitous in nature. The most commonly encountered 
arsenic forms are 3+ and 5+ valent states, including inorganic arsenite (iAsIII) and 
arsenate (iAsV) as well as organic methylated species consisting of 
monomethylarsenic acid (MMAV) and dimethylarsenic acid (DMAV). Exposure to 
arsenic compounds by the general population occurs mainly through ingestion of 
arsenic existing in drinking water and food. In freshwater systems, iAsIII and iAsV are 
major arsenic species, while minor amounts of MMAV and DMAV also exist 
[Frankenberger WT Jr, 2002c]. There is little information on the nature of arsenic 
species in human diet, except seafood. Most dietary arsenic originates from fish, 
shellfish, and seaweed products, where the major arsenic species found is nontoxic 
arsenobetaine (AB) [Frankenberger WT Jr, 2002d]. Ingested arsenic compounds can 
be readily absorbed through gastrointestinal (GI) tract into the blood stream [Le XC et 
al., 1994; Vahter M, 2002]. The reported urinary arsenic concentrations (mean ± 
standard deviation) from the general population are 9 ± 7 μg/L in America [Kalman 
DA et al., 1990], 17 ± 11 μg/L in Europe [Foa V et al., 1984], and 121 ± 101 μg/L in 
Japan [Yamauchi H et al., 1989]. It should be mentioned that the rate of absorption 
(absorbability) is dependent on the solubility and the chemical species of arsenic.  
Most of the inorganic arsenic species are metabolized in humans and many 
mammalians to methylated arsenic species including MMAV and DMAV, which are 
more readily excreted into the urine than the inorganic arsenic species [Le XC et al., 
1994]. Methylation of arsenical involves a stepwise process of two electron reduction 
of the pentavalent arsenic species to the trivalent arsenic species, followed by 




Scheme 1 [Benramdane L et al., 1999]. Glutathione, cysteine, and dithiothreitol act as 






Scheme 1. Pathway of the biomethylation of inorganic arsenic species. 
 
Association between acute and chronic exposures of humans to the arsenic 
compounds and various forms of cancers and other health problems has been well 
documented [Chen CJ et al., 1992], whereas the therapeutic actions of arsenic species 
have also been reported [Wang ZY, 2001; Niu C et al., 1999]. Conclusively, it is well 
established that the arsenicals present a paradox because they could act as both 
potential carcinogens and beneficial therapeutic agents mainly depending on their 
valent states and chemical forms. Therefore, arsenic speciation is of extensive 














































2.1.2 Analytical methods for arsenic speciation 
In many studies, high performance liquid chromatography (HPLC) was used 
for separating arsenic compounds, and a variety of detectors including hydride 
generation atomic absorption/fluorescence spectrometry (HG-AAS/AFS) [Tseng WC 
et al., 2002; Ma M and Le XC, 1998], inductively coupled plasma-atomic emission 
spectrometry (ICP-AES) [Do B et al., 2000], and the more sensitive ICP mass 
spectrometry (ICP-MS) [Yoshida K et al., 2003; McSheehy S et al., 2002] were used 
for their detection. However, the separation efficiency of HPLC is relatively low 
particularly for analysis of inorganic arsenic compounds with low molecular weights 
[Huang YM and Whang CW, 1998; Sun B et al., 2002]. In contrast, capillary 
electrophoresis (CE) was found to be an efficient alternative to simultaneously 
separate and determine arsenic species owing to its very high efficiency, ease of 
operation, low cost, and universal availability compared to the HPLC method [Huang 
YM and Whang CW, 1998; Sun B et al., 2002]. 
From a historical perspective, CE appears to have arrived on analytical scene 
rather late. It was not introduced until early 1980s by Jorgenson and Lukacs 
[Jorgenson JW and Jukacs KD, 1981; 1983]. By the end of 1980s, the CE literature 
was expanding exponentially and three manufactures had introduced CE systems. To 
date, different modes of CE have been developed mainly consisting of capillary zone 
electrophoresis (CZE), micellar electrokinetic capillary chromatography (MECC), 
capillary isoelectric focusing (CIEF), capillary isotachophoresis (CITP), and capillary 
gel electrophoresis (CGE). Amongst, CZE is not only the simplest form of CE but 
also the most commonly used.  
Simply speaking, the separation principle of CE is based on differences in 




The basic instrumentation involves a high-voltage power supply (0 to 60 kV), a 
capillary with an internal diameter ≤ 200 μm, two buffer reservoirs that can 
accommodate the capillary and the electrodes connected to the power supply, and a 













Figure 1. General schematic picture of a CE instrument. 
 
 In almost all instances, a detection technique is selected based on physical and 
chemical properties of the analyte and the requirements of the application being 
addressed. For example, the analyst uses UV absorbance for molecules that are highly 
absorbing UV. However, it is possible to indirectly detect analytes that lack desired 
physical and chemical properties. By incorporating a detectable molecule in the 
separation medium and monitoring the effect that the analyte has on the signal 




analyte. Indirect detection has been applied to CE for UV absorbance [Foret F et al., 
1990], fluorescence [Kuhr WG and Yeung ES, 1988], and electrochemical detection 
[Olefirowicz TM and Ewing AG, 1990].  
 
2.1.3 Objectives of this study 
Initially, we intended to establish a highly efficient capillary zone 
electrophoresis (CZE) method with indirect UV detection to separate the most 
commonly encountered inorganic and methylated arsenic compounds, that is, iAsIII, 
iAsV, MMAV, and DMAV. The unique advantages of CZE method probably make it a 
routine analytical method for practical applications. Thereafter by using the well 
developed CZE method, the solution type of realgar and orpiment prepared would be 
analyzed.  
Realgar (As2S2) and orpiment (As2S3) are minerals abundantly distributed in 
the earth's crust. The medicinal use of realgar and orpiment has been traced back 
thousands of years. Recently, the anticancer effects of realgar and orpiment 
particularly on leukemia have become the focus of research interests [Lu DP and 
Wang Q, 2002; Wang HY and Liu SX, 2002; Zhong L et al., 2003], partially 
prompted by the huge success of arsenic trioxide in the treatment of APL. Although 
their clinical efficacy especially on the treatment of CML and APL is evident, it is 
relatively unclear whether the effectiveness is due to the sulfides or the oxides formed 
from the parent compounds. The major difficulty limiting research in these areas is 
the lack of specific and sensitive analytical methods.  
Realgar and orpiment are both water insoluble. Therefore, traditional usage 
formulations are external paste and internal suspension. It is believed that when these 




intestinal fluids (pH 7-8) before absorption. The alkali extracts of realgar and 
orpiment have been analyzed by using ion chromatography (IC) with HG-AAS 
detector [He B et al., 2000]. The findings indicated that main components in the alkali 
extract of realgar were iAsIII and more iAsV, and those in the alkali extract of orpiment 
were iAsIII, iAsV and DMAV with varying proportions [He B et al., 2000] instead of 
intact realgar or orpiment. It should be mentioned that realgar and orpiment used in 
that study were not pure and contained impurities, such as different types of iAsIII, 
arsenic trioxide and other trace elements.  
In some practical applications, in order to improve their water solubility, 
researchers dissolved reaglar and orpiment in alkali solutions respectively to generate 
corresponding solutions [Zhong L et al., 2001]. However, the exact components in 
such alkali extractions were not identified. Therefore, in this study, the CZE method 
was chosen to identify the exact components in the alkali extracts of realgar and 
orpiment. In addition, to avoid interference of impurities to the analysis, in our study, 
As2S2 and As2S3 with high purity of above 98% were used.  
 
2.2 Materials and methods 
2.2.1 Materials 
Potassium arsenate (KH2AsO4, iAsV), dimethyl arsenic acid ((CH3)2AsO(OH), 
DMAV), arsenic trioxide (As2O3) were purchased from Sigma Chemical Co. (St. 
Louis, MO, USA). Sodium monomethyl arsonate (CH4AsNaO3⋅3/2H2O, MMAV) was 
purchased from Chem Service Inc. (West Chester, PENN, USA). Sodium hydroxide 
and hydrochloric acid (fuming 37% extra pure) were purchased from Merck KGaA 
Co. (Darmstadt, Ger). The aqueous stock solutions of iAsV, MMAV and DMAV each 




dissolution in Milli-Q water. Sodium arsenite (iAsIII) stock solution (1000 ± 5 ppm as 
molecule of NaH2AsO3) was made by first dissolving 6.69 mg As2O3 in 10 ml 0.1 M 
NaOH and then being neutralized with concentrated HCl to pH 7.0 ± 0.2 measured by 
a pH meter (ION Check 10) from Radiometer Analytical SAS (Lyon, Fr). The 
accurate arsenic concentrations of all stock solutions were further measured by 
inductively coupled plasma-optical emission spectrometry (ICP-OES, Thermo Jarrell 
Ash, IRIS/AP, Ger). Before storage, all stock solutions were filtered through a 0.2 μm 
nylon filter membrane and degassed in ultrasonic bath for 15 min. The molecular 
structures and pKa values of the arsenical analytes are shown in Table 1.  
 
Table 1. Arsenic compounds of interest. 




































 Pyridine 2,6-dicarboxylic acid (PDC) (≥98% in purity) was purchased from 
Fluka Chemicals (Buchs, Switzerland). n-Hexadecyltrimethylammonium hydroxide 





Realgar (As2S2, 98% in purity) and orpiment (As2S3, 99.9% in purity) were 
purchased from Sigma Chemical Co. (St. Louis, MO, USA). The alkali extracts was 
prepared by ultrasonically extracting the respective compounds in 0.1 M NaOH for 30 
min at an amount of 2 mg compound per 1 ml solution, and then being filtered 
through a 0.2 μm nylon filter membrane. The arsenic concentrations in the obtained 
alkali extracts were measured by ICP-OES, being 998 and 1338 ppm as As, 
respectively. All stock solutions were stored at 4 oC in dark.  
 
2.2.2 CZE separation 
2.2.2.1 Instruments 
All CZE separations were performed on a CE-L1 Capillary Electrophoresis 
System (CE Resources Pte Ltd, Singapore). This system was equipped with a 
reversible-polarity power supply (0 − ±30 kV) and an on-column VUV-H22 UV 
detector. System control as well as data acquisition and analysis were processed by a 
CSW software (CE Resources Pte Ltd, Singapore). The separations were carried out 
on an uncoated fused-silica capillary (50 μm i.d. × 360 μm o.d. × 70 cm in length) 
with a detection window located 10 cm from its extremity. Negative potential applied 
at the injection port was referred to as negative polarity. A built-in temperature 
control system was designed to maintain separation temperature and minimize Joule 
heat generated, thus enabling the CE system to use high electric field and to achieve 
very low band dispersion. The system had both pneumatic and electrokinetic injection 
modes. In order to avoid sampling bias and achieve better reproducibility, the 
pressure-based injection mode was chosen. Sample plug was consistently injected at a 




according to the Poiseulle-Hagen equation [User’s Manual]: 
Linj = (dcap)2pt/(32ηLcap) 
where dcap is the capillary inner diameter in μm, p is pressure in psi, t is the 
time of injection in s, η (0.000891 N·s /m2) is the viscosity of water at 298 K, and Lcap 
is the length of capillary in cm.  
 
2.2.2.2 Standard separation 
PDC/CTAOH background electrolyte (BGE) containing 5 mM PDC and 0.5 
mM CTAOH was freshly prepared at the beginning of each study day. Before use, it 
was vortexed for 2 min, filtered through a 0.45 μm filter membrane and degassed by 
ultrasonic for 15 min. In between runs, the capillary was subjected to preparation 
cycles including pre-rinse and precondition steps to ensure a clean and equilibrated 
surface for the following separations. At the end of the day, the capillary was rinsed 
for 3 min with 1 M NaOH and Milli-Q water for 5 min respectively and finally dried 
with air for 3 min. Milli-Q water produced by Ultra-Pure Water System (MilliPore 
Corp., Bedford, MA, USA) with a resistivity of 18 MΩ·cm was used throughout the 
experiment.  
 
2.3 Results and Discussion 
2.3.1 Separation of inorganic and organic arsenic species 
The choice of a background electrolyte (BGE) is very important in method 
development employing CZE with indirect UV detection. In general, in CZE, ion 
migration velocity, separation, column efficiency, and peak shape are sensitive to 
changes in BGE characteristics. Typically, in indirect UV detection mode for anions, 




chromophore and suitable additives such as electroosmotic flow (EOF) modifiers. 
The most widely used electrolyte co-ion for inorganic anions is chromate, 
which provides high mobility anions with a UV chromophore [Jeffrey RM and 
Khaledi MG, 1998]. It has been reported that band broadening and loss of resolution 
in the separation of some arsenic compounds were observed in a CZE method using a 
BGE containing chromate as a co-ion chromophore, borate buffer and n-
hexadecyltrimethylammonium bromide (CTAB) as an EOF modifier 
(chromate/borate/CTAB) [Schlegel D et al., 1996]. In our preliminary study, although 
separation efficiency was improved and a baseline separation was obtained as using 
chromate/borate/CTAB BGE to separate arsenic compounds in a CZE method as 
shown in Figure 2, positive and negative signal peaks simultaneously appeared. The 
presence of the positive signal peaks disagreed with the separation principle of CZE 
with indirect detection and could not be clearly elucidated. In addition, the relative 
high limit of detection (LOD), e.g., around 10 ppm as molecule for iAsV, limited the 
usage of such BGE in arsenic speciation analysis. Recently, the UV sensitive PDC 
with a medium mobility capacity was proven well suitable for the simultaneous 
analysis of both high and low mobility anions [Soga T and Imaizumi M, 2001]. 































































Figure 2. The electrophoretic separation of arsenic compounds each with 
concentration of 100 ppm as molecule. BGE composing of 10 mM chromate, 12.5 
mM borate and 0.5 mM CTAB with pH 9.4; Usetting = − 25 kV and Isetting = 15 μA; 
detection wavelength at 216 nm; at temperature of 20 oC. Peaks: 1, iAsV; 2, iAsIII; 




The EOF, which directs to cathode end, is especially adverse for anionic 
analyte detection at anode. Reducing/eliminating the EOF is required for detecting 
anions successfully. Among approaches currently applied to control the EOF, cationic 
surfactant CTAOH was reportedly effective to change capillary inner surface charge 
by adsorption and consequently the EOF direction [Soga T and Imaizumi M, 2001]. 
Therefore, PDC/CTAOH was selected as a BGE in this study, and no additional 
buffer component was used. 
To select an optimum detection wavelength, a wavelength range of 195-225 
nm was firstly tested. Figure 3 displays the electrophoregrams of iAsIII obtained by 
using 5 mM PDC/0.5 mM CTAOH BGE (pH 10.5) at various detection wavelengths. 
With an increase in the detection wavelength from 195 to 210 nm, the sensitivity of 
detection represented by the signal peak area increased, while the baseline noise 
decreased. Further increasing the detection wavelength to 225 nm, however, led to 




considering the detection sensitivity and baseline noise, 215 nm was thus selected as 





































Figure 3. The electrophoregrams of iAsIII with concentration of 10 ppm as 
molecule obtained at different detection wavelengths. BGE with pH 10.5 
containing 5 mM PDC and 0.5 mM CTAOH; Usetting = − 30 kV and Isetting = 8 μA; 
at temperature of 15 oC.  
 
 

























































In the CZE, ionic species are separated based on their charges and sizes, 




values of the analytes (Table 1), at pH 9.3 and above, theoretically, iAsV, MMAV and 
iAsIII have two negative charges, while DMAV is negatively single-charged. 
Therefore, assuming the EOF has been successfully suppressed, iAsV, MMAV and 
iAsIII would first migrate towards the detector at the anode, while DMA migrates 
more slowly according to the electrophoretic separation principle. In other CZE 
studies [Soga T and Imaizumi M, 2001], a high pH up to 12.1 was used in the BGE 
containing PDC, implying that PDC was chemically stable in a strong basic 
environment. However, an extremely high BGE pH is not recommended because 
during an electrophoretic process, generally, an increase of the electrolyte pH will 
result in increasing the dissociation of silanol group of the capillary inner surface to 
silonate group, thus enhancing the capillary inner surface charges and the EOF 
consequently. Furthermore, iAsIII tends to be oxidized to iAsV above pH 10 
[Abernathy CO et al., 1997]. Therefore, a BGE pH range of 10.0 to 11.5 with a 0.5-
step was selected and carefully adjusted. 
Figure 4 shows the effects of different BGE pH values from 10.0 to 11.5 with 
a 0.5 (± 0.02)-step on the electrophoretic separations of arsenic species. Although in 
the above pH range, theoretically, each arsenic analyte was at the same ionization 
degree: iAsIII2-, iAsV2-, MMA2- and DMA-, migration profiles were different. At low 
BGE pH of 10.0, the first two anions, iAsIII2- and iAsV2-, partially overlapped. 
Increasing the BGE pH to 10.5, baseline separation was achieved, and the migration 
order was iAsIII2-, iAsV2-, MMA2- and DMA-, and was confirmed by comparing with 
the electrophoregrams of the individual analytes. At higher BGE pH at 11.0, the 
whole migration suddenly became much slower in comparison with that at pH 10.5; 
however, with a further increase to pH 11.5, the migration pattern remained similar to 




the BGE pH. However, this situation can be changed with the addition of the EOF 
modifier CTAOH: the more negative capillary inner silica surface induced by higher 
BGE pH leads to attracting a greater amount of CTAOH till saturation. The resultant 
net charges of the capillary inner surface thus determine the actual EOF, which, in 
turn, affects the anionic analyte mobility. This could be the cause for the observed 
changes in the extent of the analyte migration time with the increasing BGE pH. The 
effects of pH on BGE resistance are shown in Table 2 and summarized as follow: 
resistance decreased with an increase in the amounts of hydroxide anions added, 
which was probably due to the high mobility of the small hydroxide anions. As a 
result, electric field strength that was represented by dividing the applied voltage by 
the total capillary length (V/cm) decreased with the decrease of the BGE resistance. 
Obviously, there was a close relationship between the actual migration times of the 
analytes and the applied electric field strength that could be affected by the BGE pH. 
It was reported that decreasing electric field strength would reduce the Joule heat and 
the convection currents in the electrophoretic medium, thus the peak would appear 
sharper and higher in the electrophoregram. Also from Figure 4, it was found that the 
detection sensitivity was improved at higher BGE pH such as at 11.0 and above. In 
the subsequent experiments, a BGE of pH 11.5 was thus selected. Although the 
chosen PDC/CTAOH BGE was not further adjusted with other buffer components, 
stable baseline and reproducible migrations were obtained within the pH range of 11.0 
to 11.5, indicating their buffer capacity was high enough so that local pH and 
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Figure 4. The effects of BGE pH on the electrophoretic separation of arsenic 
compounds each with concentration of 1 ppm as molecule. BGE composing of 5 
mM PDC and 0.5 mM CTAOH; Usetting = − 30 kV and Isetting = 8 μA; at 









Table 2. The influences of BGE pH on BGE resistance and electric field strength. 
BGE pH BGE resistance (109Ω) Electric field strength (V.cm-1) 
10.0 3.65 397.14 
10.5 3.21 348.57 
11.0 1.70 180.00 




The driving force behind the migration of ions in CZE is the electric field 
strength applied across the capillary. Effects of the applied electric field strength on 
the separation were further demonstrated by directly changing the current settings 
while fixing the voltage settings as shown in Figure 5. The findings indicated that in 
the experimental range, increasing the applied electric field strength did not increase 
the detection sensitivity but did reduce the migration times, while it slightly increased 
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Usetting = -30 kV and Isetting = 12 μA 
Figure 5. The electrophoretic separation of arsenic compounds each with 
concentration of 1 ppm as molecule under different applied voltage and current. 
5 mM PDC/0.5 mM CTAOH BGE at pH 11.5; at temperature of 15 oC. Peaks: 1, 
iAsIII2-; 2, iAsV2-; 3, MMAV2-; 4, DMA-. 
 
 
Temperature plays an important role in many separations, because both 
analyte mobility and the level of EOF are temperature-related. In general, 
electrophoretic mobility increases with increasing the temperature by about 2% per 1 
K [Foret F et al., 1993]. A temperature range of 20-35 oC was chosen and optimized. 
Figure 6 gives the electrophoretic separations of four arsenic species in the 
temperature range. In the temperature range selected, separation was almost not 
affected by the change of temperature, except the slightly faster migration and noisier 
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Figure 6. The electrophoretic separation of arsenic compounds each with 
concentration of 1 ppm as molecule under different operation temperature. 5 
mM PDC/0.5 mM CTAOH BGE at pH 11.5; Usetting = − 30 kV and Isetting = 8 μA. 




2.3.2 Calibration Parameters 
With 5 mM PDC/0.5 mM CTAOH BGE at pH 11.5, calibration curves were 
obtained for the respective arsenic species within the concentration range of 0.5 to 
500 ppm. The sensitivity, linearity, intra-day and inter-day variation of the method 
were determined as shown in Table 3. The mean correlation coefficient (r2) of each 
calibration curve with dynamic range of more than three orders of magnitude of 
concentration exceeded 0.99, indicating good linearity. Intra-day variation expressed 
as relative standard deviations (RSD%) with respect to migration times and peak areas 
from six successive injections at the analyte concentration of 10 ppm, was found to be 
0.8 – 1.7% for migration times and 3.4 – 6.9% for peak areas, respectively. The inter-
day variation for the same parameters was obtained by analyzing analyte species (10 
ppm) on 3 successive days. RSD of 1.2 –2.2% for migration times and around 3.6 –




Table 3. Parameters of the calibration curves a. 





Linear dynamic range 










iAsIII 0.23 > 3 0.9984 1.1 3.9 1.7 4.3 
iAsV 0.19 > 3 0.9993 0.8 3.4 1.2 3.6 
MMAV 0.19 > 3 0.9991 0.9 4.1 1.5 4.8 
DMAV 0.22 > 3 0.9987 1.7 6.9 2.2 7.1 
a Conditions: injection 10s at low pressure; BGE, 5 mM PDC/0.5 mM CTAOH with pH 11.5; detection wavelength 215 nm; voltage setting of –
30 kV and current setting of 8 μA. 










2.3.3 Identification of arsenic species in the alkali extracts of realgar and 
orpiment 
It was reported that the main components in the alkali extracts of realgar were 
iAsIII and iAsV, and in the alkali extract of orpiment were iAsIII, iAsV and DMAV as 
identified by IC-HG-AAS method [He B et al., 2000]. By using the established CZE 
method the alkali extracts of realgar and orpiment were analyzed. By comparing with 
the migration times with the respective standards, the corresponding 
electrophoregrams indicated that there were two main components, iAsIII and iAsV in 
the extracts. The alkali extracts were then spiked with standards. Figures 7(a) and (b) 
showed that no additional signal peak appeared after the samples were spiked 
separately with iAsIII and iAsV, while the peak intensities of iAsIII and iAsV 
respectively increased, supporting the above assumptions. These results were partially 
consistent with the other study [He B et al., 2000]. Although an amount of DMAV was 
found in the alkali extract of orpiment in He’s report [He B et al., 2000], it was 
reasonable to suspect that the DMAV might be present as impurity in their samples. 
With the established calibration curves, the concentrations of iAsIII and iAsV in both 
extracts with 1.5 ppm as As were determined. In the alkali extract of realgar (n = 3), 
there were 1.90 ± 0.10 ppm (84.61 ± 4.45%) of iAsIII and 0.39 ± 0.02 ppm (15.39 ± 
0.78%) of iAsV; whereas in the alkali extract of orpiment (n = 3), there were 1.61 ± 
0.08 ppm (75.21 ± 3.61 %) of iAsIII and 0.60 ± 0.03 ppm (24.79 ± 1.34%) of iAsV, 
respectively. This study is the first report on using CZE method to analyze the alkali 
extracts of realgar and orpiment, adding valuable information on the components 
constituting these compounds. Our finding indicated that the alkali extracting 
procedure could produce similar redox reactions between the respective As2S2 and 































































Figure 7. The electrophoregrams of the alkali extracts of realgar (1.5 ppm as As) 
(a) and orpiment (1.5 ppm as As) (b) respectively spiked with 1 ppm iAsIII (upper 
line) and 1 ppm iAsV (lower line). 5 mM PDC/0.5 mM CTAOH BGE at pH 11.5; 





The proposed CZE method with indirect UV detection showed excellent 
suitability for the simultaneous separation and determination of the inorganic and 
organic arsenic compounds by using the PDC/CTAOH BGE. It provided excellent 
linearity, intra-day and inter-day variation to identify the components in the alkali 
extracts of realgar and orpiment as well. The main components in both extracts were 
found to be iAsIII and iAsV instead of intact realgar and orpiment. Therefore, alkali 













Evaluation of the in vitro activity and in vivo 
bioavailability of realgar nanoparticles 













3.1.1 Background of realgar 
Realgar (R) (α-As4S4, also written as As2S2 or AsS) is a soft monoclinic 
crystal with orange-red color. The unit cell of realgar is shown as Figure 1. It is light 
sensitive, because realgar changes form to yellow pararealgar (β-As4S4) after a long 
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Figure 1. The unit cell of realgar.  
 
As described earlier, a recent clinical trial study of orally administered realgar 
conducted in China showed that it was highly effective and safe for both remission 
induction and maintenance in all stages of APL [Lu DP et al., 2002]. In addition, in 
the corresponding clinical pharmacokinetics (PK) study, researchers observed that 
coarse realgar powder (in capsule formulation) was absorbed rapidly and excreted 
mostly within the first 24-h urine. However, realgar is so poorly water-soluble that the 
reported high oral bioavailability of the drug from the coarse powder needs to be 
confirmed. In fact, urgent needs always exist for safe and effective delivery of poorly 
water-soluble drugs.  
The most direct approach to enhance the solubility of a compound is to 




however, our previous study showed that realgar probably reacts with alkali to 
convert to trivalent arsenite and pentavalent arsenate instead. Other advanced 
approaches currently used to enhance the delivery of poorly water-soluble drugs are 
summarized in Table 1. In most cases, solution form of a drug either in aqueous 
environment or organic solvent is preliminarily required. Physically, the poor water-
solubility of realgar is due to its high lattice energy, which leading to difficulty in 
breaking molecules apart into surrounding medium like aqueous or organic solvent 
environment. Generally, because of its too low intrinsic water-solubility, only particle 
size reduction by micronization/nanonization technique likely is a potential approach 
to improve the delivery of realgar.  
 
Table 1. Current advanced approaches to enhance delivery of poorly water-
oluble drugs. s
 
Advanced approaches Concept 
Solid dispersions 
Intimate mixture of drug substance and diluent, such as 
polyethylene glycol or polyvinylpyrrolidone. The modified 
drug is often in an amorphous, more soluble state. Due to the 
higher energy state, there is a potential for recrystallization. 
Microemulsions 
Micellular dispersion of oil/solvent-dissolved drug as 
nanometer size droplets in water. The drug can be directly 
absorbed from the droplets. There are some concerns about 
toxicity of high surfactant and cosolvent levels and the 
possibility of precipitation. Administered as a liquid. 
Self-emulsifying systems 
Mixture of drugs, oils, surfactants, and cosolvents that form an 
emulsion upon administration. phase inversion may further 
promote drug release. Can be administered as a solid dosage 
form. 
Complexation 
Formation of a reversible, noncovalent chemical complex of a 
drug with a carrier compound. Cyclodextrins are the most 
common complexing agents used to enhance drug absorption. 
Liposomes 
Encapsulation of a drug in uni- or multilayered vesicles of 
phospholipids. Specific sites can be targeted and certain drugs 
can be protected from inactivation. 
Particle size reduction Increased particle surface area enhances rate of solubilization. 
1) wet milling Particle size reduction to nano-sized particles through attrition in the presence of stabilizing agents. 







Nanotechnology has a long history. The first famous examples could be the 
nanosized heterogeneous catalysts developed in the early 19th century [Robertson AJB, 
1983]. The most important scientific advancements have taken place in the last two 
decades in the fields of photography and semiconductor, where nanoparticles (less 
than 100 nm in diameter) were produced, exhibiting extraordinary and unique 
practical properties [Mendel J et al., 1999]. Indeed, the physical and chemical 
properties of materials can be significantly improved or radically changed as their size 
is scaled down to small clusters of atoms. Colloidal gold and iron oxide nanocrystals 
are examples of nanoparticles diagnostically applied in biology and medicine 
[Moghimi SM et al., 2005]. Nanoparticles have been extensively used for systemic 
and oral administration of different types of drugs and for different purposes including 
drug targeting [Stella B et al., 2000], drug bioavailability enhancement [Liversidge 
GG and Cundy KC, 1995], and protection against degradation [Roy K et al., 1999].  
In pharmaceutical field, the term "nanoparticles" has been applied rather 
loosely to structures less than 1 μm in diameter [Kipp JP, 2004]. Present 
commercially or potentially commercially available nanoparticle engineering 
techniques of enhancement of dissolution of poorly water-soluble drugs involve the 
use of mechanical micronization techniques [Muller RH and Peters K, 1998], 
supercritical fluid processes [Tom JW and Bebenedetti PG, 1991], cryogenic spraying 
[Costantino HR et al., 2000], and solvent evaporation [Chen X et al., 2002]. Since 
realgar is not dissolved in almost all commonly used organic solvents, mechanical 
technique could be a suitable method to reduce its particle size. Co-grinding with 
water-soluble polymers and/or surfactants is one of the useful pharmaceutical 




The co-grinding technique has the advantages of being simple and economical. The 
particles can also be produced without using organic solvents [Masaaki S et al., 1998].  
 
3.1.3 Objectives of this study 
In this study, realgar nanoparticles were firstly produced by means of cryo-
grinding with water soluble and biocompatible polymer polyvinylpyrrolidone (PVP) 
and surfactant sodium dodecyl sulfate (SDS). In vitro and in vivo studies were carried 
out to characterize the realgar nanoparticles as a potential anticancer drug candidate. 
The in vitro cytotoxicity of the realgar nanoparticles was tested on human ovarian and 
cervical cancer cell lines with two normal human fibroblast cell lines as controls. For 
the in vivo study, a rat model was selected to examine the oral bioavailability of these 
realgar nanoparticles based on the urinary recovery of arsenic.  
 
3.2 Materials and methods 
3.2.1 Materials 
PVP (K29-32, MW 40,000) and SDS (ultrapure, ≥ 99.8% in purity) were 
purchased from Sigma Chemical Co. (St. Louis, MO, USA). All other chemicals used 
were of analytical reagent grade. Milli-Q water was used throughout the experiment.  
 
3.2.2 Methods 
3.2.2.1 Preparation and characterization of cryo-ground realgar particles 
(1) Preparation of cryo-ground realgar particles 
A cryo-grinding equipment (6850-115 Freezer/Mill, SPEX CertiPrep Inc., 
Metuchen, NJ, USA) was used to reduce particle size of realgar powder. The 




moderate density was approximate 8 g in each vial. Liquid nitrogen was used as a 
coolant during grinding. Three physical mixtures (5.0 g each) i.e.,  R/PVP/SDS (1/3/1, 
w/w/w), R/PVP (1/3, w/w), and R/SDS (1/1, w/w), were weighed and added into the 
respective grinding vial, whilst 5.0 g realgar as purchased was put into the last sample 
vial. These four realgar preparations were ground simultaneously to produce fine 
particles under the same grinding conditions. 
 
(2) Determination of arsenic content by using graphite furnace atomic 
absorption spectrometer (GFAAS) 
Appropriate amount of each ground realgar preparation was dispersed into 10 
ml Milli-Q water, giving a final concentration of 1 mg realgar/ml (1000 ppm as 
realgar). The dispersions were ultrasonically treated for 30 min and then shaken at 
300 rpm for 24 h. Thereafter, the dispersions were filtered through a membrane filter 
(0.2 μm). Arsenic concentrations in the resulting filtrates were measured by GFAAS 
(AAnalyst 100, Perkin Elmer Corp., Norwalk, CT, USA).  
An electrodeless discharge lamp (EDL) for arsenic operated at 5 mA was used, 
providing a 193.7 nm line with a spectral bandwidth of 1.3 nm. Argon gas was chosen 
as carrier and sheath gas. Typical analytical conditions were as follow: drying at 130 
oC, ashing at 1300 oC, atomization at 2300 oC, and cleaning at 2600 oC. Pd(NO3)2-
Mg(NO3)2 was used as a matrix modifier for such arsenic determinations. For each 
analysis, a 5 µl of matrix modifier was injected into graphite furnace tube together 
with 20 μl standard/sample solution. Three replicates were set for each 
standard/sample analysis. Five standard arsenic solutions with arsenic concentrations 
of 5, 10, 20, 30, and 50 ppb were prepared from an arsenic standard solution with a 




dilutions for calibration curve establishment together with a blank. A linear regression 
was used for calculation of arsenic content in standard and real samples. A correlation 
coefficient of 0.9984 was obtained for calibration curve by using linear regression 
across zero point.  
 
(3)  Powder X-Ray diffraction (XRD) measurement 
Powder XRD was performed with a D8 advanced X-ray diffractometer 
(Bruker AXS, Cheshire, UK) using monochromatic CuKα radiation at room 
temperature. Measurements were done at 40 kV voltage, 40 mA current, and a 
scanning angle (2θ) range from 10o to 40o. 
 
(4) Particle size analysis and zeta potential measurement 
Particle size distribution (mean diameter and polydispersity index (PI)) and 
zeta potential for each filtrate were determined by a Zetasizer 1000/2000/3000 
(Malvern Instruments Ltd., Worcs, UK). Each batch of the realgar filtrate was 
analyzed in ten repeats. Mean values of three batches with the corresponding standard 
deviations (means ± SD) were presented. 
 
(5) Transmission electron microscope (TEM) characterization 
Transmission electron microscope (Philips CM10, Eindhoven, Netherlands) 
was used to examine the morphology of the realgar ground particles in the 
corresponding filtrate and also to physically measure the sizes of the ground realgar 
nanoparticles.  
 




3.2.3.1 Cells and cell culture.  
Three human ovarian cancer cell lines (CI80-13S, OVCAR, OVCAR-3), a 
human cervical cancer cell line (HeLa), a human normal lung fibroblast cell line 
(MRC-5) and a dermal fibroblast cell line (HF) were used to test for the cytotoxicity 
of the realgar nanoparticles prepared. CI80-13S and OVCAR were obtained from 
Queensland Institute of Medical Research (Australia); HeLa, OVCAR-3 and MRC-5 
from ATCC (Manassas, VA, USA), and HF from Skin Culture Laboratory, Singapore 
General Hospital (Singapore). The HeLa, MRC-5 and HF were grown as monolayer 
in Dulbecco's modified Eagle's medium (DMEM), and CI80-13S, OVCAR and 
OVCAR-3 in RPMI-1640, supplemented with 1% penicillin/streptomycin and 10% 
fetal bovine serum (FBS, HyClone Laboratories, Logan, Utah, USA) at 37 oC in a 
humidified atmosphere containing 5% CO2. Cell viability of the stock cultures used 
for subsequent experiments was always above 95% as assessed by trypan blue 
exclusion test.  
 
3.2.3.2 Cell viability assay: Fluorometric microculture cytotoxicity assay (FMCA) 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay is 
a standard colorimetric assay for measuring cellular proliferation [Mosmann T, 1983]. 
Although MTT assay probably is most prevalent in vitro assay used, there are some 
disadvantages/limitations of this test: 1) there are cell lines that do not metabolized 
the MTT well or have an acceptable colorimetric profile for control cells; 2) 
production of the MTT product is dependent on the MTT concentration in the culture 
medium. The kinetics and degree of saturation are dependent on cell type; 3) assay is 
less effective in the absence of cell proliferation; 4) MTT cannot distinguish between 




the same media that has supported growth for a few days, which leads to 
underestimated of control and untreated samples; and 6) certain types of drugs can 
induce formazan production (MTT) and/or mitochondrial activity. Increased 
production of formazan will potentially give false positives with these drugs. 
Therefore, in this study, drug cytotoxicity and cell proliferation were 
determined using a previously described FMCA with minor modification [Larsson R 
and Nygren P, 1989]. The main advantages are its speed, high sensitivity and 
simplicity. FMCA is based on the measurement of fluorescence generated from the 
hydrolysis of fluorescein diacetate (FDA, Sigma Chemical Co., St. Louis, MO, USA) 
to fluorescein by cells with intact plasma membranes. Briefly, cells were seeded into 
96-well microtiter plates. The plates were incubated till cells reach exponentially 
growing stage (80-85% confluence). The medium in the well was then changed to 200 
μl of the respective fresh culture medium and culture medium containing the test 
compounds. After incubation period, the plates were washed with phosphate-buffered 
saline (PBS) buffer. A stock solution of FDA (10 mg/ml) was prepared in dimethyl 
sulphoxide (DMSO, ≥ 99.9% in purity, Sigma Chemical Co., St. Louis, MO, USA), 
kept frozen at -20 oC and protected from light. The FDA stock solution was freshly 
diluted to 2 μg/ml with PBS buffer and 200 μl of this solution was then added to each 
of the control, experimental and blank wells. The plates were incubated for another 30 
min at 37 oC and the fluorescence generated from each well was measured by using a 
SpectruaFluor (Tecan Systems Inc., San Jose, CA, USA) at an excitation wavelength 
of 485 nm and an emission wavelength of 535 nm. 
In a preliminary study, the fluorescence was found to be proportional to the 
number of viable cells in the well. Cell survival is presented as survival index (SI), 




of that in the control wells. IC50 was defined as the concentration giving a SI of 50%, 
and was estimated by using the software GraphPad Prism Version 4.00 (GraphPad 
Software Inc., San Diego, CA, USA). 
Cell morphological change of adherent cells before and after drug treatment 
was observed by using phase-contrast microscope (Nikon Eclipse TE2000-U, Nikon 
Corp., Tokyo, JP).   
 
3.2.3.3 Flow cytometry analysis of apoptosis and cell cycle distribution 
Apoptosis was identified and quantified by flow cytometry on a Beckman 
Coulter Epics Alfa (Beckman Coulter Inc., Fullerton, CA, USA) after propidium 
iodine (PI, ≥ 95% in purity, Sigma Chemical Co., St. Louis, MO, USA) stained. PI 
stained the late apoptotic cells which had increased membrane permeability. Cells 
were treated with various realgar nanoparticles. At the end of the incubation, all cells 
were collected and fixed in 70% ice-cold ethanol at a cell density of 1 × 106/ml, and 
kept in fridge (-20 oC) at least overnight until analysis. Fixed cells were washed twice 
with PBS buffer and treated with 1 mg/ml RNAse (DNAse-free) (Sigma Chemical 
Co., St. Louis, MO, USA) for 30 min at 37 oC. PI was then added to the solution at a 
final concentration of 50 μg/ml. Samples were filtered through a 60 μm pore size 
nylon mesh before analysis. Obtained DNA histogram was analyzed using WinMDI 
Version 2.8. Cells with DNA content less than the cells in G1 phase (sub-G1) were 
taken as apoptotic cells.  
 
3.2.3.4 DNA fragmentation assay 
Following incubation with various realgar nanoparticles at the concentration 




harvested cells were washed twice with ice-cold PBS buffer, and then re-suspended in 
0.5 ml lysis buffer (0.2% Triton X-100, 10 mM Tris pH 8.0, and 1 mM EDTA). After 
freshly added 0.25 mg Proteinase K (Sigma Chemical Co., St. Louis, MO, USA), the 
cell suspension was incubated at 55 oC for 1 h. After pelleting cell debris and proteins 
by centrifuging the cell suspension at 14,000 g at 4 oC for 20 min, the supernatant was 
saved. One-half volume of 3 M sodium acetate and 2.5 volumes of cold ethanol 
(99.7% in purity) were added to the supernatant followed by incubation overnight at -
20 oC. DNA was collected by centrifugation at 14,000 g at 4 oC for 20 min. The DNA 
pellet was then dissolved in TE buffer (10 mM Tris pH 8.0 and 1 mM EDTA). The 
DNA sample was separated by electrophoresis in a 1.5% agarose gel containing 0.5 
μg/ml ethidium bromide (EB, Bio-Rad Laboratories, Hercules, CA, USA) in Tris-
acetate-EDTA (TAE) running buffer. The gels were then visualized under UV light 
with Quantity One mode 4.5.0 (Bio-Rad Laboratories, Hercules, CA, USA).  
 
3.2.4 In vivo investigations 
3.2.4.1 Animal 
Healthy male Sprague Dawley (SD) rats (6-7 weeks of age, average weight of 
200 ± 20 g) were purchased from Laboratory Animals Centre, Singapore. They were 
housed individually in polycarbonate metabolic cages and provided with a standard 
diet (Mouse pellets, Laboratory Animals Centre, Singapore) and water ad libitum. The 
room was kept on a 12/12-h light/dark cycle at a temperature of 23 ± 1 oC and relative 
humidity of 50 ± 10%. At least three days of acclimatization period was allowed for 
rats prior to drug administration experiments. 
 




The study protocol adhered to guidelines for the humane use of animals in 
scientific research, and all animal procedures were approved by the Institutional 
Animal Care and Use Committee (National University of Singapore, Singapore). The 
SD Rats were administered various realgar suspensions orally at a dose of 50 mg 
realgar/kg body weight using a gavage needle. Urine was collected at the end of 
intervals of 0-24, 24-48 and 48-96 h after single administration. The urine samples 
were centrifuged at 3000 g for 15 min to remove particulate materials and stored at –
80oC till analysis. Arsenic concentrations in urine samples were measured by GFAAS.  
 
3.2.4.3 Normalization of urine by creatinine assay 
The concentration of creatinine in urine was measured by Jaffe method after 
slight modification [Chan MH et al., 2004]. Briefly, the formation of acid-sensitive 
chromogen after reduction of the urine sample with picrate was measured at 
absorbance of 500 nm. The urinary arsenic level was then normalized with creatinine 
concentration.  
 
3.2.5 Statistical analysis 
Data are presented as mean ± SD, and analyzed by one-way ANOVA with 
Tukey’s multiple comparison test for post test (GraphPad Prism Version 4.00). Values 
of p < 0.05 were indicative of significant differences, and those of p < 0.01 were 
indicative of very significant differences.  
 
3.3 Results and Discussion 
3.3.1 Submicron/nanoparticles formation using cryo-grinding technique 




solutions onto solid particles has been extensively studied in recent years. 
Simultaneous adsorption of PVP and SDS onto alumina or titanium dioxide has been 
reported [Ma CM and Li CL, 1989]. The dispersion stability of alumina suspensions 
was enhanced due to the adsorption of PVP and SDS [Kunio E et al., 2000]. Both 
PVP and SDS are also used as grinding additives in a dry process to reduce particle 
sizes of poorly water-soluble drugs, such as griseofulvin, glibenclamide and 
nifedipine [Koichi I et al., 2003]. Stable drug/PVP/SDS aqueous suspensions were 
obtained due to inhibition of aggregation/agglomeration by the adsorption of PVP and 
SDS on the surfaces of drug crystals. Inspired by the fact that the PVP and/or SDS 
effectively enhance solubility of crystals in aqueous environments, they were chosen 
as grinding additives in the current study. 
The filtrates from the binary R/PVP, R/SDS and ternary R/PVP/SDS ground 
mixtures were prepared as described in the Materials and Methods section. The 
filtrates from the ground alone realgar particles and the original coarse realgar powder 
(sieved through 150 μm pore size mesh before weighing) were also prepared. It might 
be noted that the filtrates from all co-ground mixtures were vague colloidal solutions 
and slightly yellowish in color, and the filtrates of the original realgar powder and 
ground realgar alone particles were clear solutions after 48 h standing at room 
temperature. Such difference probably results from the different realgar amount in the 
individual filtrate.  
The arsenic concentrations of all filtrates were measured by GFAAS and the 
values are shown in Table 2. The arsenic concentration of the filtrate from the 
R/PVP/SDS preparation was highest to give a concentration of 134.20 ppm, about 
250-fold higher than that of the filtrate from the original coarse realgar powder and 




and then followed by the binary R/PVP and R/SDS filtrates. The result indicated that 
the presence of PVP and/or SDS in the grinding mixtures facilitated the production of 
larger amounts of realgar fine particles of 200 nm or less.  
 
Table 2. Physical properties of the realgar nanoparticles in the filtrates obtained 
after filtering the respective realgar preparation through a 0.2 μm filter 


















2.53 ± 0.09 328.9 ± 32.5 0.767 ± 0.373 0.6 ± 0.2 
R/PVP  
(1/3, w/w) 121.00 ± 7.23 243.2 ± 5.3 0.184 ± 0.020 -4.3 ± 1.8 
R/SDS  
(1/1, w/w) 53.81 ± 3.89 176.1 ± 4.5 0.116 ± 0.022 -14.9 ± 9.2 
R/PVP/SDS 
(1/3/1, w/w) 134.20 ± 4.03 217.3 ± 4.9 0.209 ± 0.019 -8.7 ± 3.1 
 
 
The particle size and distribution of all filtrates were evaluated by means of 
Zetasizer, and the results are shown in Table 2. With the assistance of PVP and/or 
SDS, the mean particle sizes were slightly decreased, to less than 250 nm, when 
compared with those of the original realgar powder and the realgar ground alone 
preparation. The PI value that represents the pattern of systematic particle distribution 
is equal to 0 for a monodisperse suspension and 1 for a polydisperse suspension. The 
PI values of the co-ground preparations were significantly lower than that of the 
ground realgar alone preparation (p < 0.05), suggesting that the particle distribution 




particle size and PI of the co-ground preparations were determined after the complete 
dissolution of PVP and SDS, they might reflect the status of crystallization and/or 
aggregation of the realgar particles in the suspensions. The smaller mean particle sizes 
and PI values of all co-ground preparations might be partially attributed to the 
effective inhibition of the recrystallization and/or aggregation and/or agglomeration of 
realgar particles in water by PVP and/or SDS.  
In order to study the surface physical properties of various nanosized realgar 
particles, the zeta potentials of the realgar fine particles were investigated by Zetasizer 
and the values are shown in Table 2. The zeta potential values of the original realgar 
powder and realgar ground particles without additive were almost same with mean 
values around zero. It is probably due to the fact that realgar is unionizable. After 
grinding with PVP and/or SDS, the zeta potential values became negative. This 
indicated that the negative charged PVP and SDS were partially adsorbed onto the 
particle surfaces. The zeta potential value of the ternary R/PVP/SDS preparation was 
between those of R/PVP and R/SDS preparations.  
TEM was used to examine the morphologies of the different realgar ground 
preparations. Figure 2 displays the TEM images of the binary R/PVP, R/SDS and 
ternary R/PVP/SDS preparations. In comparison with the mean particle sizes of the 
corresponding filtrates determined by Zetasizer, the particle sizes observed by TEM 
were much smaller. This phenomenon was probably due to the particles observed by 
TEM were the individual core realgar particles, whilst the particles apparent to the 
Zetasizer were the realgar particles with PVP and/or SDS coating(s). Although the 
Zetasizer might not give very accurate measurements of the core particle size, it can 





Figure 2. TEM pictures of the nanosized realgar particles from the binary 




To study the crystallinity change of the realgar powder after cryo-grinding, the  
XRD of the respective realgar powder was scanned. Figure 3 shows the XRD patterns 




all realgar ground preparations were in agreement with that of the original realgar 
powder. The results suggested that the fine particles obtained from cryo-grinding 
included most crystalline form of realgar. This confirmed that the selected cryo-
grinding technique did not change the crystallinity of the realgar powder. Although 
decrease in drug crystallinity till amorphization or formation of metastable 
polymorphic modification are possible factors responsible for the apparent increase in 
dissolution rate [Yonemochi E et al., 1999; Otsuka M et al., 1999], both approaches at 
the same time give rise to physical and/or chemical stability problems because the 
high-energy state of the drug can revert to the thermodynamically stable form of 












Figure 3. Powder XRD patterns of various realgar preparations (from top to 
bottom): R/PVP/SDS, R/PVP, R/SDS, R ground without additive, and original R.  










In summary, nanocrystalline realgar particles were formed successfully by 
cryo-grinding. PVP and SDS not only enhanced the grinding efficiency, but also 




choice and concentration of stabilizer can be selected to promote the particles size 
reduction process and generate physically stable formulations in nanocrystalline 
systems, mainly because the stabilizer is capable of wetting the surface of the drug 
crystals and providing steric and/or ionic barrier [Hu J et al., 2004]. In PVP/SDS 
system, the steric effect could arise from the long polyvinyl chains of PVP and the 
ionic repulsing barrier from the negative charged oxygen anion of SDS. In the 
absence of an appropriate stabilizer, the high surface energy of nanosized particles 
would tend to agglomerate and/or aggregate. It has also been reported that an 
appropriate amount of stabilizer is required to obtain stable nanocrystalline 
formulations, that is, too little stabilizer induces agglomeration and/or aggregation and 
too much promotes Ostwald ripening [Kibbe AH, 2000]. Many commonly used 
pharmaceutical excipients such as cellulosics, pluronics, polysorbates and povidones 
are acceptable stabilizers for generating physically stable nanoparticle dispersions 
[Kibbe AH, 2000; Liversidge GG et al., 1992].  
Dispersion stability of co-ground preparations could be indicated by 
sedimentation rate with time, which could be observed by naked eye according to 
yellow color change and the appearance of yellow precipitate. After seven days 
standing in room temperature, R/PVP/SDS preparation showed the best stability than 
both R/PVP and R/SDS preparations. Further confirmation was done by a reducing 
order of R/PVP/SDS > R/PVP > R/SDS in terms of the arsenic concentration change 
in the top layer of the respective suspension. 
 
3.3.2 In vitro activity of the nanosized realgar particles on human ovarian and 
cervical cancer cell lines 




growth and survival were tested on human ovarian (CI80-13S, OVCAR, and 
OVCAR-3) and cervical (HeLa) cancer cell lines. For comparison, two types of 
normal human fibroblast cell lines, lung fibroblast MRC-5 and skin fibroblast HF, 
were selected and tested as controls. Exposure of these cancer cell lines on 
exponentially growing stage to the corresponding filtrates with different 
concentrations was examined every 24 h for 3 days, inhibition of cell viability in a 
dose- and time-dependent manner was found. To estimate the IC50 values after 3-day 
drug treatment, the response-dose curves were fitted to the Sigmoidal dose-response 
(variable slope) equation using the software GraphPad Prism (V4.00). The results are 
summarized in Table 3. It was found that all realgar preparations had significant 
cytotoxic effect on the target gynecological cancer cell lines with IC50 values 
comparable to that of arsenic trioxide [Bode AM and Dong ZG, 2002]. By comparing 
the IC50 values of the respective realgar preparation on the cancer cell lines, CI80-13S 
was the most sensitive cell line to all realgar preparations (with IC50 values less than 1 
μM as As2S2) (p < 0.001). The other caner cell lines had IC50 values in the range of 2-
5 μM with insignificant differences among them (p > 0.05). In each cell line, there 
was no significant difference in the IC50 values (p > 0.05) among the different realgar 
formulations. The effects of PVP and SDS alone on the cells were also studied. Their 
IC50 values were around 25.0 mM and 0.3 M, respectively, indicating that PVP and 
SDS were not responsible for the cytotoxic effects within the working concentration 
ranges (i.e. maximum working concentration of about 0.12 mM for PVP; and around 
0.04 mM for SDS). Our findings also showed that the normal human fibroblast cell 
lines, MRC-5 and HF, were relatively resistant to the various realgar preparations 






Table 3. IC50 (μM as As2S2) of various realgar particles and arsenic trioxide in 
different cell lines exposed for 3 days. Results are the mean ± SD from three 
ndependent experiments, and in each experiment there are six repeats.  i
 














0.07 2.67 ± 0.30 3.44 ± 0.42 2.98 ± 0.29 
12.67 ± 
1.67 * 
R/PVP 0.82 ± 0.08 2.81 ± 0.29 3.86 ± 0.35 2.57 ± 0.31 
14.41 ± 
1.44 * 
R/SDS 0.78 ± 0.09 3.66 ± 0.36 4.37 ± 0.61 3.69 ± 0.34 
11.41 ± 
1.00 * 





0.28 1.88 ± 0.49
 2.37 ± 0.33 1.85 ± 0.54 ND 10.02 ± 0.37 
* IC50 could not be reached in the test dose range. 
** Data was obtained from the reference: Du YH and Ho PC, 2001. 
ND: not determined. 
 
3.3.3 Assessment of the apoptotic effects of the realgar nanoparticle 
Cell death is an important variable in cancer development, cancer prevention 
and cancer therapy. In the treatment of cancer, the major approach is removal of the 
neoplasm by surgery, and/or the induction of cell death by radiation, toxic chemicals, 
antibodies and/or cells of the immune system [Zornig M et al., 2001; Kong AN et al., 
2001]. However, the mechanisms underlying the cell death are still poorly understood. 
In the recent literatures, cell death is thought to occur by two alternative modes: 
apoptosis and necrosis. Figure 4 shows typical morphological characteristics of cells 
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Apoptosis (programmed cell death) has emerged as an important biological 
mechanism that contributes to the maintenance of the integrity of multicellular 
organisms [Kerr JF et al., 1972]. It has been shown that tumors develop not only from 
abnormal cell proliferation and the inhibition of differentiation, but also from reduced 
cell death due to the inhibition of apoptosis [Elmore S, 2007]. Evidence suggests that 
the failure of cells to undergo apoptosis might be a factor in the pathogenesis of a 
variety of human diseases, including cancer, autoimmune diseases, and viral 
infections [Elmore S, 2007]. Apoptosis has become a focus of interest in oncology. 
Specific therapies are being designed to enhance the susceptibility of individual cell 
type from a variety of human cancers to undergo apoptosis. An overwhelming amount 
of evidence indicates that arsenic compounds induce apoptosis in many cell types 




Generally, apoptosis can be recognized by its characteristic morphological 
features, including cell shrinkage, chromatin condensation, cytoplasmic membrane 
blebbing and formation of apoptotic bodies containing cytoplasm, organelles and 
nuclear fragments, phagocytosis of apoptotic bodies by neighboring cells or 
macrophages. Figures 5a and 5b shows the morphologies of the target cell lines 
treated with R/PVP/SDS nanoparticles at the concentration of IC50 for 72 h observed 
by phase-contrast microscope. After treatment, almost all cancer cells retracted from 
the neighboring ones. Some typical apoptotic features were observed, including 
chromatin condensation, blebbing of the plasma membrane or formation of apoptotic 
bodies. However, no significant changes in morphology appeared in the control 
fibroblast cell lines MRC-5 and HF after same treatment. It was also observed that all 
cell lines had similar responses to other realgar particle preparations to R/PVP/SDS in 








Figure 5a. Morphologies of CI80-13S, OVCAR and OVCAR-3 cell lines before 
(left, control) and after drug (R/PVP/SDS) treatment (right, treatment) for 72 h. 
All the photos were taken after removing the culture medium under a phase-










Figure 5b. Morphologies of HeLa, MRC-5 and HF cell lines before (left, control) 
and after drug (R/PVP/SDS) treatment (right, treatment) for 72 h. All the photos 
were taken after removing the culture medium under a phase-contrast 




The distribution of cells in the various phases of cell cycle were analyzed after 
treatment with the respective realgar preparation at a concentration around IC50 for 72 




cell lines to realgar nanoparticles resulted in the appearance of cells with a fractional 
DNA content forming a well-defined sub-G1 peak, a typical profile of apoptotic cells. 
The proportions of all cancer cell lines tested in the G2/M phase were also increased. 
This result suggested that realgar induces apoptosis specifically through delay in 
G2/M phase cell in the cell cycle. Figure 6 shows the typical cell cycle histograms of 
the target cancer cell lines treated with the R/PVP/SDS nanoparticles at the 
concentration of IC50 for 72 h. Other realgar nanoparticle preparations also showed 
similar effects on target cancer cells. Results are summarized in Figure 7. As for 
MRC-5 and HF cells, no major variation in the cell phase distribution was noted in 
them after realgar treatment even at the concentration around IC50 (Figure 7). To 
obtain enough cell amounts for flow cytometry analysis, 75 cm2 culture flasks were 
used to grow the cells. It was found that for MRC-5 and HF cells, most cells survived 
even after drug treatment at concentrations around the IC50 values estimated from the 
FMCA experiments. This finding indicated that the cells could survive better in the 













Figure 6. Histograms of the cell cycle distribution of the cell lines treated with 









































































Figure 7. The changes of sub-G1 and G2/M phases after drug treatment. 1. 
Control; 2. Original realgar treatment; 2. Ground realgar particle treatment; 3. 




The activation of endogenous endonucleases resulting in double strand breaks 
in nuclear DNA at 180-200 bp-multiple intervals is a common event in apoptotic 
cascade [Alison MR and Sarraf CE, 1995]. To further confirm the induction of 
apoptosis by realgar, DNA degradation analysis by agarose gel electrophoresis was 
performed (Figure 8). After treatment for 72 h, the DNA extracted from all target 
cancer cell lines displayed the characteristic internucleosomal ladder of DNA 
fragments, suggesting apoptosis. In contrast, the MRC-5 and HF did not show any 
DNA fragmentation. Similar findings were previously obtained with nanosized 
realgar particles prepared by mechanically milling method [Deng Y et al., 2001; Ye 
HQ et al., 2005]. In their studies, nanosized realgar particles exhibited obvious anti-
proliferation effect on selected promyelocytic leukemia cell line (HL-60) and human 
umbilical vein endothelial cell line (ECV-304) by triggering apoptosis. They 




nanoparticles on HL-60 cells.  
 




















Figure 8. DNA fragmentation in the tested cell lines treated with different 
realgar nanoparticles for 72 h at respective concentration of around IC50. Lane 1 








Both arsenite and arsenic trioxide are known to activate the G2 phase 
checkpoint and induce mitotic arrest and apoptosis in a variety of cell lines including 
HeLa [Huang SC and Lee TC, 1998], U937 [Halicka HD et al., 2002; McCabe MJ Jr 
et al., 2000], and several prostate and ovarian carcinoma cells [Uslu R et al., 2000]. 
Arsenic trioxide has been suggested to induce apoptosis through three major apoptotic 
mechanisms as identified by using pharmacologic inhibitors to: 1) mitogen-activated 
protein kinases, caspase, and reactive oxygen species (ROS). Mitogen-activated 
protein kinases include c-Jun-N-terminal kinase (JNK), p38, and extracellular signal-
regulated kinase (ERK) [Garban HJ and Bonavida B, 1999; Hedlund TE et al., 1998; 
Frei K et al., 1998; Huang C et al., 1999; Namgung U and Xia Z, 2000]; 2) cascade 
reaction of caspases, a family of aspartate-specific cysteine proteases [Zhu J et al., 
2003; Chen YC et al., 1998]. Functionally, these caspases are divided into two 
subgroups: initiator (caspase-8, -9, and -10) and effector (caspase-3, -6, and -7) 
caspases; and 3) ROS, such as hydrogen peroxide, superoxide, hydroxyl radicals, and 
nitric oxide [Halliwell B and Gutteridge JM, 1990]. To date, the most critical 
mechanism and the interactions between the mechanisms involved in the arsenic 
induced apoptosis are still not clear, especially in solid cancers. The actual 
mechanisms could be compound, dose, duration of exposure and cell-type dependent.  
 
3.3.4 In vivo bioavailability investigations 
Numerous studies have shown that the particle size is crucial for uptake and 
transport of fine particles across the GI tract mucosal barrier [Katharine EC et al., 
1996]. It is known as microparticle size-dependent exclusion phenomena in the GI 
mucosal tissue that particles less than 100 nm in size show significantly greater tissue 




1995]. Nanoparticles (NP) could reduce the adverse effects of a drug associated with 
its use under conventional pharmaceutical dosage forms and improve its 
bioavailability [Mainardes RM et al., 2005]. Formulating poorly water-soluble drugs 
as nanosized crystals can have a dramatic effect on the bioavailability [Bittner B and 
Mountfield RJ, 2002]. It should be noted that size reduction to nanocrystals will not 
be of value, when bioavailability is limited by the metabolic- and/or permeation-
related factors.  
It has been suggested that urinary excretion is the major pathway of arsenic 
elimination from system circulation [Frankenberger WT Jr, 2002c]. Therefore, short-
term exposure of humans to arsenic can be evaluated by measuring urinary arsenic as 
a marker of exposure and the extent of absorption. The biological half-life of ingested 
inorganic arsenic in humans is about 10 h, and 50-80% of arsenic absorbed is excreted 
in urine in about 3 days [Goyer RA, 1991]. Absolute bioavailability of arsenic is the 
fraction or percentage of the absorbed dose to the administered dose [Candy AC et al., 
1997]. To date, the bioavailability of arsenic has been determined in a number of 
animal models, including juvenile swines [Lorenza ML et al., 1996], monkeys 
[Freeman GB et al., 1995], rabbits [Davis A et al., 1992], dogs [Hollins JG et al., 
1979], and rats [Cui X et al., 2004]. Most of these findings indicated that majority of 
absorbed arsenic could be recovered in urine. Thus, measuring arsenic recovery in 
urine is a convenient and acceptable method of evaluating bioavailability of arsenic. 
In this study, the in vivo bioavailability was estimated from the urinary recovery of 
arsenic. The results are shown in Table 4. The urinary arsenic level was normalized 
with creatinine concentration and was presented as mg of arsenic/mmol of creatinine. 
Ranging from 58.5 to 69.6% of the administered dose of arsenic was recovered in 




original realgar powder gave a urinary recovery of only 24.9%. In 96 h, up to 85.4% 
of the dose was recovered in urine after oral administration of R/PVP/SDS; whereas 
the original realgar powder gave a urinary recovery of 31.9%. Our results showed that 
nano-sizing realgar particles enhanced the bioavailability. The co-ground realgar 
preparations consistently gave higher arsenic urinary recoveries, indicating better 
bioavailability of these preparations. 
 
Table 4. Cumulated urinary arsenic recoveries from rats treated with the 
respective realgar suspensions. Values are mean ± SD for n = 6 rats. 
 
Arsenic excretion in urine (mg As2S2/mmol creatinine); recovery 
(%) Drug (50 mg 
/kg) 
0-24 h 0-48 h 0-96 h 
Original reaglar 49.6 ± 21.2; 16.5 ± 7.0% 
68.4 ± 29.2 
24.9 ± 10.6% 
79.1 ± 33.8 
31.9 ± 13.6% 
Realgar ground 
alone 
81.9 ± 17.2; 
26.1 ± 6.1% 
114.2 ± 27.9 
38.7 ± 9.5% 
125.7 ± 33.9 
46.6 ± 12.6% 
R/PVP 107.2 ± 28.8; 37.2 ± 10.0% 
163.4 ± 43.8 
59.8 ± 16.0% 
183.6 ± 51.4 
72.5 ± 20.3% 
R/SDS 90.0 ± 17.2; 38.2 ± 7.6% 
137.8 ± 29.9 
58.5 ± 12.7% 
155.4 ± 43.9 
69.9 ± 19.7% 
R/PVP/SDS 108.9 ± 15.6; 55.9 ± 6.4% 
156.1 ± 27.3 
69.6 ± 12.2% 
179.5 ± 51.3 




Nanosized realgar particles were successfully produced by cryo-grinding 
method. With the assistance of PVP and/or SDS, the grinding efficiency was 
enhanced and the physical properties of the nanoparticles, including the sizes, 
polydispersity and zeta potentials were improved.  
In in vitro study, the realgar nanoparticles were used to treat some human 
gynecological cancer cell lines, and significant anti-proliferation effects comparable 




lines CI80-13S was even more sensitive to realgar than to arsenic trioxide. Through 
cell cycle analysis, apoptosis induced by realgar nanoparticles was concluded from 
the appearance of the characterized sub-G1 phase in cell cycle histogram. This result 
was further confirmed by DNA laddering analysis.  
In this study, the extent of absorption was evaluated from the urinary recovery 
of arsenic. Since the in vivo bioavailability studies were carried out under the same 
experimental conditions, any difference in the urinary recoveries from various 
preparations would be caused by the difference in the extent of absorption. The 
compound that is not orally absorbed could be passed out in the feces. Despite this 
model could estimate the extent of availability of arsenic to the body, it gave no 
information on the concentrations of the compound in blood and various tissues. To 
determinate arsenic in blood and various tissues, a more specific and sensitive 
analytic technique than GFAAS used in this study, such as high-performance liquid 
chromatography (HPLC) – inductively coupled argon plasma mass spectrometry (ICP 
MS) could be applied in the future studies [Mandal BK et al., 2004]. 
After oral administration of the ground realgar preparation, the urinary arsenic 
excretion was significantly increased compared with that in rats given orally with the 
original realgar powder. The improvement in bioavailability was attributed to the 
realgar particles size reduction. Realgar has been suggested to be a less toxic 
compound in arsenic superfamily. The usage of realgar nanoparticles could overcome 
the usage limitation associated with its poor water-solubility and allow it being used 










Evaluation of the in vitro activity and in vivo 
bioavailability of orpiment nanoparticles 













Orpiment (O) (As2S3) is a monoclinic crystal with orange-yellow color. The 
unit cell of orpiment is shown in Figure 1. 
 
Ass    
SS  
Figure 1. The unit cell of orpiment. 
 
Inspired by the promising results of arsenic trioxide and realgar in the 
treatment of APL, orpiment was tested in the present study for in vitro activity on 
some solid cancer cell lines and in vivo bioavailability after oral administration of its 
reduced sized particles. The nanosized orpiment particles were prepared by the cryo-
grinding approach with the assistance of PVP and SDS. The in vitro cytotoxicity of 
the orpiment nanoparticles was assessed on human ovarian (OVCAR-3) and cervical 
(HeLa) cancer cell lines with two normal human fibroblast cell lines (MRC-5 and HF) 
as controls. For the in vivo study, a SD rat model was selected to estimate the oral 
bioavailability of the reduced sized orpiment particles based on the urinary recovery 
of arsenic.  
 
4.2 Materials and methods 
The materials and methods could be referred to Section of 3.2 in Chapter 3. 
 
4.3 Results and discussion 




The filtrates of the original orpiment course powder (sieved through 150 μm 
pore size mesh before weighing), ground orpiment alone particles, and co-ground 
O/PVP/SDS preparation were obtained, and some physical properties were analyzed 
as shown in Table 1. 
According to the increased amounts of soluble arsenic in the O/PVP/SDS 
filtrate, the presence of PVP and SDS facilitated the production of the larger amounts 
of orpiment fine particles of 200 nm or less during cryo-grinding process (Table 1).  
 
Table 1. Physical properties of the orpiment nanoparticles in the filtrates 
collected after filtering the respective orpiment suspensions through the 0.2 μm 






















152.8 ± 5.54 222.4 ± 5.70 0.21 ± 0.02 -8.50 ± 2.90 
 
 
Judging from the particle size (p < 0.05, O/PVP/SDS vs original orpiment; p < 
0.01, O/PVP/SDS vs ground original without additives) and PI values (p < 0.05, 
O/PVP/SDS vs original orpiment; p < 0.05, O/PVP/SDS vs groud orpiment without 
additives), more homogeneous particles were produced after co-grinding with the 
additives (Table 1).  
After pulverizing with PVP and SDS, the negative zeta potential value of the 
O/PVP/SDS nanoparticle indicated that both PVP and the negatively charged SDS 




ground R/PVP/SDS preparation as shown in Chapter 3 (Table 1). The orpiment 
nanosuspension was thus stabilized by steric and ionic barriers formed on the particle 
surface by adsorption of PVP and SDS. Similar effects of PVP and SDS on 
stabilization of drugs nanosuspensions were previously reported [Koichi I et al., 2003].  
TEM was used to examine the morphology of orpiment nanoparticles from the 
ternary O/PVP/SDS preparation. Figure 2 displays the TEM image of the O/PVP/SDS 
filtrate. Once again, the particle sizes measured by the TEM were found to be smaller 
than those observed by Zetasizer, in consistent with the observation for the 
R/PVP/SDS filtrate (see Chapter 3).   
 






















To study the crystallinity of the orpiment after the cryo-grinding treatment, the 
XRDs of the respective orpiment powders were scanned. Figure 3 shows that the 
XRD patterns of the ground orpiment alone and ternary O/PVP/SDS preparations 
almost overlaid each other, indicating there was no change in the crystallinity of the 
































2θ (o)  
 
Figure 3. Powder XRD patterns of various orpiment preparations: Orpiment 




In summary, orpiment nanocrystals were formed successfully by cryo-
grinding technique. PVP and SDS not only enhanced the grinding efficiency, but also 
helped to stabilize the corresponding orpiment nanosuspension.  
 
4.3.2 In vitro activities of the nanosized orpiment particles on human ovarian 
and cervical cancer cell lines 
For this purpose, both OVCAR-3 and HeLa cancer cell lines were chosen, 
whilst normal fibroblast MRC-5 and HF cell lines were tested as controls. Exposure 
of these cancer cell lines to the filtrates of the different orpiment preparations caused 
inhibited growth in a dose-dependent manner, and the respective IC50 values are 
summarized in Table 2. Comparing the IC50 values of O/PVP/SDS nanosuspension 
(3.11 ± 0.44 μM on OVCAR-3 cells; 3.21 ± 0.46 μM on HeLa cells) with those of 
R/PVP/SDS nanosuspension (4.06 ± 0.45 μM on OVCAR-3 cells; 3.51 ± 0.48 μM on 




on HeLa cells), the effect of orpiment nanoparticles on OVCAR-3 cells is not 
significantly different from those of realgar (p > 0.05, orpiment vs realgar) and 
arsenic trioxide (p > 0.05, orpiment vs arsenic trioxide); orpiment nanosuspension had 
similar cytotoxic effect to realgar on HeLa cells (p > 0.05), but it was less cytotoxic 
than arsenic trioxide (p < 0.05). Different types of orpiment formulations did not 
show significant differences on the anti-proliferation effect on the target cancer cells 
in terms of the IC50 values (p > 0.05). 
 
Table 2. IC50 (μM as As2S3) of different orpiment particles in OVCAR-3 and 
HeLa cells exposed for 3 days. Results are the mean ± SD from at least three 
independent experiments. 
 
IC50 (μM as As2S3)  
OVCAR-3 HeLa MRC-5 HF 
Original orpiment 
particles 3.54 ± 0.50 3.01 ± 0.39 * * 
Orpiment ground 
alone particles 3.01 ± 0.40 3.12 ± 0.31 * * 
O/PVP/SDS 3.11 ± 0.44 3.21 ± 0.46 * * 
* IC50 could not be reached in the test dose range. 
 
 
4.3.3 Assessment of the apoptotic effects of the orpiment nanosuspension 
The distribution of the target cancer cells in the various phases of cell cycle 
was analyzed after treatment with the filtrate of the O/PVP/SDS preparation for 72 h 
as shown in Figure 4. DNA content distribution histograms clearly indicated that 
exposure of all cancer cells to the O/PVP/SDS filtrate resulted in the appearance of 
cells with a fractional DNA content forming a well-defined sub-G1 peak, a typical 
profile of apoptotic cells. The proportions of all cancer cell lines tested in the G2/M 
phase were also increased. This result suggested that orpiment induced apoptosis 




treatment, no major variation in the cell phase distribution was noted in the MRC-5 
and HF cells (not shown).  
 
 




OVCAR-3 control OCVAR-3 after  
O/PVP/SDS treatment 
 
Figure 4. Histograms of the cell cycle distribution of the cell lines treated with 
the O/PVP/SDS nanoparticles at the concentration of IC50 for 72 h.  
 
 
4.3.4 In vivo bioavailability investigations 
4 5 3 
3 5 
In this study, the in vivo bioavailability was estimated based on the urinary 
recovery of arsenic. The results are shown in Table 3. After oral administration of the 
O/PVP/SDS suspension, most of the ingested arsenic (75.8 ± 27.2% of the total dose) 
was recovered in the urine within 96 h, more than twice than the arsenic recovery of 
the original orpiment course powder (33.2 ± 14.2% of the total dose). The increased 
arsenic urinary recovery after oral administration of the reduced sized orpiment 





Table 3. Cumulated urinary arsenic recoveries from rats orally given original 
rpiment and O/PVP/SDS. Values are mean ± SD for n = 6. o
 
Arsenic excretion in urine (mg As2S2/mmol creatinine; recovery %) Drug (50 mg 
/kg) 




44.2 ± 14.6; 
14.7 ± 7.0% 
62.9 ± 26.4 
22.9 ± 10.0% 
82.3 ± 33.9 
33.2 ± 14.2% 
O/PVP/SDS 92.8 ± 18.2; 47.6 ± 9.8% 
117.8 ± 25.8 
60.9 ± 16.4% 
160.4 ± 45.7 




Nanosized orpiment particles were successfully produced by cryo-grinding 
method with the assistance of PVP and SDS. In the in vitro study, the orpiment 
nanoparticles were used to treat some human gynecological cancer cell lines, and 
significant anti-proliferation effects comparable to realgar nanoparticles and arsenic 
trioxide were observed. Through cell cycle analysis, apoptosis induced by the 
orpiment nanosuspension was concluded from the appearance of the characterized 
sub-G1 phase in the cell cycle histogram.  
In this study, the extent of absorption was evaluated from the urinary recovery 
of arsenic. After oral administration of the co-ground orpiment particles, the urinary 
arsenic excretion was significantly increased, when compared to the rats given orally 
with the original orpiment course powder. The improvement in bioavailability was 
attributed to the orpiment particles size reduction. Orpiment has been suggested to be 
a less toxic compound in arsenic superfamily. The usage of orpiment nanoparticles 
could overcome the usage limitation associated with its poor water-solubility and 












Gene expression profiles of HeLa cells after 














Arsenic has sustained a mysterious and quixotic public image for a number of 
centuries. The action mechanisms of arsenic are very complex. In addition, the effects 
of arsenicals are dose [Barchowsky A et al., 1999], time [Roboz GJ et al., 2000], and 
species dependent [Styblo M et al., 2000]. In particular, several arsenic-induced 
effects exhibit a biphasic characteristic. For example, low doses of arsenic in cell 
culture increase cell proliferation and enhance endocrine signaling, whereas higher 
but still noncytotoxic doses suppress these same pathways [Barchowsky A et al., 
1999]. Likewise, patterns of altered gene expression, as detected by microarray 
studies, demonstrated very different patterns at low versus high doses [Andrew AS, 
2003].  
Cancer is a disease caused, at least in part, by somatic and inherited mutations 
in genes called oncogenes and tumor suppressor genes. Microarray is a new powerful 
tool for studying the molecular basis of interactions on a scale that is impossible using 
conventional analysis [van’t Veer LJ et al., 2002]. This technology promises to lead to 
improvement in developing rational approaches to therapy as well as to improvement 
in cancer diagnosis and prognosis.  
There are two main types of microarray: cDNA and oligonucleotide 
microarrays. The major advantages of oligonucleotide microarray might minimize any 
cross-hybridization between spots on the same array despite the representation of 
closely related members of the same gene families [Kreil DP et al., 2006].  
To better characterize the transcriptional response to realgar, orpiment, arsenic 
trioxide and arsenite, we employed oligonucleotide microarrays to assess gene 
expression profiles of cultured cervical cancer cell, HeLa. To our knowledge, this is 




and orpiment and arsenic trioxide in HeLa. 
 
5.2 Materials and methods 
5.2.1 Cell lines and drug treatments 
 HeLa cell line was chosen for assessment of gene expression profiles change 
after drug treatments. Stock solutions of nanosized realgar from the R/PVP/SDS 
preparation and nanosized orpiment from the O/PVP/SDS preparation each with a 
concentration of 100.0 ppm were made according to the procedures indicated in 
Chapter 3 and 4. As2O3 stock solution was prepared by directly dissolving As2O3 in 
PBS at a concentration of 100.0 ppm. Arsenite stock solution with a concentration of 
100.0 ppm was obtained by dissolving appropriate amount of As2O3 in 10 mM NaOH 
followed by pH adjustment using concentrated HCl to pH 7.0 ± 0.2. All were diluted 
to the respective working concentrations with culture medium before use, and the 
actual concentrations were further confirmed by GFAAS. The actual treatment 
concentrations were 1.5 and 4.5 μM for realgar, 2.0 and 6.0 μM for orpiment, 3.5 μM 
for As2O3, and 3.0 μM for arsenite. The treatment durations were kept for 24 h. 
Approximate 80% cells were live after high dose realgar and orpiment treatments, 
almost same as those after arsenic trioxide and arsenite treatments.  
 
5.2.2 Microarray analysis procedure 
Oligo GEArray® Human Cancer Microarray chips (OHS-802) were supplied 
by SuperArray Bioscience Corp. (Frederick, MD, USA), containing 440 genes that 
include members of several different pathways frequently altered during the 
progression of cancer. The corresponding gene lists could be found on the company’s 




Oligo GEArray contains a pre-biotinylated oligonucleotide with an artificial sequence 
in the lower right-hand corner of the membrane. Spots immediately to the left of the 
corner contain smaller amounts of the same oligonuceotide as shown in Picture 
below. These spots are detection controls, showing whether the detection steps were 
performed properly. A specific set of housekeeping genes (darkly circled in Picture, at 
positions of 1, 2, 14, 15, 16, 17, 164, 181, 198, 363, 378, 393, 408, 433, 449, 465, 
466, 467) was used as landmarks to insure that the array image has been placed in the 
correct orientation for data analysis as well as positive controls for the success of the 
microarray experiment. 


































In detail, the entire protocol mainly includes: 
1) Total RNA preparation and quality control. 
High quality RNA is essential for obtaining good microarray results. Total 
RNA from drug treated and untreated (as control) cancer cells were isolated and 




following manufacturer’s protocols. Purity and concentration of RNA were assessed 
by NanoDrop® ND-1000 Spectrophotometer (NanoDrop Technologies Inc., 
Wilmington, Delaware, USA) through determination of absorbance at 230 (A230), 260 
(A260) and 280 nm (A280). All RNA samples must meet all of the following criteria: 1) 
concentration by A260 should be greater than 11 ng/μl total RNA; 2) A260/A280 ratio 
should be greater than 2.0; and 3) A260/A230 ratio should be greater than 1.7. In 
addition, ribosomal RNA band integrity was also required and tested by agarose gel 
electrophoresis. The appearance of a sharp distinction at the small side of both the 
18S and 28S ribosomal RNA (rRNA) bands/peaks was verified to indicate that 









2) cRNA synthesis and labeling. 
TrueLabeling-AMPTM 2.0 Kit from SuperArray Bioscience Corp. was used for 
conversion of experimental RNA to biotinylated UTP labeled cDNA target based on 
the manufacturer’s instructions. A new proprietary in vitro transcription (IVT)-based 
RNA linear amplification technique was involved in such kit. The synthesis was 
processed in MyCyclerTM thermal cycler (BioRad Laboratories, Hercules, CA, USA). 








unincorporated nucleotide that will interfere with the calculation of the actual yield of 
the purified cRNA product required for Oligo GEArray hybridization. Therefore, 
before characterizing the cRNA yield and purity, cRNA purification was proceed by 
using SuperArray ArrayGrade cRNA Cleanup kit. Thereafter, the quantification and 




GEAhyb Hybridization Solution from SuperArray Bioscience Corp. was used 
for hybridization of the designated microarray chip with the labeled cDNA probes 
synthesized strictly according to the manufacturer’s guidelines. Prehybridization of 
the chip was required. The hybridization process was conducted in a hybridization 
oven (ProBlot 12S, Labnet International Inc., Woodbridge, NJ, USA). After 
hybridization, the chip was washed strictly following the manufacturer’s manual.  
 
4) Chemiluminescent detection. 
Chemiluminescent Detection Kit from SuperArray Bioscience Corp. was used. 
 
 5) Image and data acquisition. 
 A cooled CCD camera from Alpha Innotech Corp. (FluorChemTM 9900, San 
Leandro, CA, USA) was used for image acquisition. Their advantages include lower 
backgrounds and good dynamic ranges. Fifteen minutes exposure time was set for 
each image taken. 
 




 The microarray data were analyzed by means of GEArray Expression Analysis 
Suite 2.0. The “minimum value” was selected for background correction, and 
housekeeping genes which have stable expression so called “selected genes” were 
chosen for normalization to eliminate as much systematic variation as possible. This 
software provides a statistical means to determine the presence or absence of a gene in 
a sample. The definition of “absent/present” is based on two reasons. First, there is 
about 10% covariance in microarray printing; second, it is an empirically-derived 
value based on a lot of experiments in Superarray. In detail, a spot is considered 
“absent” if the average intensity of the spot is less than the mean value of the local 
backgrounds of the lower 75% of all non-bleeding spots. All other spots are 
considered “present”. The fold change of the DNA level was calculated by dividing 
the mean signal value of drug-treated cells by that of the control cells. The gene 
probes whose signal values were statistically different from those of the 
corresponding controls, and the fold change between the drug-treated and the control 
cells were determined to be above 2 (up-regulated genes) or below 0.5 (down-
regulated genes). Finally, gene probes whose Detection Calls gave presence in all the 
drug-treated or control cells for the above selected up- or down-regulated gene 
probes, respectively, were selected.  
 
5.3 Results and discussion 
The representative images of membrane array from the control and drug-
treated HeLa cells are shown in Figure 1 (a-g). The intensity of the signal for all the 
housekeeping genes was similar in untreated and arsenic-treated cells (p > 0.05), 



















Figure 1. The scanning results of hybridizing signals on gene chips displaying the 
gene expression alteration: (a) HeLa control; (b) after realgar treatment with 
low concentration; (c) after realgar treatment with high concentration; (d) after 
orpiment treatment with low concentration; (e) after orpiment treatment with 




Under the criteria of ≥ 2-fold and ≤ 0.05-fold differences, arsenic-treated HeLa 
cells had up-regulated genes and down-regulated genes, comparing to the control 
cells, as summarized in Table 1 (a-f). Blank, housekeeping genes, and genes which 




a c d b 









Functional gene grouping;  
Description 
Fold change GO term 
NM_006644 
HSPH1 
Other cancer-related genes;  
Heat shock 105kDa/110kDa protein 1 
2.62 ATP binding;Cytoplasm;Heat shock protein activity; 
NM_002266 
KPNA2 
Other cancer-related genes;  
Karyopherin alpha 2 (RAG cohort 1, 
importin alpha 1) 
2.47 
Protein binding;Cytoplasm;Nucleoplasm;DNA metabolism;Regulation of 
DNA recombination;Intracellular protein transport;Protein transporter 
activity;Nuclear localization sequence binding;G2 phase of mitotic cell 




Other cancer-related genes;  








Other cancer-related genes;  
Thioredoxin reductase 1 
2.25 
 
Signal transduction;Cytoplasm;Electron transport;Metal ion 
binding;Disulfide oxidoreductase activity;Oxidoreductase activity, acting on 
NADH or NADPH, disulfide as acceptor;Thioredoxin-disulfide reductase 
activity; 
    
NM_001605 
AARS 
Other cancer-related genes;  
Alanyl-tRNA synthetase 
0.30 
ATP binding;Nucleic acid binding;Cytoplasm;Ligase activity;Soluble 
fraction;TRNA binding;Protein biosynthesis;Alanine-tRNA ligase 
activity;Alanyl-tRNA aminoacylation;TRNA processing; 
NM_183356 
ASNS 
Other cancer-related genes;  
Asparagine synthetase 
0.43 
Ligase activity;Soluble fraction;Metabolism;Glutamine 




Other cancer-related genes;  
Calnexin 
0.50 
Integral to plasma membrane;Sugar binding;Heterophilic cell 
adhesion;Chaperone activity;Protein secretion;Endoplasmic reticulum 






Signal transduction;  
Signal transduction: Dishevelled, dsh 
homolog 1 (Drosophila) 
0.48 
Protein binding;Cytoplasm;Intracellular signaling cascade;Signal transducer 




Cell cycle, cell growth and 
differentiation, signal transduction; 
 Interferon induced transmembrane 
protein 1 (9-27) 
0.42 
Receptor signaling protein activity;Plasma membrane;Integral to 
membrane;Immune response;Negative regulation of cell 
proliferation;Regulation of cell cycle;Cell surface receptor linked signal 
transduction;Response to biotic stimulus; 
NM_000598 
IGFBP3 
Cell growth and differentiation;  
 Insulin-like growth factor binding 
protein 3 
0.33 
Regulation of cell growth;Extracellular;Cell growth and/or 
maintenance;Metal ion binding;Insulin-like growth factor binding;Protein 
tyrosine phosphatase activator activity;Negative regulation of signal 




Cell cycle, cell growth and 
differentiation;  
V-myc myelocytomatosis viral 
oncogene homolog (avian) 




Table 1b. The differently expressed genes (fold change ≥ 2.0) after realgar treatment with high concentration. 
 
Chip c 
GeneBank Symbol & Description Fold change GO term 
NM_183356 
ASNS 
Other cancer-related genes;  
Asparagine synthetase 
2.62 
Ligase activity;Soluble fraction;Metabolism;Glutamine 




cell cycle, cell growth and 
differentiation;  
2.37 
Hydrolase activity;Cell proliferation;Intracellular;Regulation of cyclin 
dependent protein kinase activity;Mitosis;Protein amino acid 




Cell division cycle 25A mitotic cell cycle; 
NM_001806 
CEBPG 
Other cancer-related genes; 
CCAAT/enhancer binding protein 
(C/EBP) gamma 
2.30 DNA binding;Regulation of transcription, DNA-dependent;Nucleus; 
NM_001964 
EGR1 
Other cancer-related genes;  
Early growth response 1 
3.36 Regulation of transcription, DNA-dependent;Nucleus;Transcription factor activity;Zinc ion binding; 
NM_005438 
FOSL1 
Cell growth and differentiation;  
FOS-like antigen 1 
4.65 
Nucleus;Transcription factor activity;Positive regulation of cell 
proliferation;Response to virus;Regulation of transcription from Pol II 
promoter;Chemotaxis;Cellular defense response; 
NM_004864 
GDF15 
Cell growth and differentiation;  
Growth differentiation factor 15 
2.05 
Signal transduction;Extracellular;Growth factor activity;Cell-cell 




Other cancer-related genes;  
Insulin-like growth factor 2 receptor 
2.30 
Signal transduction;Receptor activity;Lysosome;Integral to plasma 
membrane;Insulin-like growth factor receptor activity;Transporter 
activity;Receptor mediated endocytosis;Transport; 
NM_002228 
JUN 
Cell growth and differentiation;  
V-jun sarcoma virus 17 oncogene 
homolog (avian) 
2.58 
Regulation of transcription, DNA-dependent;Cell growth and/or 
maintenance;Transcription factor activity;RNA polymerase II 




Phosphoprotein enriched in astrocytes 15 
3.55 
Protein binding;Regulation of apoptosis;Anti-
apoptosis;Transport;Sugar porter activity;Negative regulation of 




Tumor necrosis factor receptor 
superfamily, member 10b 
2.63 
Integral to membrane;Signal transduction;Protein binding;Electron 
transporter activity;Induction of apoptosis;Regulation of 
apoptosis;Induction of apoptosis via death domain receptors;Positive 
regulation of I-kappaB kinase/NF-kappaB cascade;Receptor 
activity;Iron ion binding;Electron transport;TRAIL binding;Caspase 
activator activity;Caspase activation;Activation of NF-kappaB-
inducing kinase; 






Other cancer-related genes;  
Alanyl-tRNA synthetase 
0.39 
ATP binding;Nucleic acid binding;Cytoplasm;Ligase activity;Soluble 
fraction;TRNA binding;Protein biosynthesis;Alanine-tRNA ligase 
activity;Alanyl-tRNA aminoacylation;TRNA processing; 
NM_000927 
ABCB1 
Other cancer-related genes;  
ATP-binding cassette, sub-family B 
(MDR/TAP), member 1 
0.41 
ATP binding;Integral to membrane;Membrane fraction;Transporter 
activity;Transport;ATP-binding cassette (ABC) transporter 
activity;Nucleotide binding;Response to drug; 
NM_001610 
ACP2 
Other cancer-related genes;  
Acid phosphatase 2, lysosomal 
0.37 Hydrolase activity;Integral to membrane;Acid phosphatase activity;Lysosomal membrane; 
NM_000666 
ACY1 
Cell motility;  
Aminoacylase 1 
0.26 
Hydrolase activity;Proteolysis and 




Other cancer-related genes;  
Basic helix-loop-helix domain 
containing, class B, 2 
0.19 Regulation of transcription, DNA-dependent;Nucleus;Transcription factor activity; 
NM_000386 
BLMH 
Other cancer-related genes;  
Bleomycin hydrolase 
0.42 





Cell growth and differentiation;  
Calpain 1, (mu/I) large subunit 
0.44 
Hydrolase activity;Calcium ion binding;Proteolysis and 




Signal transduction;  
CD59 antigen p18-20 (antigen identified 
by monoclonal antibodies 16.3A5, EJ16, 
EJ30, EL32 and G344) 
0.41 Plasma membrane;Immune response;Membrane fraction;Cell surface receptor linked signal transduction;Blood coagulation; 
NM_001255 
CDC20 
Cell cycle;  
CDC20 cell division cycle 20 homlog (S. 
cerevisiae) 






Cell cycle, cell growth and 
differentiation;  
Cell division cycle 25B 
0.33 
Hydrolase activity;Regulation of cell cycle;Positive regulation of cell 
proliferation;Intracellular;Mitosis;Protein amino acid 
dephosphorylation;Protein tyrosine phosphatase activity;M phase of 
mitotic cell cycle; 
NM_003718 
CDC2L5 
Cell growth and differentiation;  
Cell division cycle 2-like 5 
(cholinesterase-related cell division 
controller) 
0.38 
ATP binding;Transferase activity;Protein amino acid 
phosphorylation;Protein serine/threonine kinase activity;Positive 
regulation of cell proliferation;Development;Regulation of mitosis; 
NM_004064 
CDKN1B 
Cell cycle, cell growth and 
differentiation;  
Cyclin-dependent kinase inhibitor 1B 
(p27, Kip1) 
0.46 
Nucleus;Negative regulation of cell proliferation;Cell cycle 
arrest;Cyclin-dependent protein kinase inhibitor activity;Regulation of 
cyclin dependent protein kinase activity;Transforming growth factor 
beta receptor, cytoplasmic mediator activity; 
NM_006384 
CIB1 
Other cancer-related genes;  
Calcium and integrin binding 1 
(calmyrin) 
0.30 Calcium ion binding;Cell adhesion;Protein binding;Double-strand break repair; 
NM_020990 
CKMT1B 
Other cancer-related genes;  
Creatine kinase, mitochondrial 1B 
0.17 Mitochondrion;Creatine kinase activity;Transferase activity, transferring phosphorus-containing groups; 
NM_001291 
CLK2 
Other cancer-related genes;  
CDC-like kinase 2 
0.10 
ATP binding;Transferase activity;Protein amino acid 
phosphorylation;Nucleus;Protein serine/threonine kinase 
activity;Protein-tyrosine kinase activity; 
NM_001293 
CLNS1A 
Cell growth and differentiation;  




perception;Chloride transport;Auxiliary transport protein 
activity;Regulation of cell volume; 
NM_004374 
COX6C 
Other cancer-related genes;  
Cytochrome c oxidase subunit VIc 
0.38 
Energy pathways;Integral to membrane;Oxidoreductase 
activity;Mitochondrion;Electron transport;Inner 
membrane;Cytochrome-c oxidase activity; 




Signal transduction;  
Casein kinase 1, gamma 2 
phosphorylation;Signal transduction;Protein serine/threonine kinase 
activity;Wnt receptor signaling pathway;Protein kinase activity;Casein 
kinase I activity 
NM_001905 
CTPS 
Other cancer-related genes;  
CTP synthase 
0.19 
Ligase activity;Nucleobase, nucleoside, nucleotide and nucleic acid 
metabolism;Response to drug;CTP synthase activity;Glutamine 
metabolism;Pyrimidine nucleotide biosynthesis; 
NM_001814 
CTSC 
Other cancer-related genes;  
Cathepsin C 
0.12 
Hydrolase activity;Immune response;Proteolysis and 
peptidolysis;Lysosome;Cysteine-type endopeptidase 
activity;Dipeptidyl-peptidase I activity; 
NM_003592 
CUL1 




Protein binding;Negative regulation of cell proliferation;Cell cycle 
arrest;G1/S transition of mitotic cell cycle;Cell cycle;Induction of 
apoptosis by intracellular signals; 
NM_001920 
DCN 
Other cancer-related genes;  
Decorin 
0.13 Extracellular matrix;Organogenesis; 
NM_001360 
DHCR7 
Other cancer-related genes;  
7-dehydrocholesterol reductase 
0.08 
Integral to membrane;Oxidoreductase activity;Endoplasmic 




Signal transduction;  
Dishevelled, dsh homolog 1 (Drosophila) 
0.26 
Protein binding;Cytoplasm;Intracellular signaling cascade;Signal 
transducer activity;Development;Morphogenesis;Heart 
development;Frizzled signaling pathway; 
NM_005225 
E2F1 
Apoptosis, cell cycle, cell growth and 
differentiation;  
E2F transcription factor 1 
0.14 
Regulation of transcription, DNA-
dependent;Nucleus;Apoptosis;Regulation of cell cycle;Transcription 
factor activity;Negative regulation of transcription from Pol II 
promoter;G1 phase of mitotic cell cycle;Transcription corepressor 
activity;Transcription factor complex; 
NM_000122 
ERCC3 
Other cancer-related genes;  
Excision repair cross-complenenting 
rodent repair deficiency, 
complementation group 3 (xeroderma 
0.46 
ATP binding;Hydrolase activity;Regulation of transcription, DNA-
dependent;Nucleus;Protein binding;Induction of 
apoptosis;Transcription from Pol II promoter;Damaged DNA 
binding;Perception of sound;DNA unwinding;3' to 5' DNA helicase 




pigmentosum group B complementing) III site-specific deoxyribonuclease activity;DNA 
restriction;Transcription-coupled nucleotide-excision 
repair;Transcription factor TFIIH complex; 
NM_001992 
F2R 
Apoptosis, cell cycle, cell motility, 
signal transduction;  
Coagulation factor II (thrombin) receptor 
0.41 
Golgi apparatus;Receptor binding;Signal 
transduction;Apoptosis;Regulation of cell cycle;G-protein coupled 
receptor protein signaling pathway;Positive regulation of I-kappaB 
kinase/NF-kappaB cascade;Integral to plasma membrane;Response to 
wounding;Cell motility;Blood coagulation;Caspase 
activation;Rhodopsin-like receptor activity;Thrombin receptor 
activity;STAT protein nuclear translocation;Morphogenesis;Tyrosine 
phosphorylation of STAT protein; 
NM_000138 
FBN1 
Other cancer-related genes;  
Fibrillin 1 (Marfan syndrome) 
0.44 
Calcium ion binding;Development;Extracellular matrix;Extracellular 




Cell cycle;  
FK506 binding protein 12-rapamycin 
associated protein 1 
0.44 
Transferase activity;Regulation of cell cycle;DNA 
recombination;DNA repair;Inositol or phosphatidylinositol kinase 
activity;Phosphoinositide 3-kinase complex; 
NM_001518 
GTF2I 
Other cancer-related genes;  
General transcription factor II, i 
0.28 
Signal transduction;Regulation of transcription, DNA-
dependent;Nucleus;Protein binding;Transcription factor 
activity;Transcription initiation from Pol II promoter;General RNA 
polymerase II transcription factor activity; 
NM_004494 
HDGF 
Cell growth and differentiation;  
Hepatoma-derived growth factor (high-
mobility group protein 1-like) 
0.44 Cell proliferation;Signal transduction;Cytoplasm;Extracellular space;Heparin binding;Growth factor activity; 
NM_002127 
HLA-G 
Other cancer-related genes;  
HLA-G histocompatibility antigen, class 
I, G 
0.40 
Integral to membrane;Cellular defense response;Antigen processing, 
endogenous antigen via MHC class I;MHC class I receptor 
activity;Antigen presentation, endogenous antigen;Detection of pest, 
pathogen or parasite; 




Cell cycle, cell growth and 
differentiation, signal transduction;  
Interferon induced transmembrane 
protein 1 (9-27) 
membrane;Immune response;Negative regulation of cell 
proliferation;Regulation of cell cycle;Cell surface receptor linked 
signal transduction;Response to biotic stimulus; 
NM_000598 
IGFBP3 
Cell growth and differentiation;  
Insulin-like growth factor binding protein 
3 
0.20 
Regulation of cell growth;Extracellular;Cell growth and/or 
maintenance;Metal ion binding;Insulin-like growth factor 
binding;Protein tyrosine phosphatase activator activity;Negative 
regulation of signal transduction;Positive regulation of 
apoptosis;Positive regulation of myoblast differentiation; 
NM_004517 
ILK 
Cell motility, signal transduction;  
Integrin-linked kinase 
0.31 
ATP binding;Transferase activity;Protein amino acid 
phosphorylation;Protein serine/threonine kinase activity;Cell-matrix 
adhesion;Integrin-mediated signaling pathway; 
NM_001571 
IRF3 
Other cancer-related genes;  
Interferon regulatory factor 3 
0.37 
Regulation of transcription, DNA-dependent;Nucleus;Transcription 
factor activity;RNA polymerase II transcription factor 




Cell motility, signal transduction;  
Integrin, alpha 3 (antigen CD49C, alpha 3 
subunit of VLA-3 receptor) 
0.47 Integral to membrane;Protein binding;Receptor activity;Cell-matrix adhesion;Integrin-mediated signaling pathway;Integrin complex 
NM_002291 
LAMB1 
Other cancer related genes;  
Laminin, beta 1 
0.33 Structural molecule activity;Cell adhesion;Protein binding;Basement membrane; 
NM_002337 
LRPAP1 
Cell growth and differentiation;  
Low density lipoprotein receptor-related 
protein associated protein 1 
0.32 
Plasma membrane;Integral to membrane;Calcium ion binding;Cell 
proliferation;Heparin binding;Endoplasmic reticulum;Protein 
folding;Chaperone activity;Asialoglycoprotein receptor 
activity;Lipoprotein binding;Vesicle-mediated transport; 
NM_030662 
MAP2K2 
Other cancer-related genes;  
Mitogen-activated protein kinase kinase 2 
0.37 
ATP binding;Transferase activity;Protein amino acid 
phosphorylation;Extracellular;Protein serine/threonine kinase 
activity;Protein-tyrosine kinase activity; 
NM_004635 MAPKAPK3 Other cancer-related genes;  0.45 
ATP binding;Transferase activity;Protein amino acid 





activated protein kinase 3 
kinase activity;Response to stress;MAP kinase kinase activity; 
NM_004526 
MCM2 
Cell cycle;  
MCM2 minichromosome maintenance 
deficient 2, mitotin (S. cerevisiae) 
0.38 
ATP binding;DNA binding;Regulation of transcription, DNA-
dependent;Nucleus;DNA replication;Chromatin;Cell cycle;DNA-
dependent ATPase activity;DNA replication initiation; 
NM_002467 
MYC 
Cell cycle, cell growth and 
differentiation;  
V-myc myelocytomatosis viral oncogene 
homolog (avian) 
0.09 
Cell proliferation;Nucleus;Transcription factor activity;Regulation of 




Other cancer-related genes;  
Myosin, light polypeptide 9, regulatory 
0.32 Calcium ion binding;Muscle development;Structural constituent of muscle;Regulation of muscle contraction;Muscle myosin;Myosin; 
NM_000268 
NF2 
Cell cycle, cell growth and 
differentiation;  
Neurofibromin 2 (bilateral acoustic 
neuroma) 
0.33 
Plasma membrane;Structural molecule activity;Negative regulation of 
cell cycle;Negative regulation of cell 




Cell cycle, cell growth and 
differentiation;  
Non-metastatic cells 1, protein (NM23A) 
expressed in 
0.32 
ATP binding;Transferase activity;Nucleus;Negative regulation of cell 
cycle;Negative regulation of cell proliferation;Kinase 
activity;Nucleoside-diphosphate kinase activity;CTP 




Cell cycle, cell growth and 
differentiation;  
Non-metastatic cells 2, protein (NM23B) 
expressed in 
0.39 
ATP binding;Transferase activity;Regulation of transcription, DNA-
dependent;Nucleus;Negative regulation of cell cycle;Negative 
regulation of cell proliferation;Transcription factor activity;Kinase 
activity;Nucleoside-diphosphate kinase activity;CTP 
biosynthesis;GTP biosynthesis;UTP biosynthesis;Nucleoside 
triphosphate biosynthesis; 
NM_002513 NME3 Apoptosis;  0.08 
ATP binding;Transferase activity;Induction of 




Non-metastatic cells 3, protein expressed 
in 
activity;CTP biosynthesis;GTP biosynthesis;UTP biosynthesis; 
NM_005654 
NR2F1 
Other cancer-related genes;  
Nuclear receptor subfamily 2, group F, 
member 1 
0.08 
Signal transduction;Regulation of transcription, DNA-
dependent;Nucleus;Transcription factor activity;Transcription 
coactivator activity;Steroid hormone receptor activity;Ligand-
regulated transcription factor activity; 
NM_005234 
NR2F6 
Other cancer-related genes;  
Nuclear receptor subfamily 2, group F, 
member 6 
0.16 
Signal transduction;Regulation of transcription, DNA-
dependent;Nucleus;Transcription factor activity;Steroid hormone 
receptor activity;Thyroid hormone receptor activity; 
NM_182649 
PCNA 
Cell cycle, cell growth and 
differentiation;  
Proliferating cell nuclear antigen 
0.20 
Cell proliferation;DNA binding;Nucleus;Regulation of cell 
cycle;DNA replication;DNA polymerase processivity factor 
activity;DNA repair;Regulation of DNA replication;Delta-DNA 
polymerase cofactor complex; 
NM_002596 
PCTK3 
Other cancer-related genes;  
PCTAIRE protein kinase 3 
0.16 
ATP binding;Transferase activity;Protein amino acid 
phosphorylation;Signal transduction;Protein serine/threonine kinase 
activity;Cellular_component unknown;Signal transducer activity; 
NM_002649 
PIK3CG 




Transferase activity;G-protein coupled receptor protein signaling 
pathway;Inositol or phosphatidylinositol kinase 
activity;Phosphatidylinositol 3-kinase activity;Phosphatidylinositol-




Other cancer-related genes;  
Peroxisome proliferative activated 
receptor, delta 
0.32 
Energy pathways;Nucleus;Transcription factor activity;Regulation of 




Signal transduction;  
Protein kinase, cAMP-dependent, 
regulatory, type I, alpha (tissue specific 
extinguisher 1) 
0.31 
Protein amino acid phosphorylation;Intracellular signaling 
cascade;Regulation of transcription from Pol II promoter;CAMP-
dependent protein kinase regulator activity;CAMP-dependent protein 
kinase complex;3',5'-cAMP binding; 




Other cancer-related genes;  
Prostaglandin-endoperoxide synthase 1 
(prostaglandin G/H synthase and 
cyclooxygenase) 
process;Lipid metabolism;Oxidoreductase activity, acting on single 
donors with incorporation of molecular oxygen, incorporation of two 




Cell cycle;  
Prothymosin, alpha (gene sequence 28) 
0.22 Nucleus;Regulation of cell cycle;Development;Transcription; 
NM_002880 
RAF1 
Apoptosis, cell growth and 
differentiation, signal transduction;  
V-raf-1 murine leukemia viral oncogene 
homolog 1 
0.34 
Receptor signaling protein activity;ATP binding;Transferase 
activity;Protein amino acid phosphorylation;Cell proliferation;Protein 
binding;Diacylglycerol binding;Protein serine/threonine kinase 




Cell cycle, signal transduction;  
RAP1A, member of RAS oncogene 
family 
0.20 GTP binding;GTPase activity;Small GTPase mediated signal transduction;Signal transduction;Negative regulation of cell cycle; 
NM_000964 
RARA 
Cell growth and differentiation;  
Retinoic acid receptor, alpha 
0.33 
Signal transduction;Regulation of transcription, DNA-
dependent;Nucleus;Cell growth and/or maintenance;Transcription 
factor activity;Transcription coactivator activity;Steroid hormone 
receptor activity;Retinoic acid receptor activity; 
NM_000321 
RB1 
Cell cycle;  
Retinoblastoma 1 (including 
osteosarcoma) 
0.35 
Regulation of transcription, DNA-dependent;Nucleus;Negative 
regulation of cell cycle;Transcription factor activity;Negative 




Cell cycle, cell growth and 
differentiation;  
Retinoblastoma binding protein 4 
0.16 
Regulation of transcription, DNA-dependent;Nucleus;Negative 




Cell growth and differentiation;  
Prohibitin 2 
0.31 Cellular_component unknown;Receptor activity;Negative regulation of transcription;Estrogen receptor binding; 





V-rel reticuloendotheliosis viral oncogene 
homolog A, nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 3, 
p65 (avian) 
binding;Anti-apoptosis;Transcription factor activity;Signal transducer 
activity;Positive regulation of I-kappaB kinase/NF-kappaB 
cascade;Transcription from Pol II promoter;Transcription factor 
complex;Response to toxin; 
NM_002951 
RPN2 
Other cancer-related genes;  
Ribophorin II 
0.39 
Transferase activity;Integral to membrane;Protein 
modification;Dolichyl-diphosphooligosaccharide-protein 
glycotransferase activity;N-linked glycosylation via 
asparagine;Oligosaccharyl transferase complex; 
NM_003944 
SELENBP1 
Other cancer-related genes;  
Selenium binding protein 1 
0.44 Selenium binding; 
NM_015129 
SEPT6 
Cell cycle;  
Septin 6 
0.50 GTP binding;Protein binding;Cellular_component unknown;Cell cycle;Cytokinesis; 
NM_006142 
SFN 




Cell proliferation;Signal transduction;Cytoplasm;Regulation of cell 
cycle;Extracellular space;Protein domain specific binding;Protein 





CD27-binding (Siva) protein 
0.33 
Receptor signaling protein activity;Cytoplasm;Apoptosis;Induction of 
apoptosis by extracellular signals;Positive regulation of 
apoptosis;CD27 receptor binding;Defense response; 
NM_005415 
SLC20A1 
Other cancer-related genes;  
Solute carrier family 20 (phosphate 
transporter), member 1 
0.49 
Phosphate metabolism;Signal transducer activity;Positive regulation of 
I-kappaB kinase/NF-kappaB cascade;Receptor 
activity;Membrane;Integral to plasma membrane;Transport;Phosphate 




Other cancer-related genes;  
Staphylococcal nuclease domain 
containing 1 
0.35  




Other cancer-related genes;  
Small nuclear ribonucleoprotein 
polypeptide B” 




Cell motility, signal transduction;  
Signal transducer and activator of 
transcription 3 (acute-phase response 
factor) 
0.29 
Regulation of transcription, DNA-
dependent;Nucleus;Cytoplasm;Intracellular signaling 
cascade;Transcription factor activity;Negative regulation of 
transcription from Pol II promoter;Signal transducer activity;Acute-
phase response;Cell motility;JAK-STAT 
cascade;Neurogenesis;Hematopoietin/interferon-class (D200-domain) 
cytokine receptor signal transducer activity; 
NM_004749 
TBRG4 
Cell cycle, cell growth and 
differentiation;  
Transforming growth factor beta 
regulator 4 
0.27 Positive regulation of cell proliferation;Cell cycle arrest;G1 phase of mitotic cell cycle; 
NM_000545 
TCF1 
Other cancer-related genes;  
Transcription factor 1, hepatic; LF-B1, 
hepatic nuclear factor (HNF1), albumin 
proximal factor 
0.49 
Nucleus;Transcription factor activity;Regulation of transcription from 
Pol II promoter;RNA polymerase II transcription factor 




Cell cycle, cell growth and 
differentiation;  
Transcription factor Dp-1 
0.04 
Nucleus;Regulation of cell cycle;Transcription factor 
activity;Regulation of transcription from Pol II promoter;Transcription 
factor complex;Transcription coactivator activity; 
NM_003243 
TGFBR3 
Other cancer-related genes;  
Transforming growth factor, beta receptor 
III (betaglycan, 300kDa) 
0.26 
Integral to membrane;Signal transduction;Development;Receptor 
activity;Glycosaminoglycan binding;Transforming growth factor beta 
receptor signaling pathway; 
NM_003258 
TK1 
Other cancer-related genes;  
Thymidine kinase 1, soluble 
0.39 ATP binding;Transferase activity;Cytoplasm;Kinase activity;DNA metabolism;Thymidine kinase activity; 





Tumor necrosis factor receptor 
superfamily, member 1B 




Apoptosis, cell cycle;  
Tumor protein p53 (Li-Fraumeni 
syndrome) 
0.20 
ATP binding;Cell proliferation;Regulation of transcription, DNA-
dependent;Protein binding;Negative regulation of cell 
cycle;Apoptosis;Mitochondrion;Transcription factor activity;Zinc ion 
binding;DNA damage response, signal transduction resulting in 
induction of apoptosis;Cell cycle arrest;Nucleolus;Cell cycle 
checkpoint;DNA strand annealing activity;Copper ion 
binding;Nuclease activity;DNA recombination;Base-excision 
repair;Caspase activation via cytochrome c;Cell aging;Cell 
differentiation;Induction of apoptosis by hormones;Negative 
regulation of cell growth;Nucleotide-excision repair;Regulation of 
mitochondrial membrane permeability;Protein tetramerization 
activity;Negative regulation of helicase activity; 
NM_004881 
TP53I3 
Other cancer-related genes;  
Tumor protein p53 inducible protein 3 
0.38 
Cellular_component unknown;Zinc ion binding;Alcohol 




Other cancer-related genes;  
Ubiquitin specific peptidase 7 (herpes 
virus-associated) 
0.47 
Hydrolase activity;Nucleus;Ubiquitin-dependent protein 





Voltage-dependent anion channel 1 
0.35 
Integral to membrane;Mitochondrial outer 
membrane;Mitochondrion;Apoptotic program;Apoptogenic 
cytochrome c release channel activity;Voltage-dependent anion 




Other cancer-related genes;  
Peptidylprolyl isomerase H (cyclophilin 
H) 
0.39 
Protein complex assembly;Protein folding;Isomerase 
activity;Chaperone activity;Peptidyl-prolyl cis-trans isomerase 
activity;Nuclear mRNA splicing, via spliceosome;Spliceosome 
complex;Cyclosporin A binding;SnRNP protein-nucleus import; 




Other cancer-related genes;  
X-ray repair complementing defective 
repair in Chinese hamster cells 5 (double-
strand-break rejoining; Ku autoantigen, 
80kDa) 
activity;Helicase activity;Double-stranded DNA binding;Double-
strand break repair via nonhomologous end-joining;Regulation of 
DNA repair;DNA-dependent protein kinase complex; 
NM_003404 
YWHAB 
Other cancer-related genes;  
Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, beta 
polypeptide 




Table 1c. The differently expressed genes (fold change ≥ 2.0) after orpiment treatment with low concentration. 
 
Chip d 
GeneBank Symbol & Description Fold change GO term 
NM_001605 
AARS 
Other cancer-related genes;  
Alanyl-tRNA synthetase 
2.25 
ATP binding;Nucleic acid binding;Cytoplasm;Ligase activity;Soluble 
fraction;TRNA binding;Protein biosynthesis;Alanine-tRNA ligase 
activity;Alanyl-tRNA aminoacylation;TRNA processing; 
NM_000927 
ABCB1 
Other cancer-related genes;  
ATP-binding cassette, sub-family B 
(MDR/TAP), member 1 
2.74 
ATP binding;Integral to membrane;Membrane fraction;Transporter 
activity;Transport;ATP-binding cassette (ABC) transporter 
activity;Nucleotide binding;Response to drug; 
NM_005759 
ABI2 
Other cancer-related genes;  
AbI interactor 2 
2.28 DNA binding;Cytoplasm;SH3/SH2 adaptor protein activity;Kinase activity;SH3 domain binding;Biological_process unknown; 
NM_001154 
ANXA5 
Other cancer-related genes;  
Annexin A5 
2.51 Calcium ion binding;Blood coagulation;Calcium-dependent phospholipid binding;Phospholipase inhibitor activity;Negative regulation of coagulation; 
NM_004034 ANXA7 Other cancer-related genes;  2.26 
Calcium ion binding;Calcium-dependent phospholipid binding;Negative 







Other cancer-related genes;  
Asparagine synthetase 
2.01 
Ligase activity;Soluble fraction;Metabolism;Glutamine 




Other cancer-related genes;  
Calnexin 
2.44 
Integral to plasma membrane;Sugar binding;Heterophilic cell 
adhesion;Chaperone activity;Protein secretion;Endoplasmic reticulum 
membrane;Calcium ion storage activity 
NM_006367 
CAP1 
Other cancer-related genes;  
CAP, adenylate cyclase-associated 
protein 1 (yeast) 
3.79 Signal transduction;Membrane;Establishment and/or maintenance of cell polarity;Adenylate cyclase activation; 
NM_005186 
CAPN1 
Cell growth and differentiation;  
Calpain 1, (mu/I) large subunit 
3.03 
Hydrolase activity;Calcium ion binding;Proteolysis and peptidolysis;Positive 




Cell growth and differentiation;  
Calpain, small subunit 1 
2.39 Calcium ion binding;Positive regulation of cell proliferation;Calpain activity; 
NM_001255 
CDC20 
Cell cycle;  
CDC20 cell division cycle 20 
homolog (S, cerevisiae) 
3.81 Regulation of cell cycle;Mitosis;Ubiquitin-dependent protein catabolism;Spindle; 
NM_004358 
CDC25B 
Cell cycle, cell growth and 
differentiation;  
Cell division cycle 25B 
2.40 
Hydrolase activity;Regulation of cell cycle;Positive regulation of cell 
proliferation;Intracellular;Mitosis;Protein amino acid 




Cell growth and differentiation;  
Cell division cycle 25C 
2.03 
Hydrolase activity;Cell proliferation;Nucleus;Regulation of cyclin dependent 
protein kinase activity;Protein amino acid dephosphorylation;Protein 
tyrosine phosphatase activity;Regulation of mitosis;Traversing start control 
point of mitotic cell cycle; 
NM_006384 
CIB1 
Other cancer-related genes;  
Calcium and integrin binding 1 







Signal transduction;  
Casein kinase 1, gamma 2 
2.36 
ATP binding;Transferase activity;Protein amino acid phosphorylation;Signal 
transduction;Protein serine/threonine kinase activity;Wnt receptor signaling 
pathway;Protein kinase activity;Casein kinase I activity 
NM_004941 
DHX8 
Other cancer-related genes;  
DEAH (Asp-Glu-Ala-His) box 
polypeptide 8 
2.09 
ATP binding;RNA binding;Pre-mRNA splicing factor activity;RNA 
splicing;ATP-dependent RNA helicase activity;Hydrogen-transporting ATP 
synthase activity, rotational mechanism;Hydrogen-transporting ATPase 
activity, rotational mechanism;ATP synthesis coupled proton 
transport;Nuclear mRNA splicing, via spliceosome;Proton-transporting two-
sector ATPase complex;Spliceosome complex; 
NM_005225 
E2F1 
Apoptosis, and cell cycle, and cell 
growth and differentiation;  
E2F transcription factor 1 
2.17 
Regulation of transcription, DNA-dependent;Nucleus;Apoptosis;Regulation 
of cell cycle;Transcription factor activity;Negative regulation of 
transcription from Pol II promoter;G1 phase of mitotic cell 
cycle;Transcription corepressor activity;Transcription factor complex; 
    
NM_002026 
FN1 
Cell motility;  
Fibromectin 1 
0.34 
Cell adhesion;Extracellular;Oxidoreductase activity;Collagen 
binding;Extracellular matrix structural constituent;Heparin binding;Acute-
phase response;Cell migration;Metabolism;Response to wounding 
NM_002127 
HLA-G 
HLA-G histocompatibility antigen, 
class I, G 
0.38 
Integral to membrane;Cellular defense response;Antigen processing, 
endogenous antigen via MHC class I;MHC class I receptor activity;Antigen 
presentation, endogenous antigen;Detection of pest, pathogen or parasite 
NM_006389 
HYOU1 
Other cancer-related genes;  
Hypoxia up-regulated 1 
0.44 ATP binding;Response to stress;Endoplasmic reticulum;Chaperone activity; 
NM_003897 
IER3 
Apoptosis, and cell growth and 
differentiation;  
Immediate early response 3 
0.39 Integral to membrane;Cell growth and/or maintenance;Molecular_function unknown;Apoptosis;Anti-apoptosis;Morphogenesis; 
NM_002467 
MYC 
Cell cycle, and cell growth and 
differentiation;  
V-myc myelocytomatosis viral 




oncogene homolog (avian) 
NM_024408 
NOTCH2 
Apoptosis, cell cycle, cell growth 
and differentiation, signal 
transduction;  
Notch homolog 2 (Drosophila) 
0.36 
Calcium ion binding;Regulation of transcription, DNA-
dependent;Nucleus;Protein binding;Induction of apoptosis;Anti-
apoptosis;Negative regulation of cell proliferation;Cell cycle arrest;Receptor 
activity;Integral to plasma membrane;Cell 
differentiation;Neurogenesis;Protein heterodimerization activity;Cell fate 
determination;Cell growth;Regulation of development;Hemopoiesis;Cell 
surface;Morphogenesis of an epithelial sheet;Ligand-regulated transcription 
factor activity;Notch signaling pathway;Determination of left/right 





Phosphoprotein enriched in astrocytes 
15 
0.31 
Protein binding;Regulation of apoptosis;Anti-apoptosis;Transport;Sugar 




Other cancer-related genes;  
Peroxisome proliferative activated 
receptor, gamma 
0.33 
Energy pathways;Response to nutrients;Signal 
transduction;Nucleus;Transcription factor activity;Regulation of 
transcription from Pol II promoter;Steroid hormone receptor activity;Lipid 
metabolism;White adipocyte differentiation; 
NM_004162 
RAB5A 
Signal transduction;  
RAB5A, member RAS oncogene 
family 
0.41 GTP binding;GTPase activity;Protein transport;Small GTPase mediated signal transduction;Protein binding;Endocytosis;Early endosome; 
NM_002880 
RAF1 
Apoptosis, cell growth and 
differentiation, signal transduction; 
V-raf-1 murine leukemia viral 
oncogene homolog 1 
0.47 
Receptor signaling protein activity;ATP binding;Transferase activity;Protein 
amino acid phosphorylation;Cell proliferation;Protein 
binding;Diacylglycerol binding;Protein serine/threonine kinase 




Cell growth and differentiation;  
Prohibitin 2 
0.50 Cellular_component unknown;Receptor activity;Negative regulation of transcription;Estrogen receptor binding; 




Other cancer-related genes;  
Ribophorin II 
diphosphooligosaccharide-protein glycotransferase activity;N-linked 




Table 1d. The differently expressed genes (fold change ≥ 2.0) after orpiment treatment with high concentration. 
 
Chip e 
GeneBank Symbol & Description Fold change GO term 
NM_183356 
ASNS 
Other caner-related genes;  
Asparagine synthetase 
2.68 
Ligase activity;Soluble fraction;Metabolism;Glutamine 




Cell cycle, and cell growth and 
differentiation;  
Cyclin-dependent kinase inhibitor 2B 
(p15, inhibits CDK4) 
2.28 
Nucleus;Cytoplasm;Negative regulation of cell cycle;Negative 
regulation of cell proliferation;Cell cycle arrest;Cell cycle;Cyclin-
dependent protein kinase inhibitor activity;Regulation of cyclin 




Other cancer-related genes;  
CCAAT/enhancer binding protein 
(C/EBP), gamma 
3.27 
 DNA binding;Regulation of transcription, DNA-dependent;Nucleus; 
NM_000755 
Crat 





acetyltransferase activity;Acyl-CoA metabolism;Energy derivation by 
oxidation of organic compounds;Peroxisome 
NM_001554 
CYR61 
Cell growth and differentiation;  
Cysteine-rich, angiogenic inducer, 61 
2.90 
Cell adhesion;Cell proliferation;Regulation of cell 




Other cancer-related genes;  
Fibrillin 2 (congenital contractual 
arachnodactyly) 







Cell growth and differentiation;  
FOS-like antigen 1 
6.36 
Nucleus;Transcription factor activity;Positive regulation of cell 
proliferation;Response to virus;Regulation of transcription from Pol II 
promoter;Chemotaxis;Cellular defense response; 
NM_006389 
HYOU1 
Other cancer-related genes;  
Hypoxia up-regulated 1 
2.65 ATP binding;Response to stress;Endoplasmic reticulum;Chaperone activity; 
NM_000876 
IGF2R 
Other cancer-related genes;  
Insulin-like growth factor 2 receptor 
2.38 
Signal transduction;Receptor activity;Lysosome;Integral to plasma 
membrane;Insulin-like growth factor receptor activity;Transporter 
activity;Receptor mediated endocytosis;Transport; 
NM_005564 
LCN2 
Other cancer-related genes;  
Lipocalin 2 (oncogene 24p3) 
2.18 Cytoplasm;Soluble fraction;Transporter activity;Transport;Binding; 
NM_003768 
NFKB2 
Cell growth and differentiation;  
Phosphoprotein enriched in astrocytes 15 
2.69 
Protein binding;Regulation of apoptosis;Anti-
apoptosis;Transport;Sugar porter activity;Negative regulation of 




Phosphoprotein enriched in astrocytes 15 
3.55 
Protein binding;Regulation of apoptosis;Anti-
apoptosis;Transport;Sugar porter activity;Negative regulation of 
glucose import;Microtubule associated complex; 
NM_183079 
PRNP 
Other cancer-related genes;  
Prion protein (p27-30) (Creutzfeld-Jakob 
disease, Gerstmann-Strausler-Scheinker 




Other cancer-related genes;  
V-rel reticuloendotheliosis viral oncogene 
homolog B, nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 3 
(avian) 
2.94 
Regulation of transcription, DNA-dependent;Nucleus;Protein 
binding;Transcription factor activity;Transcription corepressor 
activity; 
NM_006513 SARS Other cancer-related genes;  2.46 
ATP binding;Cytoplasm;Ligase activity;Soluble fraction;Protein 




Seryl-tRNA synthetase activity;Seryl-tRNA aminoacylation; 
NM_003028 
SHB 
Signal transduction;  
Src homology 2 domain containing 
adaptor protein B 




Tumor necrosis factor receptor 
superfamily, member 10b 
2.56 
Integral to membrane;Signal transduction;Protein binding;Electron 
transporter activity;Induction of apoptosis;Regulation of 
apoptosis;Induction of apoptosis via death domain receptors;Positive 
regulation of I-kappaB kinase/NF-kappaB cascade;Receptor 
activity;Iron ion binding;Electron transport;TRAIL binding;Caspase 




Other cancer related genes;  
Translocation associated membrane 
protein 1 
4.21 Integral to membrane;Receptor activity;Endoplasmic reticulum;Cotranslational membrane targeting;Protein targeting; 
NM_003330 
TXNRD1 
Other cancer-related genes;  
Thioredoxin reductase 1 
2.39 
Signal transduction;Cytoplasm;Electron transport;Metal ion 
binding;Disulfide oxidoreductase activity;Oxidoreductase activity, 
acting on NADH or NADPH, disulfide as acceptor;Thioredoxin-
disulfide reductase activity; 
    
NM_000666 
ACY1 
Cell motility;  
Aminoacylase 1 
0.34 
Hydrolase activity;Proteolysis and 




Other cancer-related genes;  
Basic helix-loop-helix domain 
containing, class B, 2 
0.30 Regulation of transcription, DNA-dependent;Nucleus;Transcription factor activity; 
NM_000386 
BLMH 
Other cancer-related genes;  
Bleomycin hydrolase 
0.34 
Hydrolase activity;Aminopeptidase activity;Proteolysis and 
peptidolysis;Nucleus;Cytoplasm;Bleomycin hydrolase 
activity;Carboxypeptidase activity; 








Signal transduction;  
CD59 antigen p18-20 (antigen identified 
by monoclonal antibodies 16.3A5, EJ16, 
EJ30, EL32 and G344) 
0.35 Plasma membrane;Immune response;Membrane fraction;Cell surface receptor linked signal transduction;Blood coagulation; 
NM_004358 
CDC25B 
Cell cycle, and cell growth and 
differentiation;  
Cell division cycle 25B 
0.32 
Hydrolase activity;Regulation of cell cycle;Positive regulation of cell 
proliferation;Intracellular;Mitosis;Protein amino acid 
dephosphorylation;Protein tyrosine phosphatase activity;M phase of 
mitotic cell cycle; 
NM_020990 
CKMT1B 
Other cancer-related genes;  
Creatine kinase, mitochondrial 1B 
0.34 Mitochondrion;Creatine kinase activity;Transferase activity, transferring phosphorus-containing groups; 
NM_001291 
CLK2 
Other cancer-related genes;  
CDC-like kinase 2 
0.34 
ATP binding;Transferase activity;Protein amino acid 
phosphorylation;Nucleus;Protein serine/threonine kinase 
activity;Protein-tyrosine kinase activity; 
NM_001905 
CTPS 
Other cancer-related genes;  
CTP synthase 
0.39 
Ligase activity;Nucleobase, nucleoside, nucleotide and nucleic acid 
metabolism;Response to drug;CTP synthase activity;Glutamine 
metabolism;Pyrimidine nucleotide biosynthesis; 
NM_001814 
CTSC 
Other cancer-related genes;  
Cathepsin C 
0.15 
Hydrolase activity;Immune response;Proteolysis and 
peptidolysis;Lysosome;Cysteine-type endopeptidase 
activity;Dipeptidyl-peptidase I activity; 
NM_001920 
DCN 
Other cancer-related genes;  
Decorin 
0.08 Extracellular matrix;Organogenesis; 
NM_001360 
DHCR7 
Other cancer-related genes;  
7-dehydrocholesterol reductase 
0.14 
Integral to membrane;Oxidoreductase activity;Endoplasmic 




Apoptosis, cell cycle, cell motility, 
signal transduction;  
0.44 
Golgi apparatus;Receptor binding;Signal 
transduction;Apoptosis;Regulation of cell cycle;G-protein coupled 




Coagulation factor II (thrombin) receptor kinase/NF-kappaB cascade;Integral to plasma membrane;Response to 
wounding;Cell motility;Blood coagulation;Caspase 
activation;Rhodopsin-like receptor activity;Thrombin receptor 
activity;STAT protein nuclear translocation;Morphogenesis;Tyrosine 
phosphorylation of STAT protein; 
NM_021078 
GCN5L2 
Other cancer-related genes;  
GCN5 general control of amino-acid 
synthesis 5-like 2 (yeast) 
0.44 
Transferase activity;Nucleus;Regulation of transcription from Pol II 
promoter;Transcription coactivator activity;Chromatin remodeling;N-
acetyltransferase activity;Histone acetyltransferase activity;Protein 
amino acid acetylation; 
NM_001518 
GTF2I 
Other cancer-related genes;  
General transcription factor II, i 
0.41 
Signal transduction;Regulation of transcription, DNA-
dependent;Nucleus;Protein binding;Transcription factor 
activity;Transcription initiation from Pol II promoter;General RNA 
polymerase II transcription factor activity 
NM_002127 
HLA-G 
HLA-G histocompatibility antigen, 
class I, G 
0.49 
Integral to membrane;Cellular defense response;Antigen processing, 
endogenous antigen via MHC class I;MHC class I receptor 
activity;Antigen presentation, endogenous antigen;Detection of pest, 
pathogen or parasite; 
NM_003641 
IFITM1 
Cell cycle, cell growth and 
differentiation, signal transduction;  
Interferon induced transmembrane 
protein 1 (9-27) 
0.30 
Receptor signaling protein activity;Plasma membrane;Integral to 
membrane;Immune response;Negative regulation of cell 
proliferation;Regulation of cell cycle;Cell surface receptor linked 
signal transduction;Response to biotic stimulus; 
NM_000598 
IGFBP3 
Cell growth and differentiation; 
Insulin-like growth factor binding protein 
3 
0.19 
Regulation of cell growth;Extracellular;Cell growth and/or 
maintenance;Metal ion binding;Insulin-like growth factor 
binding;Protein tyrosine phosphatase activator activity;Negative 
regulation of signal transduction;Positive regulation of 
apoptosis;Positive regulation of myoblast differentiation; 
NM_002291 
LAMB1 
Other cancer-related genes;  
Laminin, beta 1 
0.28 Structural molecule activity;Cell adhesion;Protein binding;Basement membrane; 
NM_002337 LRPAP1 Cell growth and differentiation; Low 0.47 
Plasma membrane;Integral to membrane;Calcium ion binding;Cell 




density lipoprotein receptor-related 
protein associated protein 1 
folding;Chaperone activity;Asialoglycoprotein receptor 
activity;Lipoprotein binding;Vesicle-mediated transport; 
NM_002467 
MYC 
Cell cycle, cell growth and 
differentiation; 
 V-myc myelocytomatosis viral oncogene 
homolog (avian) 
0.20 
Cell proliferation;Nucleus;Transcription factor activity;Regulation of 





 Non-metastatic cells 3, protein expressed 
in 
0.27 
ATP binding;Transferase activity;Induction of 
apoptosis;Apoptosis;Kinase activity;Nucleoside-diphosphate kinase 
activity;CTP biosynthesis;GTP biosynthesis;UTP biosynthesis; 
NM_005654 
NR2F1 
Other cancer-related genes;  
Nuclear receptor subfamily 2, group F, 
member 1 
0.21 
Signal transduction;Regulation of transcription, DNA-
dependent;Nucleus;Transcription factor activity;Transcription 
coactivator activity;Steroid hormone receptor activity;Ligand-
regulated transcription factor activity; 
NM_005234 
NR2F6 
Other cancer-related genes;  
Nuclear receptor subfamily 2, group F, 
member 6 
0.36 
Signal transduction;Regulation of transcription, DNA-
dependent;Nucleus;Transcription factor activity;Steroid hormone 
receptor activity;Thyroid hormone receptor activity; 
NM_182649 
PCNA 
Cell cycle, cell growth and 
differentiation;  
Proliferating cell nuclear antigen 
0.50 
Cell proliferation;DNA binding;Nucleus;Regulation of cell 
cycle;DNA replication;DNA polymerase processivity factor 
activity;DNA repair;Regulation of DNA replication;Delta-DNA 
polymerase cofactor complex; 
NM_002596 
PCTK3 
Other cancer-related genes;  
PCTAIRE protein kinase 3 
0.25 
ATP binding;Transferase activity;Protein amino acid 
phosphorylation;Signal transduction;Protein serine/threonine kinase 
activity;Cellular_component unknown;Signal transducer activity; 
NM_002884 
RAP1A 
Cell cycle, signal transduction;  
RAP1A, member of RAS oncogene 
family 
0.31 GTP binding;GTPase activity;Small GTPase mediated signal transduction;Signal transduction;Negative regulation of cell cycle 




Selenium binding protein 1 
NM_015129 
SEPT6 
Cell cycle;  
Septin 6 
0.48 GTP binding;Protein binding;Cellular_component unknown;Cell cycle;Cytokinesis; 
NM_007111 
TFDP1 
Cell cycle, cell growth and 
differentiation; 
 Transcription factor Dp-1 
0.25 
Nucleus;Regulation of cell cycle;Transcription factor 
activity;Regulation of transcription from Pol II promoter;Transcription 
factor complex;Transcription coactivator activity; 
NM_003243 
TGFBR3 
Other cancer-related genes;  
Transforming growth factor, beta receptor 
III (betaglycan, 300kDa) 
0.26 
Integral to membrane;Signal transduction;Development;Receptor 
activity;Glycosaminoglycan binding;Transforming growth factor beta 




 Tumor necrosis factor receptor 
superfamily, member 1B 
0.16 
Integral to membrane;Apoptosis;Receptor activity;Tumor necrosis 




Apoptosis, cell cycle; 
 Tumor protein p53 (Li-Fraumeni 
syndrome) 
0.38 
ATP binding;Cell proliferation;Regulation of transcription, DNA-
dependent;Protein binding;Negative regulation of cell 
cycle;Apoptosis;Mitochondrion;Transcription factor activity;Zinc ion 
binding;DNA damage response, signal transduction resulting in 
induction of apoptosis;Cell cycle arrest;Nucleolus;Cell cycle 
checkpoint;DNA strand annealing activity;Copper ion 
binding;Nuclease activity;DNA recombination;Base-excision 
repair;Caspase activation via cytochrome c;Cell aging;Cell 
differentiation;Induction of apoptosis by hormones;Negative 
regulation of cell growth;Nucleotide-excision repair;Regulation of 
mitochondrial membrane permeability;Protein tetramerization 
activity;Negative regulation of helicase activity; 
NM_006297 
XRCC1 
Other cancer-related genes;  
X-ray repair complementing defective 
repair in Chinese hamster cells 1 




Table 1e. The differently expressed genes (fold change ≥ 2.0) after As2O3 treatment.  
Chip f 
GeneBank Symbol & Description Fold change GO term 
NM_000611 
CD59 
Signal transduction;  
CD59 antigen p18-20 (antigen identified 
by monoclonal antibodies 16.3A5, EJ16, 
EJ30, EL32 and G344) 
2.00 Plasma membrane;Immune response;Membrane fraction;Cell surface receptor linked signal transduction;Blood coagulation; 
NM_005438 
FOSL1 
Cell growth and differentiation; FOS-
like antigen 1 
2.31 
Nucleus;Transcription factor activity;Positive regulation of cell 
proliferation;Response to virus;Regulation of transcription from Pol II 
promoter;Chemotaxis;Cellular defense response; 
NM_006644 
HSPH1 
Other cancer-related genes;  
Heat shock 105kDa/110kDa protein 1 
2.20 ATP binding;Cytoplasm;Heat shock protein activity; 
    
NM_183356 
ASNS 
Other cancer-related genes;  
Asparagine synthetase 
0.44 
Ligase activity;Soluble fraction;Metabolism;Glutamine 




Other cancer-related genes;  
Calnexin 
0.49 
Integral to plasma membrane;Sugar binding;Heterophilic cell 
adhesion;Chaperone activity;Protein secretion;Endoplasmic reticulum 
membrane;Calcium ion storage activity; 
NM_004421 
DVL1 
Signal transduction;  Dishevelled, dsh 
homolog 1 (Drosophila) 
0.38 
Protein binding;Cytoplasm;Intracellular signaling cascade;Signal 
transducer activity;Development;Morphogenesis;Heart 
development;Frizzled signaling pathway; 
NM_002026 
FN1 
Cell motility;  
Fibromectin 1 
0.44 
Cell adhesion;Extracellular;Oxidoreductase activity;Collagen 
binding;Extracellular matrix structural constituent;Heparin 




Cell cycle, cell growth and 
differentiation, signal transduction; 
0.29 
Receptor signaling protein activity;Plasma membrane;Integral to 
membrane;Immune response;Negative regulation of cell 




 Interferon induced transmembrane 
protein 1 (9-27) 
signal transduction;Response to biotic stimulus; 
NM_000598 
IGFBP3 
Cell growth and differentiation; 
Insulin-like growth factor binding protein 
3 
0.25 
Regulation of cell growth;Extracellular;Cell growth and/or 
maintenance;Metal ion binding;Insulin-like growth factor 
binding;Protein tyrosine phosphatase activator activity;Negative 
regulation of signal transduction;Positive regulation of 
apoptosis;Positive regulation of myoblast differentiation; 
NM_002291 
LAMB1 
Other cancer-related genes;  
Laminin, beta 1 
0.42 Structural molecule activity;Cell adhesion;Protein binding;Basement membrane; 
NM_002294 
LAMP2 
Other cancer-related genes;  
Lysosomal-associated membrane protein 
2 
0.46 Integral to plasma membrane;Lysosomal membrane; 
NM_004990 
MARS 
Other cancer-related genes;  
Methionine-tRNA synthetase 
0.41 
ATP binding;Cytoplasm;Ligase activity;Soluble fraction;Methionine-




Cell cycle, cell growth and 
differentiation; 
 V-myc myelocytomatosis viral oncogene 
homolog (avian) 
0.25 
Cell proliferation;Nucleus;Transcription factor activity;Regulation of 





Nuclear factor of kappa light polypeptide 
gene enhancer in B-cells 1 (p105) 
0.36 
Signal transduction;Regulation of transcription, DNA-
dependent;Nucleus;Protein binding;Cytoplasm;Apoptosis;Anti-
apoptosis;Transcription factor activity;Inflammatory 
response;Transcription from Pol II promoter;Response to pathogenic 




 Non-metastatic cells 3, protein expressed 
in 
0.37 
ATP binding;Transferase activity;Induction of 
apoptosis;Apoptosis;Kinase activity;Nucleoside-diphosphate kinase 
activity;CTP biosynthesis;GTP biosynthesis;UTP biosynthesis; 




Other cancer-related genes;  
Peroxisome proliferative activated 
receptor, gamma 
transduction;Nucleus;Transcription factor activity;Regulation of 
transcription from Pol II promoter;Steroid hormone receptor 
activity;Lipid metabolism;White adipocyte differentiation; 
NM_003321 
TUFM 
Other cancer-related genes;  
Tu translation elongation factor, 
mitochondrial 




Table 1f. The differently expressed genes (fold change ≥ 2.0) after arsenite treatment. 
 
Chip g 
GeneBank Symbol & Description Fold change GO term 
NM_000927 
ABCB1 
Other cancer-related genes;  
ATP-binding cassette, sub-family B 
(MDR/TAP), member 1 
3.23 
ATP binding;Integral to membrane;Membrane fraction;Transporter 
activity;Transport;ATP-binding cassette (ABC) transporter 
activity;Nucleotide binding;Response to drug; 
NM_005759 
ABI2 
Other cancer-related genes;  
AbI interactor 2 
3.17 DNA binding;Cytoplasm;SH3/SH2 adaptor protein activity;Kinase activity;SH3 domain binding;Biological_process unknown; 
NM_005157 
ABL1 
Apoptosis, cell cycle, cell growth and 
differentiation, signal transduction;  
V-abl Abelson murine leukemia viral 
oncogene homolog 1 
2.43 
ATP binding;Transferase activity;Protein amino acid 
phosphorylation;DNA binding;Regulation of transcription, DNA-
dependent;Nucleus;Cell growth and/or maintenance;Intracellular 
signaling cascade;Protein-tyrosine kinase activity;Regulation of cell 
cycle;DNA damage response, signal transduction resulting in 




Signal transduction;  
V-abl Abelson murine leukemia viral 
oncogene homolog 2 (arg, Abelson-
3.40 
ATP binding;Transferase activity;Protein amino acid 
phosphorylation;Cytoplasm;Cell growth and/or 








Other cancer-related genes;  
Annexin A5 
2.38 
Calcium ion binding;Blood coagulation;Calcium-dependent 
phospholipid binding;Phospholipase inhibitor activity;Negative 
regulation of coagulation; 
NM_001746 
CANX 
Other cancer-related genes;  
Calnexin 
2.32 
Integral to plasma membrane;Sugar binding;Heterophilic cell 
adhesion;Chaperone activity;Protein secretion;Endoplasmic reticulum 
membrane;Calcium ion storage activity; 
NM_006367 
CAP1 
Other cancer-related genes;  
CAP, adenylate cyclase-associated 
protein 1 (yeast) 
5.58 Signal transduction;Membrane;Establishment and/or maintenance of cell polarity;Adenylate cyclase activation; 
NM_001749 
CAPNS1 
Cell growth and differentiation;  
Calpain, small subunit 1 
2.04 Calcium ion binding;Positive regulation of cell proliferation;Calpain activity; 
NM_001789 
CDC25A 
Cell cycle, cell growth and 
differentiation;  
Cell division cycle 25A 
9.41 
Hydrolase activity;Cell proliferation;Intracellular;Regulation of cyclin 
dependent protein kinase activity;Mitosis;Protein amino acid 
dephosphorylation;Protein tyrosine phosphatase activity;M phase of 
mitotic cell cycle; 
NM_001790 
CDC25C 
Cell growth and differentiation;  
Cell division cycle 25C 
3.42 
Hydrolase activity;Cell proliferation;Nucleus;Regulation of cyclin 
dependent protein kinase activity;Protein amino acid 
dephosphorylation;Protein tyrosine phosphatase activity;Regulation of 
mitosis;Traversing start control point of mitotic cell cycle; 
NM_000389 
CDKN1A 
Apoptosis, cell cycle, cell growth and 
differentiation;  
Cyclin-dependent kinase inhibitor 1A 
(p21, Cip1) 
2.10 
Nucleus;Negative regulation of cell proliferation;Cell cycle 
arrest;Protein kinase activity;Cyclin-dependent protein kinase inhibitor 
activity;Regulation of cyclin dependent protein kinase activity;Kinase 
activity;Induction of apoptosis by intracellular signals; 
NM_001903 
CTNNA1 
Other cancer-related genes;  
Catenin (cadherin-associated protein), 
alpha 1, 102kDa 
2.75 Structural molecule activity;Cell adhesion;Protein binding;Cytoskeleton; 




Other cancer-related genes;  
DEAH (Asp-Glu-Ala-His) box 
polypeptide 8 
splicing;ATP-dependent RNA helicase activity;Hydrogen-transporting 
ATP synthase activity, rotational mechanism;Hydrogen-transporting 
ATPase activity, rotational mechanism;ATP synthesis coupled proton 
transport;Nuclear mRNA splicing, via spliceosome;Proton-
transporting two-sector ATPase complex;Spliceosome complex; 
NM_004423 
DVL3 
Signal transduction;  
Dishevelled, dsh homolog 3 (Drosophila) 
3.04 
Protein binding;Intracellular signaling cascade;Signal transducer 
activity;Development;Intracellular;Kinase activity;Neurogenesis;Heart 
development;Frizzled signaling pathway; 
NM_001949 
E2F3 
Cell cycle;  
E2F transcription factor 3 
2.60 
Regulation of transcription, DNA-dependent;Nucleus;Protein 
binding;Regulation of cell cycle;Transcription factor 




Other cancer-related genes;  
Early growth response 1 
2.49 Regulation of transcription, DNA-dependent;Nucleus;Transcription factor activity;Zinc ion binding; 
NM_005240 
ETV3 
Other cancer-related genes;  
Ets variant gene 3 
16.11 Regulation of transcription, DNA-dependent;Nucleus;Transcription factor activity; 
NM_001987 
ETV6 
Cell growth and differentiation;  
Ets variant gene 6 (TEL oncogene) 
4.84 Regulation of transcription, DNA-dependent;Nucleus;Cell growth and/or maintenance;Transcription factor activity; 
NM_005438 
FOSL1 
Cell growth and differentiation; FOS-
like antigen 1 
2.59 
Nucleus;Transcription factor activity;Positive regulation of cell 
proliferation;Response to virus;Regulation of transcription from Pol II 
promoter;Chemotaxis;Cellular defense response; 
NM_003468 C2orf31 Chromosome 2 open reading frame 31 3.45 
Wnt receptor signaling pathway;G-protein coupled receptor protein 
signaling pathway;Development;Integral to plasma membrane;G-
protein coupled receptor activity;Non-G-protein coupled 7TM 
receptor activity;Establishment of tissue polarity; 
NM_003508 
FZD9 
Signal transduction;  
Frizzled homolog 9 (Drosophila) 
2.71 
Plasma membrane;Integral to membrane;G-protein coupled receptor 
protein signaling pathway;Development;Neurogenesis;G-protein 







Other cancer-related genes;  
Heat shock 70kDa protein 4 
2.11 ATP binding;Cytoplasm;Heat shock protein activity; 
NM_006644 
HSPH1 
Other cancer-related genes;  
Heat shock 105kDa/110kDa protein 1 
3.13 ATP binding;Cytoplasm;Heat shock protein activity; 
NM_000876 
IGF2R 
Other cancer-related genes;  
Insulin-like growth factor 2 receptor 
2.25 
Signal transduction;Receptor activity;Lysosome;Integral to plasma 
membrane;Insulin-like growth factor receptor activity;Transporter 




 Phosphoprotein enriched in astrocytes 15 
2.15 
Protein binding;Regulation of apoptosis;Anti-
apoptosis;Transport;Sugar porter activity;Negative regulation of 
glucose import;Microtubule associated complex; 
    
NM_001664 
RHOA 
Cell growth and differentiation, signal 
transduction;  
Ras homolog gene family, member A 
0.48 
GTP binding;GTPase activity;Protein transport;Small GTPase 
mediated signal transduction;Rho protein signal transduction;Signal 
transducer activity;Positive regulation of I-kappaB kinase/NF-kappaB 
cascade;Membrane;Cytoskeleton;Magnesium ion binding;Actin 




Cell growth and differentiation, signal 
transduction;  
Ras homolog gene family, member B 
0.28 GTP binding;GTPase activity;Rho protein signal transduction;Cell growth and/or maintenance; 
NM_003670 
BHLHB2 
Other cancer-related genes;  
Basic helix-loop-helix domain 
containing, class B, 2 
0.40 Regulation of transcription, DNA-dependent;Nucleus;Transcription factor activity; 
NM_000386 
BLMH 
Other cancer-related genes;  
Bleomycin hydrolase 
0.40 
Hydrolase activity;Aminopeptidase activity;Proteolysis and 
peptidolysis;Nucleus;Cytoplasm;Bleomycin hydrolase 
activity;Carboxypeptidase activity; 
NM_000077 CDKN2A Cell cycle, cell growth and 0.47 
Nucleus;Negative regulation of cell cycle;Negative regulation of cell 





Cyclin-dependent kinase inhibitor 2A 
(melanoma, p16, inhibits CDK4) 
kinase inhibitor activity;Regulation of cyclin dependent protein kinase 
activity;Kinase activity;Cell cycle checkpoint; 
NM_001293 
CLNS1A 
Cell growth and differentiation;  




perception;Chloride transport;Auxiliary transport protein 
activity;Regulation of cell volume; 
NM_001865 
COX7A2 
Other cancer-related genes;  
Cytochrome c oxidase subunit VIIa 
polypeptide 2 (liver) 
0.40 
Electron transporter activity;Oxidoreductase 
activity;Mitochondrion;Electron transport;Inner 
membrane;Cytochrome-c oxidase activity; 
NM_001814 
CTSC 
Other cancer-related genes;  
Cathepsin C 
0.19 
Hydrolase activity;Immune response;Proteolysis and 
peptidolysis;Lysosome;Cysteine-type endopeptidase 
activity;Dipeptidyl-peptidase I activity; 
NM_003592 
CUL1 




Protein binding;Negative regulation of cell proliferation;Cell cycle 
arrest;G1/S transition of mitotic cell cycle;Cell cycle;Induction of 
apoptosis by intracellular signals; 
NM_003472 
DEK 
Cell growth and differentiation;  
DEK oncogene (DNA binding) 
0.31 
GTP binding;Signal transduction;DNA binding;Nucleus;Cell growth 
and/or maintenance;Specific RNA polymerase II transcription factor 
activity;Regulation of transcription from Pol II promoter;Viral genome 
replication;RNA binding;Histone binding;SRP-dependent 
cotranslational membrane targeting;Signal recognition particle; 
NM_006389 
HYOU1 
Other cancer-related genes;  
Hypoxia up-regulated 
0.47 ATP binding;Response to stress;Endoplasmic reticulum;Chaperone activity; 
NM_003641 
IFITM1 
Cell cycle, cell growth and 
differentiation, signal transduction; 
 Interferon induced transmembrane 
protein 1 (9-27) 
0.34 
Receptor signaling protein activity;Plasma membrane;Integral to 
membrane;Immune response;Negative regulation of cell 
proliferation;Regulation of cell cycle;Cell surface receptor linked 
signal transduction;Response to biotic stimulus; 




Cell growth and differentiation; 
Insulin-like growth factor binding protein 
3 
maintenance;Metal ion binding;Insulin-like growth factor 
binding;Protein tyrosine phosphatase activator activity;Negative 
regulation of signal transduction;Positive regulation of 
apoptosis;Positive regulation of myoblast differentiation; 
NM_002291 
LAMB1 
Other cancer-related genes;  
Laminin, beta 1 
0.14 Structural molecule activity;Cell adhesion;Protein binding;Basement membrane; 
NM_002337 
LRPAP1 
Cell growth and differentiation; Low 
density lipoprotein receptor-related 
protein associated protein 1 
0.30 
Plasma membrane;Integral to membrane;Calcium ion binding;Cell 
proliferation;Heparin binding;Endoplasmic reticulum;Protein 
folding;Chaperone activity;Asialoglycoprotein receptor 
activity;Lipoprotein binding;Vesicle-mediated transport; 
NM_004635 
MAPKAPK3 
Other cancer-related genes;  
Mitogen-activated protein kinase-
activated protein kinase 3 
0.46 
ATP binding;Transferase activity;Protein amino acid 
phosphorylation;Signal transduction;Nucleus;Protein serine/threonine 
kinase activity;Response to stress;MAP kinase kinase activity; 
NM_004526 
MCM2 
Cell cycle;  
MCM2 minichromosome maintenance 
deficient 2, mitotin (S. cerevisiae) 
0.46 
ATP binding;DNA binding;Regulation of transcription, DNA-
dependent;Nucleus;DNA replication;Chromatin;Cell cycle;DNA-
dependent ATPase activity;DNA replication initiation; 
NM_002467 
MYC 
Cell cycle, cell growth and 
differentiation;  
V-myc myelocytomatosis viral oncogene 
homolog (avian) 
0.07 
Cell proliferation;Nucleus;Transcription factor activity;Regulation of 





Nuclear factor of kappa light polypeptide 
gene enhancer in B-cells 1 (p105) 
0.44 
Signal transduction;Regulation of transcription, DNA-
dependent;Nucleus;Protein binding;Cytoplasm;Apoptosis;Anti-
apoptosis;Transcription factor activity;Inflammatory 
response;Transcription from Pol II promoter;Response to pathogenic 
bacteria;Antibacterial humoral response (sensu Vertebrata); 
NM_000269 
NME1 
Cell cycle, cell growth and 
differentiation;  
0.29 
ATP binding;Transferase activity;Nucleus;Negative regulation of cell 
cycle;Negative regulation of cell proliferation;Kinase 




Non-metastatic cells 1, protein (NM23A) 
expressed in 




Cell growth and differentiation;  
Non-metastatic cells 2, protein (NM23B) 
expressed in 
0.35 
ATP binding;Transferase activity;Regulation of transcription, DNA-
dependent;Nucleus;Negative regulation of cell cycle;Negative 
regulation of cell proliferation;Transcription factor activity;Kinase 
activity;Nucleoside-diphosphate kinase activity;CTP 





 Non-metastatic cells 3, protein expressed 
in 
0.10 
ATP binding;Transferase activity;Induction of 
apoptosis;Apoptosis;Kinase activity;Nucleoside-diphosphate kinase 
activity;CTP biosynthesis;GTP biosynthesis;UTP biosynthesis; 
NM_024408 
NOTCH2 
Cell cycle, cell growth and 
differentiation, signal transduction;  
Notch homolog 2 (Drosophila) 
0.47 
Calcium ion binding;Regulation of transcription, DNA-
dependent;Nucleus;Protein binding;Induction of apoptosis;Anti-
apoptosis;Negative regulation of cell proliferation;Cell cycle 
arrest;Receptor activity;Integral to plasma membrane;Cell 
differentiation;Neurogenesis;Protein heterodimerization activity;Cell 
fate determination;Cell growth;Regulation of 
development;Hemopoiesis;Cell surface;Morphogenesis of an 
epithelial sheet;Ligand-regulated transcription factor activity;Notch 
signaling pathway;Determination of left/right symmetry;Positive 
regulation of RAS protein signal transduction;Stem cell maintenance; 
NM_015869 
PPARG 
Other cancer-related genes;  
Peroxisome proliferative activated 
receptor, gamma 
0.32 
Energy pathways;Response to nutrients;Signal 
transduction;Nucleus;Transcription factor activity;Regulation of 
transcription from Pol II promoter;Steroid hormone receptor 
activity;Lipid metabolism;White adipocyte differentiation; 
NM_182649 
PCNA 
Cell cycle, cell growth and 
differentiation;  
Proliferating cell nuclear antigen 
0.20 
Cell proliferation;DNA binding;Nucleus;Regulation of cell 
cycle;DNA replication;DNA polymerase processivity factor 
activity;DNA repair;Regulation of DNA replication;Delta-DNA 
polymerase cofactor complex; 
NM_006406 PRDX4 Other cancer-related genes;  0.37 








Other cancer-related genes;  
Prostaglandin-endoperoxides synthase 1 
(prostaglandin G/H synthase and 
cyclooxygenase) 
0.48 
Oxidoreductase activity;Peroxidase activity;Membrane;Physiological 
process;Lipid metabolism;Oxidoreductase activity, acting on single 
donors with incorporation of molecular oxygen, incorporation of two 




Cell cycle;  
Prothymosin, alpha (gene sequence 28) 
0.29 Nucleus;Regulation of cell cycle;Development;Transcription; 
NM_004162 
RAB5A 
Signal transduction;  
RAB5A, member RAS oncogene family 
0.45 
GTP binding;GTPase activity;Protein transport;Small GTPase 




Cell motility, signal transduction;  
Ras-related C3 botulinum toxin substrate 
1 (rho family, small GTP binding protein 
Rac1) 
0.47 
GTP binding;GTPase activity;Protein transport;Small GTPase 




Apoptosis, cell growth and 
differentiation, signal transduction;  
V-raf-1 murine leukemia viral oncogene 
homolog 1 
0.42 
Receptor signaling protein activity;ATP binding;Transferase 
activity;Protein amino acid phosphorylation;Cell proliferation;Protein 
binding;Diacylglycerol binding;Protein serine/threonine kinase 




Cell cycle, cell growth and 
differentiation;  
Retinoblastoma binding protein 4 
0.24 
Regulation of transcription, DNA-dependent;Nucleus;Negative 




Cell growth and differentiation;  
Probibitin 2 
0.29 Cellular_component unknown;Receptor activity;Negative regulation of transcription;Estrogen receptor binding; 
NM_002951 
RPN2 
Other cancer-related genes;  
Ribophorin II 
0.30 
Transferase activity;Integral to membrane;Protein 
modification;Dolichyl-diphosphooligosaccharide-protein 




asparagine;Oligosaccharyl transferase complex; 
NM_006142 
SFN 




Cell proliferation;Signal transduction;Cytoplasm;Regulation of cell 
cycle;Extracellular space;Protein domain specific binding;Protein 





CD27-binding (Siva) protein 
0.30 
Receptor signaling protein activity;Cytoplasm;Apoptosis;Induction of 
apoptosis by extracellular signals;Positive regulation of 
apoptosis;CD27 receptor binding;Defense response; 
NM_005415 
SLC20A1 
Other cancer-related genes;  
Solute carrier family 20 (phosphate 
transporter), member 1 
0.39 
Phosphate metabolism;Signal transducer activity;Positive regulation of 
I-kappaB kinase/NF-kappaB cascade;Receptor 
activity;Membrane;Integral to plasma membrane;Transport;Phosphate 




Cell cycle, cell growth and 
differentiation;  
Transforming growth factor beta 
regulator 4 
0.27 Positive regulation of cell proliferation;Cell cycle arrest;G1 phase of mitotic cell cycle; 
NM_000358 
TGFBI 
Cell growth and differentiation;  
Transforming growth factor, beta-induced 
68kDa 
0.45 
Cell adhesion;Cell proliferation;Protein binding;Negative regulation of 
cell adhesion;Extracellular matrix;Extracellular space;Integrin 
binding;Visual perception;Extracellular matrix (sensu Metazoa); 
NM_003254 
TIMP1 
Cell growth and differentiation, cell 
motility;  
TIMP metallopeptidase inhibitor 1 
0.48 
Proteolysis and peptidolysis;Positive regulation of cell 
proliferation;Development;Extracellular matrix;Metalloendopeptidase 
inhibitor activity;Extracellular matrix (sensu Metazoa);Negative 




 Tumor necrosis factor receptor 
superfamily, member 1B 
0.29 
Integral to membrane;Apoptosis;Receptor activity;Tumor necrosis 
factor receptor activity;Cytokine and chemokine mediated signaling 
pathway; 
NM_000546 TP53 Apoptosis, cell cycle; 0.49 
ATP binding;Cell proliferation;Regulation of transcription, DNA-




 Tumor protein p53 (Li-Fraumeni 
syndrome) 
cycle;Apoptosis;Mitochondrion;Transcription factor activity;Zinc ion 
binding;DNA damage response, signal transduction resulting in 
induction of apoptosis;Cell cycle arrest;Nucleolus;Cell cycle 
checkpoint;DNA strand annealing activity;Copper ion 
binding;Nuclease activity;DNA recombination;Base-excision 
repair;Caspase activation via cytochrome c;Cell aging;Cell 
differentiation;Induction of apoptosis by hormones;Negative 
regulation of cell growth;Nucleotide-excision repair;Regulation of 
mitochondrial membrane permeability;Protein tetramerization 
activity;Negative regulation of helicase activity; 
NM_004881 
TP53I3 
Other cancer-related genes;  
Tumor protein p53 inducible protein 3 
0.21 
Cellular_component unknown;Zinc ion binding;Alcohol 




Other cancer-related genes;  
Tu translation elongation factor, 
mitochondrial 




Voltage-dependent anion channel 1 
0.23 
Integral to membrane;Mitochondrial outer 
membrane;Mitochondrion;Apoptotic program;Apoptogenic 
cytochrome c release channel activity;Voltage-dependent anion 




Other cancer-related genes;  
X-ray repair complementing defective 
repair in Chinese hamster cells (double-
strand-break rejoining; Ku autoantigen 
80kDa) 
0.29 
Nucleus;DNA recombination;ATP-dependent DNA helicase 
activity;Helicase activity;Double-stranded DNA binding;Double-
strand break repair via nonhomologous end-joining;Regulation of 





For realgar-treated HeLa cells, there were 4 up-regulated and 7 down-
regulated genes after low dose treatment, whilst at high dose treatment, more genes 
altered, i.e. 10 up-regulated and 86 down-regulated genes. This finding further 
indicates that the effect of realgar on cancer cell is dose-dependent. All changed genes 
were categorized based on their specific functions as respective functional gene 
groups, i.e. apoptosis, cell cycle, cell growth and differentiation, cell motility, signal 
transduction, and other cancer-related genes, as summarized in Table 1 as well. 
For orpiment-treated HeLa cells, from Table 1 (c and d), high dose did cause 
more genes changed than low dose, similar to the observation for realgar-treated cells. 
There were 17 up-regulated and 12 down-regulated genes after low dose treatment 
compared to 19 up-regulated and 34 down-regulated genes after high dose treatment.  
For As2O3-treated HeLa cells, total 18 genes altered including 3 up-expressed 
genes and 15 down-expressed genes. 
Arsenite induced 25 genes up expressed and 46 genes down expressed.  
 In order to diminish the impact of dose variation on the results, the drug 
concentrations chosen were those which could cause about 80% cells alive after 24 h 
treatment. For realgar and orpiment, the lower concentrations were one third of 
respective higher concentrations. Therefore, omitting the dose effects on gene 
expression, the effects of arsenic compounds on cancer cells did be species-
dependent.  
In order to clearly view them, Table 2 outlines the altered gene profiles of 
cells after high dose realgar, high dose orpiment, arsenic trioxide, and arsenite 
treatments, respectively. From Table 1 and Table 2, it could be seen that the 













AARS ↓↓ − − − 
ABCB1 ↓ − ↑↑↑ − 
ABI2 − − ↑↑↑ − 
ABL1 − − ↑ − 
ABL2 − − ↑↑↑ − 
ACP2 ↓↓ − − − 
ACY1 ↓↓↓ ↓↓ − − 
ANXA5 − − ↑ − 
RHOA − − ↓ − 
RHOB − − ↓↓↓ − 
ASNS ↑↑ ↑↑ − ↓ 
BHLHB2 ↓↓↓ ↓↓↓ ↓ − 
BLMH ↓ ↓↓ ↓ − 
CANX − − ↑ ↓ 
CAP1 − − ↑↑↑ − 
CAPN1 ↓ − − − 
CAPNS1 − − ↑ − 
CCNE1 − ↓↓↓ − − 
CD59 ↓ ↓↓ − ↑ 
CDC20 ↓↓ − − − 
CDC25A ↑ − ↑↑↑ − 
CDC25B ↓↓↓ ↓↓↓ − − 
CDC25C − − ↑↑↑ − 
CDC2L5 ↓↓ − − − 
CDKN1A − − ↑ − 
CDKN1B ↓ − − − 
CDKN2A − − ↓ − 
CDKN2B − ↑ − − 
CEBPG ↑ ↑↑↑ − − 
CIB1 ↓↓↓ − − − 
CKMT1B ↓↓↓ ↓↓ − − 
CLK2 ↓↓↓ ↓↓ − − 
CLNS1A ↓↓↓ − ↓↓↓ − 
COX6C ↓↓ − − − 
COX7A2 − − ↓ − 
Crat − ↑ − − 
CSNK1G2 ↓↓↓ − − − 
CTNNA1 − − ↑↑ − 
CTPS ↓↓↓ ↓↓ − − 
CTSC ↓↓↓ ↓↓↓ ↓↓↓ − 
CUL1 ↓ − ↓ − 
CYR61 − ↑↑ − − 
DCN ↓↓↓ ↓↓↓ − − 
DEK − − ↓↓↓ − 




DHX8 − − ↑↑ − 
DVL1 ↓↓↓ − − ↓↓ 
DVL3 − − ↑↑↑ − 
E2F1 ↓↓↓ − − − 
E2F3 − − ↑↑ − 
EGR1 ↑↑↑ − ↑ − 
ERCC3 ↓ −  − 
ETV3 − − ↑↑↑ − 
ETV6 − − ↑↑↑ − 
F2R ↓ ↓ − − 
FBN1 ↓ − − − 
FBN2 − ↑ − − 
FN1 − − − ↓ 
FOSL1 ↑↑↑ ↑↑↑ ↑↑ ↑ 
FRAP1 ↓ −  − 
C2orf31 − − ↑↑↑ − 
FZD9 − − ↑↑ − 
GCN5L2 − ↓ − − 
GDF15 ↑ − − − 
GTF2I ↓↓↓ ↓ − − 
HDGF ↓ − − − 
HLA-G ↓ ↓ − − 
HSPA4 − − ↑ − 
HSPH1 − − ↑↑↑ ↑ 
HYAL1 − − − − 
HYOU1 − ↑↑ ↓ − 
IER3 − − − − 
IFITM1 ↓↓↓ ↓↓↓ ↓↓ ↓↓↓ 
IGF2R ↑ ↑ ↑ − 
IGFBP3 ↓↓↓ ↓↓↓ ↓↓↓ ↓↓↓ 
ILK ↓↓↓ − − − 
IRF3 ↓↓ − − − 
ITGA3 ↓ − − − 
JUN ↑↑ − − − 
KPNA2 − − − − 
LAMB1 ↓↓↓ ↓↓↓ ↓↓↓ ↓ 
LAMP2 − − − ↓ 
LCN2 − ↑ − − 
LRPAP1 ↓↓↓ ↓ ↓↓↓ − 
MAP2K2 ↓↓ −  − 
MAPKAPK3 ↓ − ↓ − 
MARS − − − ↓ 
MCM2 ↓↓ − ↓ − 
MGST1 − − − − 
MYC ↓↓↓ ↓↓↓ ↓↓↓ ↓↓↓ 
MYL9 ↓↓↓ − − − 
NF2 ↓↓↓ − − − 
NFKB1 − − ↓ ↓↓ 




NME1 ↓↓↓ − ↓↓↓ − 
NME2 ↓↓ − ↓↓ − 
NME3 ↓↓↓ ↓↓↓ ↓↓↓ ↓↓ 
NOTCH2 − − ↓ − 
NR2F1 ↓↓↓ ↓↓↓ − − 
NR2F6 ↓↓↓ ↓↓ − − 
PCNA ↓↓↓ ↓ ↓↓↓ − 
PCTK3 ↓↓↓ ↓↓↓ − − 
PEA15 ↑↑↑ ↑↑↑ ↑ − 
PIK3CG ↓ − − − 
PPARD ↓↓↓ − − − 
PPARG − − ↓↓↓ ↓ 
PRDX4 − − ↓↓ − 
PRKAR1A ↓↓↓ − − − 
PRNP − ↑ − − 
PTGS1 ↓↓ − ↓ − 
PTMA ↓↓↓ − ↓↓↓ − 
RAB5A − − ↓ − 
RAC1 − − ↓ − 
RAF1 ↓↓ − ↓ − 
RAP1A ↓↓↓ ↓↓↓ − − 
RARA ↓↓↓ − − − 
RB1 ↓↓ − − − 
RBBP4 ↓↓↓ − ↓↓↓ − 
PHB2 ↓↓↓ − ↓↓↓ − 
RELA ↓↓ − − − 
RELB − ↑↑ − − 
RPN2 ↓↓ − ↓↓↓ − 
SARS − ↑ − − 
SELENBP1 ↓ ↓↓↓ − − 
SEPT6 ↓ ↓ − − 
SFN ↓↓ − ↓↓↓ − 
SHB − ↑ − − 
SIVA ↓↓↓ − ↓↓↓ − 
SLC20A1 ↓ − ↓↓ − 
SND1 ↓↓ − − − 
SNRPB2 ↓ − − − 
STAT3 ↓↓↓ − − − 
TBRG4 ↓↓↓ − ↓↓↓ − 
TCF1 ↓ − − − 
TFDP1 ↓↓↓ ↓↓↓ − − 
TGFBI − − ↓ − 
TGFBR3 ↓↓↓ ↓↓↓ − − 
TIMP1 − − ↓ − 
TK1 ↓↓ − − − 
TNFRSF10B ↑↑ ↑↑ − − 
TNFRSF1B ↓↓ ↓↓↓ ↓↓↓ − 
TP53 ↓↓↓ ↓↓ ↓ − 




TRAM1 − ↑↑↑ − − 
TUFM − − ↓↓ ↓ 
TXNRD1 − ↑ − − 
USP7 ↓ − − − 
VDAC1 ↓↓ − ↓↓↓ − 
PPIH ↓↓ − − − 
XRCC1 − ↓ − − 
XRCC5 ↓↓↓ − ↓↓↓ − 
YWHAB ↓ − − − 
↓: Down-regulated gene (fold change between 2.0-2.5); ↓↓: Down-regulated gene 
(fold change between 2.5-3.0); ↓↓↓: Down-regulated gene (fold change > 3.0). 
↑: Up-regulated gene (fold change between 2.0-2.5); ↑↑: Up-regulated gene (fold 
change between 2.5-3.0); ↑↑↑: Up-regulated gene (fold change > 3.0).  




Special concern was focused on those selected genes (total 25 genes with 
yellow background highlight in Table 2) which were expressed significantly (fold 
change ≥ 5.0 and ≤ 0.2). Here we try to explain the possible underlying biological 
process of those significantly altered genes involved in one by one as follow: 
 
1. BHLHB2  
Of class B of basic helix-loop-helix (bHLH) proteins binding to the E box 
sequence (5’-CANNTG-3’), BHLHB2 (also referred to as DEC1/Eip1/SHARP-
2/Stra13/Clast5) is transcription factor that contains a unique orange domain. It 
represses the transcription of target gene not only via binding to the E box sequence 
but also via protein-protein interactions with other transcription factors. BHLHB2 is 
widely expressed in both embryonic and adult tissues.  
BHLHB1 expression is regulated in a cell type-specific manner by various 
extracellular stimuli including growth factors, serum starvation, hypoxia, hormones, 
nutrient, cytokines, light, and infection etc [Yamada K and Miyamoto K, 2005]. 




biological processes including development, cell differentiation, cell growth, cell 
death, oncogenesis, immune systems, circadian rhythm, and homeostasis.  
 The cellular BHLHB2 expression level was significantly decreased after 
reaglar treatment. Similar responses with the lower expression levels from orpiment- 
and arsenite-treated cells were also observed.  
 In a recent study, researchers identified BHLHB2 as a STAT3 partner and 
provided a consistent line of evidence for BHLHB2 involvement into regulation of 
apoptosis via the STAT pathways [Ivanova AV et al., 2004]. In our study, decreased 
STATS expression induced by realgar was also observed. STAT3 has been classified 
as an oncogene because constitutively active STAT3 can mediate oncogenic 
transformation in cell culture and in nude mice [Turkson J and Jove R, 2000]. 
Whether there is an association between these two genes in the current study co-
mediated by realgar need to be further investigated.  
  
2. CAP1  
Many extracellular signals elicit changes in the actin cytoskeleton. One family 
of proteins that plays a role in regulating actin remodelling in response to cellular 
signals are the cyclise-associated proteins (CAPs). CAPs are highly conserved 
monomeric actin binding proteins present in a wide range of organisms including 
yeast, fly, plants, and mammals. Two different CAP genes, CAP1 and CAP2, share at 
least 64% amino acid identity in mammals [Yu G et al, 1994].  
The significant up-expression of CAP1 gene was found for arsenite treated 
cells compared to non-change for other arsenicals treated cells. Actin filaments 
provide basic infrastructure for maintaining cell morphology and functions such as 




shows that actin remodelling plays a pivotal role in regulating the morphologic and 
phenotypic events of a malignant cell. Since CAP1 has a central role in actin 
remodelling, it could be assumed that arsenite probably stimulated actin remodelling 
to inhibit cell growth. 
 
3. CDC25A  
CDC25A is a member of the CDC25 (cell division cycle) family of 
phosphatases. CDC25A is required for progression from G1 to the S phase of the cell 
cycle. It activates the cyclin-dependent kinases (CDKs) by removing two phosphate 
groups. CDC25A is specifically degraded in response to DNA damage, which 
prevents cells with chromosomal abnormalities from progressing through cell 
division. A regulatory role of CDC25A in the G2-M transition has also been 
suggested. CDC25A is an oncogene, although its exact role in oncogenesis has not 
been demonstrated. Two transcript variants encoding different isoforms have been 
found for this gene. 
 CDC25 has been shown to be overexpressed in a number of cancers 
[Kristjansdottir K and Rudolph J, 2004]. The central role of CDC25A in the cell cycle 
makes it a potential target for novel anti-cancer drugs. However, to date, no clinically-
viable compounds targeting this enzyme have been described. The over-expression of 
CDC25A of cells after arsenite treatment probably indicated that arsenite might 
inhibit cell proliferation through CDC25A-independent pathway.  
 
4. CKMT1B 
Official full name of CKMT1B is creatine kinase, mitochondrial 1 B. 




transfer of high energy phosphate from mitochondria to the cytosolic carrier, creatine. 
It belongs to the creatine kinase (CK) isoenzyme family. It exists as two isoenzymes, 
sarcomeric and ubiquitous forms, encoded by separate genes. CKMT occurs in two 
different oligomeric forms: dimers and octamers, in contrast to the exclusively 
dimeric cytosolic CK isoenzymes. Many malignant cancers with poor prognosis have 
shown overexpression of ubiquitous CKMT; this may be related to high energy 
turnover and failure to eliminate cancer cells via apoptosis. Ubiquitous CKMT has 
80% homology with the coding exons of sarcomeric mitochondrial creatine kinase. 
Two genes located near each other on chromosome 15 have been identified which 
encode identical mitochondrial creatine kinase proteins. 
In addition, CTMK1B has been implicated in the regulation of the Ca2+-
induced mitochondrial permeability transition pore (PTP) [O’Gorman E et al., 1997]. 
PTP is involved in triggering apoptosis by releasing proapoptotic factor into the 
cytosol [Crompton M, 1999].  
 The response of CKMT1B gene of HeLa cells to realgar was obviously down-
regulated, but not to arsenic trioxide and arsenite. There was an opposite observation 
in oral squamous cell carcinoma reported by Onda T et al. [Onda T et al., 2006], 
where researcher found that down-regulation of CKMT1B was involved in the oral 
carcinogenesis and they also concluded that epigenetic mechanism may regulate loss 
of its expression, leading to block apoptosis through specialized systems such as 
mitochondrial PTP in oral cancer cells. 
 
5. CLK2  
CDC-line kinase 2 (CLK2) encodes a member of the CLK family of dual 




phosphorylate, serine- and arginine-rich (SR) proteins of the spliceosomal complex, 
which is a part of the regulatory mechanism that enables the SR proteins to control 
RNA splicing. This protein kinase is involved in the regulation of several cellular 
processes and may serve as a link between cell cycle progression, apoptosis, and 
telomere length regulation. 
Recent studies on human tumor cells demonstrated that over-expression of 
CLK2 renders the cell hypersensitive to apoptosis triggered by oxidative stress or 
DNA replication block and gradually increases telomere length [Jiang N et al., 2003].  
 Only realgar significantly induced CLK2 expression down-regulated.  
  
6. CTPS  
The catalytic conversion of UTP to CTP is accomplished by the enzyme 
cytidine-5-prime-triphosphate synthetase (CTPS). The enzyme is important in the 
biosynthesis of phospholipids and nucleic acids, and plays a key role in cell growth, 
development, and tumorigenesis. The region to which the CTPS gene has been 
mapped is the location of breakpoints involved in several tumor types. 
 CTPS is a key enzyme in nucleic acid and phospholipid biosythesis and its 
activity is increased in certain human cancers, making it a promising drug target 
[Verschuur AC et al., 2000].  Antiproliferative drugs targeted specifically towards 
CTPS have been developed, with the aim of depleting cancer cells of CTP and thus 
slowing down tumour growth, such as cyclopentenyl cytosine (CPEC), acivicin and 3-
deazauridine [Verschuur AC et al., 2000]. Down-regulation of CTPS was observed 
for realgar treated HeLa cells, indicating that the activity of CTPS in cancerous cells 





7. CTSC  
The protein encoded by cathepsin C (CTSC), a member of the peptidase C1 
family, is a lysosomal cysteine proteinase that appears to be a central coordinator for 
activation of many serine proteinases in immune/inflammatory cells. It is composed 
of a dimer of disulfide-linked heavy and light chains, both produced from a single 
protein precursor. It requires chloride ions for activity and can degrade glucagon. 
Defects in the encoded protein have been shown to be a cause of Papillon-Lefevre 
syndrome, an autosomal recessive disorder characterized by palmoplantar keratosis 
and periodontitis. Two transcript variants encoding different isoforms have been 
found for this gene. 
High expression of CTSC in human skin cancer was reported [Dang C et al., 
2006]. Except arsenic trioxide, other arsenicals inactivated CTSC significantly.  
 
8. DCN  
Decorin (DCN) is a proteoglycan on average 90-140 kD in size. The protein 
encoded by this gene is a small cellular or pericellular matrix proteoglycan that is 
closely related in structure to biglycan protein. The encoded protein and biglycan are 
thought to be the result of gene duplication. This protein is a component of connective 
tissue, binds to type I collagen fibrils, and plays a role in matrix assembly. It contains 
one attached glycosaminoglycan chain. This protein is capable of suppressing the 
growth of various tumor cell lines. There are multiple alternatively spliced transcript 
variants known for this gene. This gene is a candidate gene for Marfan syndrome. 
 DCN belongs to tumor suppressing gene. Inhibition of growth of different 
cancer cells by DCN has been reported, by neutralizing the epidermal growth factor 




epidermal growth factor receptor [Lozzo RV et al., 1999], or by a mechanism 
involving the SMAD4 transduction pathway [Chen WB et al., 2002]. In this study, 
however, the down-regulation of DCN after realgar and orpiment treatments likely 
indicated that realgar and orpiment induced the cells death through DCN-independent 
pathways. In some publications, DCN could influence bioactivity of TGF-β1 
positively or negatively. Similar response trend of TGF-β receptor-TGFBP3 with 
slightly lower expression levels to realgar and orpiment probably implied that 
regulation of cell growth by DCN could be involved in TGF-β signaling pathway. 
 
9. DHCR7  
 In mammals, 7-dehydroxholesterol reductase (DHCR7) is the terminal enzyme 
in cholesterol biosynthesis. Smith-Lemli-Opitz syndrome (SLOS) is a severe 
developmental disorder caused by mutations in the DHCR7 gene, which is also 
current research focus.  
 Both realgar and orpiment significantly down-regulated DHCR7 compared to 
arsenic trioxide and arsenite. The association between this down expression and 
inhibition of cell growth is not clear yet.    
 
10. E2F1  
E2F stands for family of transcription factors in higher eukaryotes. E2F1 is 
one of three activators. The E2F family plays a crucial role in the control of cell cycle 
and action of tumor suppressor proteins and is also a target of the transforming 
proteins of small DNA tumor viruses. The E2F proteins contain several evolutionally 
conserved domains found in most members of the family. These domains include a 




differentiation regulated transcription factor proteins (DP), a transactivation domain 
enriched in acidic amino acids, and a tumor suppressor protein association domain 
which is embedded within the transactivation domain. This protein and another 2 
members, E2F2 and E2F3, have an additional cyclin binding domain. This protein 
binds preferentially to retinoblastoma protein pRB in a cell-cycle dependent manner. 
It can mediate both cell proliferation and p53-dependent/independent apoptosis. 
 It should be emphasized that some E2F family members behave as both 
oncogene and tumor suppressor gene [Johnson DG and Degregori J, 2006]. For 
example, down-regulated E2F1 expression can either promote or inhibit 
tumorigenesis depending on the nature of the other oncogenic mutations that are 
present.  
In this study, only realgar induced E2F1 down-regulation.   
 
11. ETV3  
 Full name of ETV3 is ETS variation gene 3. ETS transcription factors family 
plays important roles in cell development, cell differentiation, cell proliferation, 
apoptosis and tissue remodelling. Most of them are downstream nuclear targets of 
Ras-MAP kinase signalling, and the deregulation of ETS genes results in malignant 
transformation of cells. Considering that some ETS transcription factors are involved 
in malignant transformation and tumor progression, including invasion, metastasis 
and neo-angiogenesis through the activation of cancer-related genes, they could be 
potential molecular targets for selective cancer therapy [Oikawa T, 2004]. ETV3 
functions as repressors to inhibit growth-related genes such as c-myc and cdc2 but 
they do not inhibit differentiation-related genes [Klappacher GW et al., 2002]. Thus, it 





Only arsenite obviously increased ETV3 expression.  
 
12. FOSL1  
The Fos gene family consists of 4 members: FOS, FOSB, FOSL1, and FOSL2. 
These genes encode leucine zipper proteins that can dimerize with proteins of the 
JUN family, thereby forming the transcription factor complex AP-1. As such, the FOS 
proteins have been implicated as regulators of cell proliferation, differentiation, and 
transformation. 
  There was a summary reporting that misregulated activation of AP-1 can lead 
to tumorigenesis and that JUN and FOS can function as oncogenic transcription 
factors [Young MR and Colburn NH, 2006]. Therefore, up-regulation of FOSL1 after 
arsenicals treatments especially orpiment possibly suggests the oncogenic properties 
of arsenicals.  
   
13. IGFBP3  
This gene is a member of the insulin-like growth factor binding protein 
(IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin 
type-I domain. The protein forms a ternary complex with insulin-like growth factor 
acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II. In 
this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their 
interaction with cell surface receptors. IGFBP3 is the most abundant protein, 
accounting for 80% of all IGF binding. Alternate transcriptional splice variants, 
encoding different isoforms, have been characterized.  




and are thought to be important in tumour development. Early studies on risk of 
several cancers suggested that high circulating IGF-I concentrations are associated 
with an increased risk of cancer, whereas high IGFBP3 concentrations are associated 
with a decreased risk [Renehan AG et al., 2004]. Down-regulation of IGFBP3 
induced by all four types of arsenicals was observed, positively influencing the cell 
growth.  
 
14. LAMB1  
Laminins, a family of extracellular matrix glycoproteins, are the major 
noncollagenous constituent of basement membranes. They have been implicated in a 
wide variety of biological processes including cell adhesion, differentiation, 
migration, signaling, neurite outgrowth and metastasis. Laminins are composed of 3 
non identical chains: laminin alpha, beta and gamma (formerly A, B1, and B2, 
respectively) and they form a cruciform structure consisting of 3 short arms, each 
formed by a different chain, and a long arm composed of all 3 chains. Each laminin 
chain is a multidomain protein encoded by a distinct gene. Several isoforms of each 
chain have been described. Different alpha, beta and gamma chain isomers combine 
to give rise to different heterotrimeric laminin isoforms which are designated by 
Arabic numerals in the order of their discovery, i.e. alpha1beta1gamma1 heterotrimer 
is laminin 1. The biological functions of the different chains and trimer molecules are 
largely unknown, but some of the chains have been shown to differ with respect to 
their tissue distribution, presumably reflecting diverse functions in vivo. This gene 
encodes the beta chain isoform laminin, beta 1. The beta 1 chain has 7 structurally 
distinct domains which it shares with other beta chain isomers. The C-terminal helical 




contain several EGF-like repeats, and domains IV and VI have a globular 
conformation. Laminin, beta 1 is expressed in most tissues that produce basement 
membranes, and is one of the 3 chains constituting laminin 1, the first laminin isolated 
from Engelbreth-Holm-Swarm (EHS) tumor. A sequence in the beta 1 chain that is 
involved in cell attachment, chemotaxis, and binding to the laminin receptor was 
identified and shown to have the capacity to inhibit metastasis. 
 Integrin- and non-integrin-mediated laminin signalling activate several 
regulatory pathways that are involved in metastasis of cancer cells [Patarroyo M et al., 
2002; Givant-Horwitz V et al., 2005]. All arsenicals seem to trigger down-regulated 
alteration of LAMB1 gene, especially for arsenite, meaning that they positively 
inhibit the possible metastasis of cancer cells. 
 
15. MYC  
Full name of MYC is v-myc myelocytomatosis viral oncogene homology. The 
protein encoded by this gene is a multifunctional, nuclear phosphoprotein that plays a 
role in cell cycle progression, apoptosis and cellular transformation. It functions as a 
transcription factor that regulates transcription of specific target genes. Mutations, 
overexpression, rearrangement and translocation of this gene have been associated 
with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt 
lymphoma. There is evidence to show that alternative translation initiations from an 
upstream, in-frame non-AUG (CUG) and a downstream AUG start site result in the 
production of two isoforms with distinct N-termini. The synthesis of non-AUG 
initiated protein is suppressed in Burkitt's lymphomas, suggesting its importance in 
the normal function of this gene. 




MYC pathway is an attractive target for tailored cancer treatment. Significant down-
regulation of MYC induced by arsenicals tested probably suggested that arsenicals 
killed the cells via MYC-dependent pathways.   
 
16. NME3  
 nm23 gene family has been associated with metastasis suppression and 
differentiation. nm23 proteins have functional characteristics, such as kinase activity, 
leucine-zipper motif for transcriptional factor dimerization, and the integrin binding 
dowain arginine-glycine-aspartic acid (RGD), suggesting that they are multiple role 
proteins. NME3 (also called DR-nm23) is the third member of nm23 gene family, 
which shows 70% homology with other two members of nm23-H1 and nm23-H2 
[Amendola R et al., 2001]. Reportedly, DR-nm23 is involved in differentiation and 
apoptotic process in myeloid and neuroblastoma cells [Venturelli D et al., 1995; 
Amendola R et al., 1997]. DR-nm23 possesses NDP kinase activity.  
Both realgar and arsenite caused reduced expression of NME3.  
 
17. NR2F1  
 Steroid/thyroid hormones play an important role in regulating cellular 
differentiation, development and homeostasis in eukaryotes. They function through 
binding to their cognate nuclear receptors which are ligand-inducible transcription 
factors. Chicken ovalbumin upstream promoter-transcription factors (COUP-TFs) are 
the orphan memebers of the nuclear receptor superfamily [Tsai SY and Tsai MJ, 
1997]. Two COUP-TFs members are identified, COUP-TFI (also called NR2F1) and 
COUP-TFII (also called NR2F6).  






18. NR2F6  
 
19. PCNA  
The protein encoded by proliferating cell nuclear antigen (PCNA) is found in 
the nucleus and is a cofactor of DNA polymerase delta. The encoded protein acts as a 
homotrimer and helps increase the processivity of leading strand synthesis during 
DNA replication. In response to DNA damage, this protein is ubiquitinated and is 
involved in the RAD6-dependent DNA repair pathway. Two transcript variants 
encoding the same protein have been found for this gene. Pseudogenes of this gene 
have been described on chromosome 4 and on the X chromosome.  
PCNA in mammalian cells plays a key role in controlling several reactions 
through the coordination and organization of different partners. Down-regulation of 
PCNA mediated by realgar and arsenite were observed. Reduced PCNA expression 
and inhibited cell growth by arsenical in nasopharyngeal cancer xenografted SCID 
mice were reported [Li D et al., 2002].  
 
20. PCTK3  
 PCTK3, also called PCTAIRE3, is a CDC2 family protein kinase.  
 An overexpression of PCTK3 was found in sporadic breast cancer in Mexican 
women [Valladares A et al., 2006]. In our study, only realgar significantly reduced 
PCTK3 expression.  
 




The product of this gene belongs to the family of RAS-related proteins. These 
proteins share approximately 50% amino acid identity with the classical RAS proteins 
and have numerous structural features in common. The most striking difference 
between RAP proteins and RAS proteins resides in their 61st amino acid: glutamine 
in RAS is replaced by threonine in RAP proteins. The product of this gene counteracts 
the mitogenic function of RAS because it can interact with RAS GAPs and RAF in a 
competitive manner. Two transcript variants encoding the same protein have been 
identified for this gene. 
 RAS and RAS-related proteins are often deregulated in cancers, leading to 
increased invasion and metastasis, and decreased apoptosis. Down-regulation of 
RAP1A induced by realgar was observed.  
 
22. RBBP4  
Retinoblastoma binding protein 4 (RBBP4) encodes a ubiquitously expressed 
nuclear protein which belongs to a highly conserved subfamily of WD-repeat 
proteins. Another name of RBBP4 is RBAP48. It is present in protein complexes 
involved in histone acetylation and chromatin assembly. It is part of the Mi-2 complex 
which has been implicated in chromatin remodeling and transcriptional repression 
associated with histone deacetylation. This encoded protein is also part of co-
repressor complexes, which is an integral component of transcriptional silencing. It is 
found among several cellular proteins that bind directly to retinoblastoma protein to 
regulate cell proliferation. This protein also seems to be involved in transcriptional 
repression of E2F-responsive genes. 
 Very little is known about the role of RBB4 in cancers, although its expression 




acute lymphoblastic leukemia [Fukuoka J et al., 2004; Song H et al., 2003; Casas S et 
al., 2003]. Only realgar stimulated RBBP4 down-expressed.   
 
23. TFDP1  
The E2F transcription factor family (see MIM 189971) regulates the 
expression of various cellular promoters, particularly those involved in the cell cycle. 
E2F factors bind to DNA as homodimers or heterodimers in association with 
dimerization partner DP1. TFDP1 function as binding partner for E2F transcription 
factor and may be the first example of a family of related transcription factors; see 
TFDP2 (MIM 602160). 
The association of TFDP with E2F directly enhances both DNA binding 
affinity ad the transactivation function of the heterodimer. Although DP proteins 
might not possess a biological function on their own, they are indispensable for 
regulating E2F activity and thus play a central role in important cellular functions 
such as apoptosis. Furthermore, active TFDP1/E2F1 promotes apoptosis in both a 
p53-dependent and –independent manners [Hitchens MR and Robbins PD, 2003]. 
Down-regulation of TFDP1 was triggered by realgar treatment, same trend were 
found for the change of E2F1 gene.  
 
24. TNFRSF1B  
The protein encoded by this gene is a member of tumor necrosis factor 
receptor (TNFR) superfamily. This protein and TNF-receptor 1 form a heterocomplex 
that mediates the recruitment of two anti-apoptotic proteins, c-IAP1 and c-IAP2, 
which possess E3 ubiquitin ligase activity. The function of IAPs in TNF-receptor 




apoptosis by the ubiquitination and degradation of TNF-receptor-associated factor 2, 
which mediates anti-apoptotic signals. Knockout studies in mice also suggest a role of 
this protein in protecting neurons from apoptosis by stimulating antioxidative 
pathways. 
 TNFR superfamily members can induce a context-dependent apoptosis or cell 
activation. However, the mechanisms by which these opposing programs are selected 
remain unclear. Particularly, the mechanism of TNFRSF1B-mediated cell death 
remains under-investigated. Influence of orpiment on TNFRSF1B was to down-
regulate its expression, probably showing that orpiment induced cell death through 
TNFRSF1B-dependent pathways.  
 
25. TP53  
Tumor protein 53 (TP53), a nuclear protein, plays an essential role in the 
regulation of cell cycle, specifically in the transition from G0 to G1. It is found in 
very low levels in normal cells, however, in a variety of transformed cell lines, it is 
expressed in high amounts, and believed to contribute to transformation and 
malignancy. p53 is a DNA-binding protein containing DNA-binding, oligomerization 
and transcription activation domains. It is postulated to bind as a tetramer to a p53-
binding site and activate expression of downstream genes that inhibit growth and/or 
invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently 
occur in a number of different human cancers fail to bind the consensus DNA binding 
site, and hence cause the loss of tumor suppressor activity. Alterations of the TP53 
gene occur not only as somatic mutations in human malignancies, but also as germline 
mutations in some cancer-prone families with Li-Fraumeni syndrome. 








 Although most of altered genes need to be further confirmed by other methods 
such as RT-PCR, the microarray analysis has provided a global view of molecular 
alterations induced by specific arsenic compounds. Furthermore, the microarray data 
also suggest the complexity of tumor suppression of arsenic compounds, which likely 











determined by isotope dilution LC/MS/MS in 













Currently there is evidence that ROS can cause cell and tissue damage, 
consequently leading to various diseases including cancer [Hu CW et al., 2004]. 
There is great interest in studying the DNA damage caused by oxidation and various 
biomarkers associated with the damage. Urinary 8-hydroxy-2’-deoxyguanosine (8-
OH-dGuo) is reported to be the most acceptable biomarker of the oxidative DNA 
damage, because of its good water-solubility, stability, non-invasive sampling, 
absence of artifacts as encountered in DNA extraction, relatively high abundance, and 
more importantly etiological role in mutations and gene expression (causing G:C to 
T:A transversion) [Cheng KC et al., 1992; Kasai H, 1997]. Urinary 8-OH-dGuo also 
represents the average rate of damage in the total body. Therefore, determination of 
urinary 8-OH-dGuo can be used for investigation of different types of exposure to 
DNA-damaging factors, such as carcinogen and body irradiation [Cheng KC et al., 
1992; Kasai H, 1997; Peoples MC and Karnes HT, 2005]. 8-OH-dGuo has as well 
been identified as a biomarker for a few types of cancers including breast, lung, and 
liver cancers [Ma YF et al., 2004]. Therefore, determination of urinary 8-OH-dGuo 
has been considered as a noninvasive method for cancer diagnosis. Mei SR et al [Mei 
SR et al., 2005] analyzed 9 urine samples of healthy persons and 28 of cancer 
patients, and found that the excretion level of 8-OH-dGuo in cancer patients was 
significantly higher than in healthy persons, suggesting that the routine clinical 
determination of urinary 8-OH-dGuo could be a useful cancer biomarker. However, 
the concentration of 8-OH-dGuo in urine is normally as low as 1-10 nM, which makes 
detection difficult in most cases [Ma YF et al., 2004].  
 




 8-OH-dGuo has been analyzed using various instruments, mainly including 
HPLC with electrochemical detection (ECD) [Helbock HJ et al., 1998], enzyme-
linked immunosorbent assays (ELISA) [Kubota R et al., 2006], gas chromatography 
with mass spectrometry (GC/MS) [Dizdaroglu M, 1998], and HPLC with tandem 
mass spectrometry (LC/MS/MS) [Li CS et al., 2005]. GC-MS is currently the most 
commonly used method for analysis of modified nucleobase and nucleoside. 
However, artificial oxidation during sample preparation and analysis procedures has 
been reported [Cadet J et al., 1998; Dizdaroglu M, 1998]. From a practical point of 
view, an ideal method of analysis should include a minimum sample preparation, fast 
analysis time, and specific and sensitive detection. LC/MS/MS has the advantages 
over GC/MS of not requiring analyte derivatization to avoid artifact formation, and 
over HPLC/ECD of being chemospecific. Comparisons between LC/MS/MS method 
and commercial ELISA kit method on analysis of 8-OH-dGuo have been made by Hu 
CW et al. [2004]. In that study, the researchers found that the commercial ELISA kit 
method could have over-estimated the 8-OH-dGuo levels in urine. The reason might 
be due to the monoclonal antibody N45.1, used for the commercial ELISA kit, being 
not sufficiently specific toward urinary 8-OH-dGuo; the crude urine samples could 
contain considerable amounts of cross-reacting substances and other structurally 
related compounds competing for the N45.1 antibody.  
Comprehensively considering the unique advantages and instrumental 
availability, in this study, LC/MS/MS was selected to determine the changes of 
urinary 8-OH-dGuo in rats after drug treatments. Urine is a very complex matrix 
containing numerous endogenous compounds. When co-eluted with the analyte 
urinary matrix can cause electrospray ionization (ESI) suppression or enhancement, 




leading to serious quantitation errors. To solve such problem, our method involves 
solid-phase extraction to remove intensively the urine matrix contaminations.  
 
6.1.2 Objectives of this study 
 Arsenic is a well-established human carcinogen based on epidemiological 
studies, although the underlying mechanisms of carcinogenesis remain unclear. 
Induction of ROS by arsenic has been observed in some in vitro and in vivo 
experiments [Hei TK and Filipic M, 2004; Yamanaka K et al., 1989]. In spite of such 
evidences, it is still difficult to accurately assess health effects of arsenic on human, 
because its therapeutic applications also have a long history. It is well known that the 
toxicity of arsenicals depends on their chemical states [Tchounwou PB et al., 2003]. 
In addition, the toxicity of arsenicals depends on the exposure dose, frequency and 
duration, the biological species, age and gender, as well as on individual 
susceptibilities, genetic and nutritional factors [Tchounwou PB et al., 2003]. 
In order to examine possible associations between arsenic intake and the 
possible oxidative stress caused, we compared the urinary levels of the commonly 
accepted DNA damage biomarkers, 8-OH-dGuo, in rats after arsenite, realgar and 
orpiment administrations with control rats. The findings would add valuable 
information to the toxicity of arsenite, realgar and orpiment and safety in their future 
clinical applications.  
 
6.2 Materials and methods 
6.2.1 Chemicals 
8-Hydroxy-2’-deoxyguanosine (8-OH-dGuo, 100% in purity) with molecular 




with molecular weight of 267.2 were purchased from Berry & Associates Inc. (Ann 
Arbor, MI, USA). Stable heavy isotope labeled [15N5]-8-OH-dGuo (98% in purity) 
with molecular weight of anhydrous basis of 288.2 was obtained from Cambridge 
Isotope Laboratories (Andover, MA, USA). 2’-Deoxyguanosine monohydrate (dGuo, 
99-100% in purity) with molecular weight of 267.2 and formic acid of mass 
spectrometry grade were purchased from Sigma Chemical Corp. (St. Louis, MO, 
USA). Methanol of HPLC grade was obtained from Merck Corp. (Darmstadt, 
Germany). Milli-Q water was used throughout experiment. Aqueous stock standard 
solutions of 8-OH-dGuo and [15N5]-8-OH-dGuo, dGuo, and 8-OH-dAdo were 
prepared by dissolving them respectively in Milli-Q water to give a concentration of 
10 μg/ml, and stored at –80 oC (under these conditions, the stocks were stable over at 
least six months). The concentration of 8-OH-dGuo could be further confirmed by 
UV spectrophotometry using the absorption coefficient of 9908 M-1 cm-1 at 245 nm, 
and that of 8-OH-dAdo could be further determined using the absorption coefficient 
of 12764 M-1 cm-1 at 270 nm [Cavalieri LF and Bendich A, 1950]. Working standard 
solutions of 8-OH-dGuo (0.5 to 10 ng/ml) were freshly prepared by series dilution 
with Milli-Q water.  
 The respective suspensions of realgar (R/PVP/SDS) and orpiment 
(O/PVP/SDS) were prepared by individually dispersing the R/PVP/SDS and 
O/PVP/SDS preparations into Milli-Q water at a concentration of 4.0 mg drug/ml (the 
details could be referred to Chapter 3). Arsenite solution with a concentration of 2.0 
mg arsenite/ml was prepared by firstly dissolving exact amount of arsenic trioxide 
into 1 N NaOH followed by adjustment of pH to 7.0 ± 0.2 with concentrated HCl.  
 




Healthy male Sprague-Dawley (SD) rats (6-7 weeks of age, with average body 
weight of 200 ± 20 g) were purchased from Laboratory Animals Center, Singapore. 
They were randomly selected and housed individually in polycarbonate metabolic 
cages and provided with a standard diet (Mouse pellets, Laboratory Animals Centre, 
Singapore) and water ad libitum. The housing conditions were kept on a 12/12-h 
light/dark cycle at a temperature of 23 ± 1 oC and relative humidity of 50 ± 10%. At 
least one week of acclimatization period was allowed for rats prior to drug 
administration experiments. The animal experiment protocol followed the guidelines 
for proper and humane care of animals in scientific research.  
Rats were divided randomly into four groups of six rats each: one control 
group and three experimental groups. The three experimental groups received 
individual arsenic compounds by gavage administration for consecutive 15 days, 
whilst the control group received drinking water instead. Dosages were 20 mg pure 
drug/kg body weight for realgar and orpiment suspensions, and 10 mg arsenite/kg 
body weight for arsenite solution. After the experiment, all rats were euthanized by 
carbon dioxide gas inhalation. 
 
6.2.3 Urine sample collection, normalization and purification 
Every 24 hour urine outputs were collected and stored frozen at –80 oC until 
analysis. Prior to analysis, each sample was thawed at 37 oC for 10 min to re-dissolve 
possible 8-OH-dGuo precipitate during freezing storage [Weimann A et al., 2001], 
vigorously mixed, and then centrifuged at 1500 g for 10 min to obtain a clear 
supernatant.  
Since the urine concentration is highly variable between different subjects and 




according to its creatinine concentration level measured by Jaffe method after slight 
modification [Chan MH, 2004]. Briefly, the formation of acid-sensitive chromogen 
after reduction of the urine sample with picrate was measured at UV absorbance of 
500 nm. The different creatinine concentration can be reflected by different color by 
the present modified Jaffe method as shown in picture below. The urine was then 
normalized according to creatinine concentration by adding appropriate amount of 
10% formic acid. Normalized urine samples were then subjected to further 
purification steps.  
 
 
Line 2 to 10: Gradually reduced 
creatinine concentration






The solid phase extraction (SPE) clean-up procedure was processed and 
optimized by Waters Oasis® HLB Vac cartridges (Waters Corp., Milford, MA, USA) 
according to the standard protocol after slight modification. A volume of 1 ml of the 
normalized urine was loaded into a preconditioned SPE cartridge. The cartridge was 
then washed with 2 ml of water. The fraction containing 8-OH-dGuo was eluted with 
1 ml of HPLC running buffer. To optimize and evaluate the recovery of 8-OH-dGuo 
after clean-up procedure, isotope labeled [15N5]-8-OH-dGuo equaling to 10 ng/ml 





6.2.4 Analysis of 8-OH-dGuo by LC/MS/MS 
The HPLC system used was Agilent 1200 Series LC systems (Agilent 
Technologies Inc., Santa Clara, CA, USA). A Waters Symmetry300TM C18 column 
(150 × 1.0 mm i.d., 3.5 μm particle size) (Waters Ltd., Watford, UK) with an identical 
guard column (10 × 2.0 mm, 3.5 μm) was used. The isocratic mobile phase was 30% 
methanol with 0.1% formic acid, delivered at a flow rate of 50 μl/min. The HPLC was 
connected to an API 3200 Qtrap® mass spectrometer (Applied Biosystems, Foster, 
CA, USA) equipped with a TurboIonSprayTM source. Electrospray ionization (ESI) 
was performed. Multiple reaction monitoring (MRM) mode with positive ionization 
was used. Optimization of mass responses (compound parameters) was achieved by 
infusion of the 8-OH-dGuo solution in mobile phase with 1 μg/ml at a flow rate of 10 
μl/min by using a syringe pump. Major mass conditions used include: curtain gas at 
40 psi, ionspray source voltage at 5500 V, ionspray probe temperature at 450 oC,  ion 
source gas 1 at 50 psi and gas 2 at 30 psi, declustering potential at 25 V, entrance 
potential at 4.0 V, collision energy at 15.4 V, and collision cell exit potential at 8.0 V. 
A volume of 10 μl of purified urine sample was injected into the LC/MS/MS 
instrument for urinary 8-OH-dGuo determination.  
Data were acquired and processed with Analyst® 1.4.2 software (Applied 
Biosystems, Foster, CA, USA). The urinary concentration of 8-OH-dGuo was 
corrected by using individual urinary creatinine concentration (ng/mg creatinine).  
 
6.2.5 Measurement of urinary arsenic concentration by GFAAS  
 Determination of urinary arsenic concentration by GFAAS could be referred 





6.2.6 Statistical methods 
The results were presented as mean ± standard deviation (SD). Differences 
among data were determined using one-way ANOVA with the post hoc Tukey’s 
multiple comparison test (GraphPad Prism V4.0). Linear regression model was 
applied to study the association of the urinary arsenic recovery levels with urinary 8-
OH-dGuo levels (GraphPad Prism 4.0). A p-value < 0.05 was considered a significant 
difference.  
 
6.3 Results and discussion 
6.3.1 8-OH-dGuo and [15N5]-8-OH-dGuo: Typical mass spectra and 
chromatograms 
Production-ion spectra of 8-OH-dGuo and [15N5]-8-OH-dGuo were acquired 
respectively at optimum MS/MS conditions as shown in Figures 1a and 1b. The most 
abundant fragment of 8-OH-dGuo was detected at m/z 168, resulting from cleavage of 
the N-glycosidic bond accompanied by transfer of a hydrogen atom from the sugar 
moiety. A following intense daughter ion was observed at m/z 117, molecular ion 
[M+H]+ at m/z 284 was also observed. Corresponding fragmentation scheme was 
proposed in Figure 1a, and consistent with previous reports [Serrano J et al., 1996; 
Pietta PG et al., 2003]. [15N5]-8-OH-dGuo has been reported to be a stable internal 
standard [Frelon S et al., 2000; Singh R et al., 2003] and was thus selected in this 
study, yielding a same fragmentation pattern as 8-OH-dGuo (Figure 1b). The 
advantages of the isotope-dilution method are to correct for losses during the sample 
preparation and variations in the mass spectrometric response by calibration with 
isotopically labeled internal standard. In a recent study it was shown that tandem mass 




sensitivity over in selected ion monitoring (SIM) mode, mainly because using MRM 
mode led to a significant reduction in background noise to consequently generate an 
apparently overall increase in sensitivity [Podmore ID et al., 2000]. Therefore, the 
MRM mode was selected in the present study, and according to the individual 
production-ion spectra transition ion pairs chosen were 284/168 for 8-OH-dGuo and 















































































Figure 1. Positive production-ion spectra of 8-OH-dGuo (a, product ion scan of 





Chromatographic conditions for LC were established by using several types of 




mass spectrometer, 70% 0.1% formic acid with 30% methanol was selected. This 
elution system was simple and well suited for LC/MS. A typical chromatogram of a 
mixture of 8-OH-dGuo and [15N5]-8-OH-dGuo in standard aqueous solution is shown 
in Figure 2. Both 8-OH-dGuo and [15N5]-8-OH-dGuo were simultaneously eluted at 
the same retention time of 3.5 min, which also makes the isotope internal standard as 
an extra control in case the retention time of the analyte would somehow change 
























Figure 2. MRM chromatogram for an aqueous standard solution of 8-OH-dGuo 
(4.0 ng/ml, blue line) and [15N5]-8-OH-dGuo (5.0 ng/ml, red line).  
 
 
A separation chromatogram of purified urine sample spiked with 8-OH-dGuo 
and [15N5]-8-OH-dGuo is shown in Figure 3. The rat urine sample was randomly 




OH-dGuo and [15N5]-8-OH-dGuo from interferences in the urine matrix was 
obtained, indicating the urine matrix did not affect the detection of the analytes, 
although SPE clean-up procedure did not remove the urine matrix entirely. LOD 
value for [15N5]-8-OH-dGuo in urine matrix was about 0.5 ng/ml, which was 
comparable with that in the aqueous standard, suggesting that urinary contaminants 
left after clean-up of the urine matrix with SPE did not much affect the detection 
sensitivity of analyte. However, both peaks of urinary 8-OH-dGuo and [15N5]-8-OH-
dGuo became broader compared with those in corresponding aqueous solutions. For 
comparison, zero blank and double blank chromatograms of purified urine samples 












Figure 3. MRM chromatogram for 8-OH-dGuo (1.0 ng/ml added, blue line) and 


















































Figure 4. Zero blank (a, with addition of 1.0 ng/ml isotope, red line) and double 
blank (b) chromatograms of purified control urine sample randomly selected 
from control group.  
 
Besides 8-OH-dGuo, dozens of different forms of DNA damage products are 
known to be produced by oxygen radicals. 2-Hydroxy-2’-deoxyadenosine (2-OH-
dAdo) and 8-hydroxy-2’-deoxyadenosine (8-OH-dAdo) are the major oxidative 




OH-dAdo in DNA is much lower than that of 8-OH-dAdo after external stimulation 
as determined by GC/MS [Jaruga P et al., 2001]. For LC/MS analysis, there was no 
authentic compound available for 2-OH-dAdo probably because of its too low 
concentration [Jaruqa P et al., 2001]. Therefore, 8-OH-dAdo becomes study focus, 
and it has been implicated in mutagenesis, carcinogenesis, and aging [Tan XZ et al., 
1999]. For example, lesions induce A → G and A→ C mutations in mammalian cells 
[Tan XZ et al., 1999]. In addition, adenosine works as a universal protective agent 
against hypoxia, ischemia, excitotoxicity, toxicities induced by other substances and 
trauma [Engler RL, 1991]. The measurement of urinary adenosine can contribute to 
evaluation of renal injury in various clinical settings [Katholi RE et al., 1995; Heyne 
N et al., 2004]. Therefore, the primary aim of this study was to measure 
simultaneously the urinary 8-OH-dGuo and 8-OH-dAdo.  
Since 8-OH-dAdo has the same molecular weight as dGuo, for identification 
purpose, dGuo was included for the initial method development. According to the 
product ion spectra and proposed fragmental schemes of 8-OH-dAdo and dGuo 
(Figures 5a and 5b), their transition ion pairs were same, i.e. 268/152. Figure 6 gives 
the chromatogram of an aqueous mixture of 8-OH-dGuo, [15N5]-8-OH-dGuo, dGuo 
and 8-OH-dAdo. It could be seen that 8-OH-dGuo/[15N5]-8-OH-dGuo, dGuo and 8-
OH-dAdo were well separated, following the eluting order of dGuo, 8-OH-
dGuo/[15N5]-8-OH-dGuo, and 8-OH-dAdo. The eluting order was confirmed by 
chromatographic analysis of the individual analytes.  In order to improve the 
separation, the mobile phase was changed to 80% 0.1% formic acid with 20% 
methanol, whilst the operation parameters were also adjusted accordingly. The 
different chromatographic retention time of 8-OH-dAdo from that of dGuo may be 




HPLC, isomeric 8-OH-dAdo elutes later than dGuo probably because the 8-hydroxy 
group and oxygen on the sugar chain mask some of its polar groups, making 8-OH-
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Figure 5. Positive product-ion spectra of dGuo (a, production-ion scan of [M+H]+ 



















Figure 6. MRM chromatogram for an aqueous standard solution of dGuo (5.0 
ng/ml, first red line), 8-OH-dGuo (3.0 ng/ml, blue line), [15N5]-8-OH-dGuo (4.0 
ng/ml, green line), and 8-OH-dAdo (5.0 ng/ml, last red line).  
 
 
However, it was found in this study that 8-OH-dAdo was undetectable in the 
urine samples. It was due to the low concentration less than the limit of quantitation of 
our assay. Our finding is consistent with the observations by Weimann A et al. 
[Weimann A et al., 2001; Cadet J et al., 2002], but in contrast to the findings by 
GC/MS [Rehman A et al., 1998; Podmore ID et al., 1998], which could be due to 
artifacts from oxidation during derivatizaiton for GC/MS method and/or the GC run. 
Our finding is also in agreement with the fact that ۠OH-mediated oxidation of the 
adenine moiety as inferred from the measured formation of 8-OH-dAdo is, at least, 
10-fold lower than that of 8-OH-dGuo within both isolated and cellular DNA [Cadet J 
et al., 2002]. Therefore, only the concentration of 8-OH-dGuo in the urine samples 





6.3.2 Characteristics of SPE LC/MS/MS method for quantification of urinary 
8-OH-dGuo 
It is troublesome and unnecessary to completely remove the endogenous 8-
OH-dGuo in the urine matrix. Therefore, for the accurate determination of 8-OH-
dGuo in the urine samples, its stable isotope was used as an internal standard [Frelon 
S et al., 2000; Singh R et al., 2003].  
In this study, urinary calibration curve for 8-OH-dGuo measurement was built 
on [15N5]-8-OH-dGuo spiked urine samples. A linear urinary calibration curve, Y = 
0.7126 X, with correlation coefficient (r2) better than 0.995 was obtained in the 
selected concentration range from 1.0 to 10.0 ng/ml of [15N5]-8-OH-dGuo (calibration 
samples at 1.0, 2.0, 4.0, 6.0, 8.0, 10.0 ng/ml were conducted in triplicate respectively). 
The calibration range was chosen to match the range of concentrations actually 
measured. The limit of quantitation (LOQ) of 1 ng/ml for [15N5]-8-OH-dGuo was 
determined as the concentration that gave signal to noise (S/N) ratio of 10.5 in rat 
urine matrix. The adverse effects of interference from urine matrix could be clearly 
demonstrated by disappearance of the analyte peak for intact urine samples without 
SPE purification even after spiked with a high concentration of the 8-OH-dGuo 
standard solution (data not shown). The present recovery of 8-OH-dGuo after SPE 
was more than 65%.  
 In order to verify the diminishment of matrix effects after SPE treatment, the 
accuracy and recovery of the present method was ascertained by performing five 
replicate determinations of spiked [15N5]-8-OH-dGuo in four different urine samples 
on the same day. The results are shown in Table 1. As can be seen, all spiked urine 




variation were less than 7.31% for the analysis of urinary [15N5]-8-OH-dGuo. 
 
Table 1. Accuracy and recovery of the SPE isotope dilution LC/MS/MS method 





(mean ± SD, 
ng/ml) 
Recovery (%) CV (%) 
1.0 0.93 ± 0.07 93.0 7.31 
5.0 5.12 ± 0.30 102.4 5.78 
1 There were four urine samples tested which were randomly selected from 6 rats from 
the respective control group, arsenite-, realgar- and orpiment-treated groups on the 
same day; 1.0 ng/ml [15N5]-8-OH-dGuo was added to individual urine samples 
selected from day zero, and 5.0 ng/ml [15N5]-8-OH-dGuo was added to individual 




 The methodological reproducibility was examined by repeated measurements 
of [15N5]-8-OH-dGuo spiked urine samples on the same day (intra-day) and on three 
consecutive days (inter-day) (Table 2). In all cases, the reproducibilities expressed by 
the coefficient of variation for [15N5]-8-OH-dGuo were less than 10%. 
 
 
Table 2. Reproducibility of the SPE isotope dilution LC/MS/MS method for 
nalyzing spiked [15N5]-8-OH-dGuo in urine samples. a
 
Added [15N5]-8-OH-dGuo (ng/ml) 
Measured value1 
(mean ± SD, 
ng/ml) 
CV (%) 
Intra-day 0.96 ± 0.06 6.67 
1.0 
Inter-day 0.93 ± 0.09 9.14 
Intra-day 5.11 ± 0.26 5.00 
5.0 
Inter-day 5.07 ± 0.42 8.22 
1 One urine sample for inter-day and intra-day studies was randomly selected among 
24 rats from four groups on the same day; 1.0 ng/ml [15N5]-8-OH-dGuo was added to 
the urine sample selected from day zero, and 5.0 ng/ml [15N5]-8-OH-dGuo was added 





The method developed in the present study is fast, robust, and easily 
automated to measure two and potentially more oxidative DNA products, and is thus 
applicable to large scale epidemiological studies. Furthermore, the possibility of using 
stable isotopically marked internal standard in mass spectrometry (isotope dilution) 
adds increased reliability to the method. A drawback of the method is that the 
equipment is expensive. 
 
6.3.3 Concentrations of 8-OH-dGuo in rats urines before and after arsenic 
compounds administrations 
Arsenic is unusual, as it is one of the few demonstrated human carcinogens for 
which carcinogenicity in laboratory animals has not been firmly established [Goeing 
PL et al., 1999; Basu A et al., 2001]. Recent studies have reported that some arsenic 
compounds such as dimenthylarsinic acid (DMA) induced elevated formation of 8-
OH-dGuo in rodent animals [Wanibuchi H et al., 1997; Vijayaraghavan M et al., 
2001; Patlolla AK and Tchounmou PB, 2005].  
  The concentrations of urinary 8-OH-dGuo for control and treated rats were 
measured by the established SPE isotope dilution LC/MS/MS method.  In most 
studies, urinary 8-OH-dGuo levels were normalized with corresponding urinary 
creatinine levels [Dizdaroglu M, 1998; Li CS et al., 2005], which was adopted in this 
study. Table 3 lists the creatinine-adjusted urinary 8-OH-dGuo concentrations in the 
rats studied. A large inter-individual variation in terms of mean urinary 8-OH-dGuo 
concentrations was found, with the values of coefficient of variation (CV) up to 40%. 
Despite the relatively high CVs among the individuals, comparison analysis by one-
way ANOVA showed that all arsenic compounds-treated rats had significantly higher 




(control vs arsenite-treated group, p < 0.001; control vs realgar-treated group, p < 
0.001; control vs orpiment-treated group, p < 0.001); at current dosages, arsenite 
released more urinary 8-OH-dGuo than both realgar (p < 0.01) and orpiment (p < 
0.01), and there was no significant difference between realgar and orpiment on the 
induction of urinary 8-OH-dGuo (p > 0.05). Arsenite induced the elevated formation 
of urinary 8-OH-dGuo instantly at day 1 (p < 0.01) but not further increased thereafter 
(p > 0.05), so did realgar and orpiment. In addition, the mean urinary 8-OH-dGuo 
concentrations (ng/mg creatinine) of all intact rats including the control rats and 
experimental rats before treatment were in the range of 3.70 - 4.30, comparable with 
the reported values [Yasuhara T et al., 2007; Zhou H et al., 2006].  
 
 
Table 3. Urinary 8-OH-dGuo production in rats before and after arsenic 
administrations, measured by current SPE LC/MS/MS method. Data are 
presented as mean ± SD (n = 6). 
 









Day 0 3.86 ± 1.06 3.94 ± 1.19 4.00 ± 1.23 3.73 ± 1.19 
Day 1 3.94 ± 1.22 57.44 ± 24.55 40.26 ± 17.39 42.05 ± 18.92 
Day 2 4.27 ± 1.26 60.89 ± 20.80 43.43 ± 17.16 44.19 ± 17.67 
Day 3 4.10 ± 1.28 59.78 ± 24.12 42.41 ± 18.74 45.70 ± 17.64 
Day 4 3.75 ± 1.31 61.23 ± 25.83 46.89 ± 18.19 42.40 ± 18.28 
Day 5 3.90 ± 1.13 63.19 ± 19.40 43.99 ± 18.37 44.66 ± 18.92 
Day 6 3.95 ± 1.15 58.06 ± 25.27 46.72 ± 17.04 45.00 ± 18.19 
Day 7 4.07 ± 1.20 61.78 ± 19.10 42.31 ± 17.78 47.33 ± 17.94 
Day 8 3.94 ± 1.18 59.93 ± 24.38 44.64 ± 15.52 47.80 ± 18.30 
Day 9 3.82 ± 1.13 64.49 ± 23.08 44.99 ± 16.67 44.96 ± 17.98 
Day 10 4.01 ± 1.23 60.11 ± 26.31 47.00 ± 18.41 43.99 ± 18.07 
Day 11 3.78 ± 1.24 59.91 ± 22.49 49.30 ± 17.19 42.38 ± 17.98 
Day 12 3.86 ± 1.32 62.30 ± 19.40 45.09 ± 17.74 45.80 ± 18.55 
Day 13 4.19 ± 1.13 63.17 ± 19.18 46.38 ± 16.96 46.01 ± 18.55 






After oral ingestion, over 90% of inorganic arsenics are absorbed [Le XC et al., 
1994]. The ingested inorganic arsenics undergo methylation metabolism in the liver 
and about 60-70% is excreted in the urine [Vahter M, 2002]. The rest may then be 
deposited in other tissues. Since arsenic is rapidly metabolized and excreted into 
urine, detection of arsenic in urine thus has been used as a marker of recent arsenic 
exposure [Hwang YH et al., 1997]. Therefore, in the present study, the urinary arsenic 
recovery in rats after the arsenic compounds administrations was measured as shown 
in Table 4. In order to adjust the variability of urinary volume among individuals, the 
urinary arsenic concentrations were also corrected with corresponding urinary 
creatinine concentrations.  
 
Table 4. The urinary arsenic recovery in rats after the arsenic compounds 
dministrations. Data are presented as mean ± SD (n = 6). a
 







Day 1 70.38 ± 21.01 77.88 ± 22.25 67.75 ± 22.54 
Day 2 71.62 ± 22.69 78.21 ± 23.04 68.21 ± 19.47 
Day 3 71.93 ± 22.92 78.78 ± 25.00 68.96 ± 19.01 
Day 4 72.99 ± 21.78 78.98 ± 25.28 68.76 ± 20.96 
Day 5 73.21 ± 19.76 77.62 ± 23.45 70.23 ± 20.16 
Day 6 73.27 ± 20.64 79.01 ± 23.10 69.89 ± 20.45 
Day 7 74.01 ± 19.85 78.21 ± 24.93 70.21 ± 20.60 
Day 8 74.17 ± 19.89 79.01 ± 25.84 70.33 ± 21.38 
Day 9 75.64 ± 22.09 78.21 ± 23.26 69.41 ± 20.86 
Day 10 75.71 ± 20.14 79.37 ± 23.77 69.21 ± 20.08 
Day 11 77.21 ± 20.42 80.01 ± 23.77 70.89 ± 20.66 
Day 12 77.88 ± 26.74 78.54 ± 23.81 69.81 ± 19.59 
Day 13 78.21 ± 24.73 78.14 ± 24.49 70.26 ± 20.03 
Day 14 78.32 ± 24.56 79.61 ± 23.28 71.77 ± 19.21 
 
 
It should be mentioned that the urinary arsenic concentrations in all intact rats 




detectable under current instrumental conditions. Theoretically, urinary arsenic 
recovery should gradually increase with daily arsenic compounds intake, because the 
reported biological half-life for arsenic has been estimated to between 1 to 3 days 
[Hwang YH et al., 1997]. However, in this study, from the statistical point of view, 
similar increase of daily urinary arsenic recovery with time (~70 μg/mg creatinine) 
were not found for each study group (p > 0.05). This result probably was due to the 
fact that the doses used were so low that they would be mostly and promptly 
eliminated by rats within 24 h. Dosages were 20 mg pure drug/kg body weight for 
realgar and orpiment suspensions, and 10 mg arsenite/kg body weight for arsenite 
solution. About 50% of daily administered arsenite was excreted into the urine, 
compared to around 20% of daily administered realgar and orpiment. The relatively 
lower urinary arsenic recoveries for realgar and orpiment suspensions when compared 
to arsenite solution probably were resulted from the extra dissolution step involved 
with the suspending particles.  
Besides urinary excretion, the real body distribution and elimination by other 
pathways such as feces except urine of daily dosed arsenic compounds were not 
determined in the present study. Table 3 showed that consecutive administration of 
arsenicals for 15 days did not significantly change the production of 8-OH-dGuo, the 
indicator of the whole body oxidative damage rate. Data in Table 3 and Table 4 
indicated there were likely positive correlations between urinary arsenic levels and 
corresponding urinary 8-OH-dGuo levels in each study group. Therefore, the urinary 
arsenic-adjusted 8-OH-dGuo concentrations were also calculated and listed in Table 5. 
Comparison analysis again showed similar results to what have been obtained with 
the creatinine-adjusted 8-OH-dGuo concentrations. That is, arsenite triggered more 8-





contrast, there was significant difference between realgar and orpiment on the 
formation of 8-OH-dGuo (p < 0.001). It might be concluded that arsenite caused more 
oxidative DNA damage, and therefore, was more toxicogenic than both realgar and 
orpiment.  
 
Table 5. The urinary arsenic-corrected 8-OH-dGuo concentrations. Data are 
resented as mean ± SD (n = 6). p
 







Day 1 0.86 ± 0.21 0.55 ± 0.29 0.58 ± 0.16 
Day 2 0.87 ± 0.21 0.54 ± 0.13 0.62 ± 0.13 
Day 3 0.83 ± 0.21 0.51 ± 0.12 0.64 ± 0.12 
Day 4 0.83 ± 0.22 0.59 ± 0.16 0.58 ± 0.14 
Day 5 0.86 ± 0.10 0.54 ± 0.13 0.60 ± 0.16 
Day 6 0.76 ± 0.29 0.57 ± 0.07 0.61 ± 0.13 
Day 7 0.83 ± 0.15 0.52 ± 0.12 0.65 ± 0.10 
Day 8 0.77 ± 0.21 0.56 ± 0.08 0.66 ± 0.11 
Day 9 0.86 ± 0.22 0.57 ± 0.08 0.62 ± 0.12 
Day 10 0.75 ± 0.25 0.57 ± 0.09 0.61 ± 0.13 
Day 11 0.77 ± 0.14 0.61 ± 0.11 0.58 ± 0.22 
Day 12 0.82 ± 0.12 0.55 ± 0.10 0.65 ± 0.18 
Day 13 0.83 ± 0.17 0.58 ± 0.07 0.67 ± 0.22 
Day 14 0.85 ± 0.45 0.60 ± 0.10 0.68 ± 0.20 
 
 
In order to further examine whether there are positive correlations existing 
between urinary 8-OH-dGuo and urinary arsenic levels as assumed earlier, a linear 
regression analysis was used. Figure 7 gives correlations between urinary arsenic 
recovery values and urinary 8-OH-dGuo concentrations in each experimental group. 
Positive correlations were obtained (arsenite-treated group, n = 84, r2 = 0.5946, p < 
0.001; realgar-treated group, n = 84, r2 = 0.7883, p < 0.001; orpiment-treated group, n 
= 84, r2 = 0.8426, p < 0.001), in agreement with the reported findings [Fujino Y et al., 




Figure 7. Correlation between urinary 8-OH-dGuo and urinary arsenic recovery levels in three arsenic compounds-treated groups (a, 
arsenite-treated group; b, realgar-treated group; c, orpiment-treated group.). 
 













































































































































































 It should be mentioned that so far the measured urinary 8-OH-dGuo values in 
both intact animal and healthy human samples were quite variable even after 
normalized with creatinine. Some reported results are summarized in Table 6. That 
can be explained by the variability between animals and humans, the different 
methodology used for 8-OH-dGuo and creatinine analysis, the different sample 
extraction and cleanup procedures performed and by the reduced number of 
experiments done. In general, the range of the 8-OH-dGuo levels analyzed differs 10-
1000-fold depending on the analysis method used [Kasai H, 1997].  
Table 6. Summary of recent reported urinary 8-OH-dGuo in intact animal and 
ealthy human samples. h
 
Animals 8-OH-dGuo (ng/mg creatinine) Approach Ref. 
Male SD rats, 8 
weeks, 200-250g 
 
Male SD rats, 230-
250g 
 
Male Wistar rats, 10-
11 weeks 
 
Male Wistar rats, 10 
weeks, 200 g around 
 
Male Wistar rats, 10 
weeks, 200g around 
 
 
Male Wistar rats, 10-
11 weeks 
 
Male Wistar rats, 8 




55 days, 226-250 g 
 
49 male healthy 
workers, 44.7 years 
 
3 healthy persons 
2.0 ± 0.4 
 
 
7.05 ± 1.49 
 
 
3.7 ± 0.6 
 
 
89.34 ± 27.34 
 
 




3.7 ± 0.6 
 
 
10.89 ± 2.59 
 
 
22.2 ± 6.8 
 
 
5.69 ± 3.34 
14.69 ± 12.84 
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 The SPE isotope dilution LC/MS/MS method for quantitative analysis of 
urinary 8-OH-dGuo was established. Practical application of the present method on 
the analysis of association of arsenic intake and the biomarkers of DNA oxidative 
damage imply that the evaluation of such biomarkers in body after invasion is an 
effective method to understand the in vivo response to potential drug candidate. 
Urinary 8-OH-dGuo analysis could be used to assess the responses to therapy and 
help to know the effect of the therapy for the next treatment. To our knowledge, this is 
the first study concerning the potential oxidative stress caused by realgar and 
orpiment. Our findings pointed out in certain dose range, arsenite could cause more 
oxidative DNA damage indicated by the induction of more urinary 8-OH-dGuo than 
realgar and orpiment. It has been recognized that increased levels of DNA base 
oxidation products such as 8-OH-dGuo do not always lead to malignancy [Halliwell 
B, 2007]. The nature of the DNA damages and the effectiveness of their subsequent 
























7.1 Final conclusions  
For identifying the components in the alkali extracts of realgar and orpiment, a 
CZE assay with indirect UV detector by using the PDC/CTAOH as a BGE was 
established. The developed CZE method provided excellent linearity, intra-day and 
inter-day variation, sensitivity to identify the components in the alkali extracts of 
realgar and orpiment. The main components in both extracts were found to be iAsIII 
and iAsV. The finding also showed that the method was suitable for simultaneous 
separation and determination of the inorganic and organic arsenic compounds, 
including arsenite, arsenate, MMAV and DMAV. The method could be applied to 
standardize pharmaceutical arsenic formulations. Since the major components in the 
alkali extracts of realgar and orpiment were arsenite and arsenate instead of the intact 
realgar and orpiment, alkali extraction could not be an appropriate approach to 
solubilize realgar/orpiment powder. The findings thus suggested that other approaches 
should be employed to improve the water-solubility of realgar and orpiment.  
In order to improve the water-solubility of realgar and orpiment, cryo-grinding 
technique was used to mechanically reduce their particle sizes to nanograde with the 
assistance of PVP and/or SDS. The presence of PVP and/or SDS was found not only 
to enhance the grinding efficiency but also to stabilize realgar/orpiment colloidal 
solution. The adsorption of PVP and/or SDS onto the surface of the realgar/orpiment 
particle was able to form a coating, that provided steric and/or ionic barrier to prevent 
aggregation and/or agglomeration.  
The cytotoxicity of the realgar nanoparticle preparations, i.e. realgar ground 
alone, R/PVP, R/SDS, R/PVP/SDS, on the selected cell lines were evaluated. In in 
vitro study, the realgar nanoparticle preparations were used to treat some human 




and significant anti-proliferation effects comparable to arsenic trioxide were observed, 
whereas they did not cause much cytotoxicity on two control human fibroblast cell 
lines, MRC-5 and HF. Through cell cycle analysis, apoptosis induced by realgar 
nanoparticles was concluded depending on the appearance of the characterized sub-G1 
phase in cell cycle histograms. The induction of apoptosis was further confirmed by 
the morphological observation and DNA fragmentation assay. Similar results were 
found when using the orpiment nanoparticle preparations (orpiment ground alone and 
O/PVP/SDS) to treat the HaLa and OVCAR-3 cells.  
In in vivo studies, the extent of absorption and bioavailability were estimated 
based on the urinary recovery of arsenic. After oral administrations of the ground 
realgar and orpiment preparations, the urinary arsenic excretions in SD rats were 
significantly increased when compared to those in rats after oral administrations of the 
corresponding original realgar and orpiment powders. The improvement in absorption 
and bioavailability was attributed to the particle size reduction of realgar and orpiment. 
Both realgar and orpiment have been considered to be less toxic compounds in arsenic 
superfamily. The usage of realgar and orpiment nanoparticles could overcome the 
usage limitations associated with the poor water-solubility and the consequent poor 
absorption and bioavailability and allow them being used clinically.   
In order to clearly understand the possible underlying action mechanisms of 
realgar and orpiment and arsenite, microarray technique was used. The altered gene 
expression profiles of HeLa cells after these arsenical treatments were different. These 
suggested that their effects were very complicated and compound-dependent. Further 
confirmation studies would be required to verify the microarray findings before the 
exact mechanisms of action could be proposed.  




compounds, the partial reason of such classification probably is due to their poor 
water-solubility and the consequent low absorption instead of their intrinsic toxicity. 
In recent years, the urinary 8-OH-dGuo was used as the most commonly acceptable 
biomarker of oxidative DNA damage. The oxidative DNA damage has been proved to 
be associated with many types of diseases. Therefore, it is important to find out the 
association of the arsenical intake and the resulting urinary 8-OH-dGuo level, an 
indicator of oxidative DNA damage by the arsenicals. For this purpose, a LC/MS/MS 
method for quantitative analysis of urinary 8-OH-dGuo was established. By using the 
established LC/MS/MS method, urinary 8-OH-dGuo levels in rats after oral 
administrations of arsenite, realgar, and orpiment were measured. In terms of the 
urinary 8-OH-dGuo levels, the findings suggested that both realgar and orpiment 
could cause oxidative DNA damage to the similar extent, but slightly less than that 
caused by arsenite.  
 
7.2 Proposed future studies 
In this study, the grinding yield of the cryo-grinding approach is low. 
Therefore, it warrants increasing the grinding efficiency, e.g., the selection and 
optimization of stabilizers such as polymers and surfactants for further improvement 
of the productivity. With suitable solvents for recrystalizing realgar and orpiment, 
nanosized realgar and orpiment particles could be produced chemically. Generally, 
chemical method has advantages over mechanical method, as the former approach 
gives more homogeneous and controllable particle distribution. The productivity of 
realgar and orpiment nanoparticles could also be easily enhanced by the chemical 
method. However, the potential toxicity of the solvent used could be a concern.  




elucidated in this study. It warrants putting more efforts in this area, because 
understanding of the mechanisms provides the foundation for the potential 
combination therapies for better treatment outcomes. The preliminary microarray 
study gave some valuable information on some most affected cancer-related genes 
regulated by realgar and orpiment. Future study could focus on these genes and verify 
the involvement of these genes in the activities.  
In this study, the urinary arsenic recovery was used to reflect the extent of the 
absorption and bioavailability of realgar and orpiment. However, the disposition and 
metabolism profiles of realgar and orpiment after oral administration are unknown. It 
would be especially important to study the metabolism and tissue distribution of 
arsenicals when they are used as therapeutics, and the relationship of DMPK profiles 
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